

NN

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
25 October 2001 (25.10.2001)

PCT

(10) International Publication Number
WO 01/79274 A2

(51) International Patent Classification⁷: C07K 14/195

(74) Agent: PLOUGMANN, VINGTOFT & PARTNERS
A/S; Sankt Annæ Plads 11, P.O. Box 3007, DK-1021
Copenhagen K (DK).

(21) International Application Number: PCT/DK01/00276

(81) Designated States (*national*): AE, AG, AL, AM, AT, AT
(utility model), AU, AZ, BA, BB, BG, BR, BY, BZ, CA,
CH, CN, CO, CR, CU, CZ, CZ (utility model), DE, DE
(utility model), DK, DK (utility model), DM, DZ, EE, EE
(utility model), ES, FI, FI (utility model), GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
SK (utility model), SL, TJ, TM, TR, TT, TZ, UA, UG, US,
UZ, VN, YU, ZA, ZW.

(22) International Filing Date: 19 April 2001 (19.04.2001)

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PA 2000 00666 19 April 2000 (19.04.2000) DK
PA 2001 00283 21 February 2001 (21.02.2001) DK

(71) Applicant (*for all designated States except US*):
STATENS SERUM INSTITUT [DK/DK]; Artillerivej 5,
DK-2300 Copenhagen S (DK).

Published:

— without international search report and to be republished
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 01/79274 A2

(54) Title: M. TUBERCULOSIS ANTIGENS

(57) Abstract: The present invention is based on the identification and characterization of a number of novel *M. tuberculosis* derived proteins and protein fragments. The invention is directed to the polypeptides and immunologically active fragments thereof, the genes encoding them, immunological compositions such as vaccines and skin test reagents containing the polypeptides.

M. TUBERCULOSIS ANTIGENS

Field of invention

The present invention discloses new immunogenic polypeptides and new immunogenic compositions based on polypeptides derived from the short time culture filtrate of *M. tuberculosis*.

General Background

Human tuberculosis caused by *Mycobacterium tuberculosis* (*M. tuberculosis*) is a severe global health problem, responsible for approx. 3 million deaths annually, according to the WHO. The world-wide incidence of new tuberculosis (TB) cases had been falling during the 1960s and 1970s but during recent years this trend has markedly changed in part due to the advent of AIDS and the appearance of multidrug resistant strains of *M. tuberculosis*.

The only vaccine presently available for clinical use is BCG, a vaccine whose efficacy remains a matter of controversy. BCG generally induces a high level of acquired resistance in animal models of TB, but several human trials in developing countries have failed to demonstrate significant protection. Notably, BCG is not approved by the FDA for use in the United States because BCG vaccination impairs the specificity of the Tuberculin skin test for diagnosis of TB infection.

20

This makes the development of a new and improved vaccine against TB an urgent matter, which has been given a very high priority by the WHO. Many attempts to define protective mycobacterial substances have been made, and different investigators have reported increased resistance after experimental vaccination. However, the demonstration of a specific long-term protective immune response with the potency of BCG has not yet been achieved.

Immunity to *M. tuberculosis* is characterized by some basic features; specifically sensitized T lymphocytes mediates protection, and the most important mediator molecule seems to be interferon gamma (IFN- γ).

M. tuberculosis holds, as well as secretes, several proteins of potential relevance for the generation of a new TB vaccine. For a number of years, a major effort has been put into

the identification of new protective antigens for the development of a novel vaccine against TB. The search for candidate molecules has primarily focused on proteins released from dividing bacteria. Despite the characterization of a large number of such proteins only a few of these have been demonstrated to induce a protective immune response as subunit vaccines in animal models, most notably ESAT-6 and Ag85B (Brandt et al 2000).

In 1998 Cole et al published the complete genome sequence of *M. tuberculosis* and predicted the presence of approximately 4000 open reading frames (Cole et al 1998). Among others, nucleotide sequences comprising Rv0284, Rv0285, Rv0455c, Rv0569, Rv1195, Rv1386, Rv3477, Rv3878 and Rv3879c are described, and putative protein sequences for the above sequences are suggested. However important, this sequence information cannot be used to predict if the DNA is translated and expressed as proteins *in vivo*. More importantly, it is not possible on the basis of the sequences to predict whether a given sequence will encode an immunogenic or an inactive protein. The only way to determine if a protein is recognized by the immune system during or after an infection with *M. tuberculosis* is to produce the given protein and test it in an appropriate assay as described herein.

Diagnosing *M. tuberculosis* infection in its earliest stage is important for effective treatment of the disease. Current diagnostic assays to determine *M. tuberculosis* infection are expensive and labour-intensive. In the industrialized part of the world the majority of patients exposed to *M. tuberculosis* receive chest x-rays and attempts are made to culture the bacterium *in vitro* from sputum samples. X-rays are insensitive as a diagnostic assay and can only identify infections in a very progressed stage. Culturing of *M. tuberculosis* is also not ideal as a diagnostic tool, since the bacteria grows poorly and slowly outside the body, which can produce false negative test results and take weeks before results are obtained. The standard tuberculin skin test is an inexpensive assay, used in third world countries, however it is far from ideal in detecting infection because it cannot distinguish *M. tuberculosis*-infected individuals from *M. bovis* BCG-vaccinated individuals and therefore cannot be used in areas of the world where patients receive or have received childhood vaccination with bacterial strains related to *M. tuberculosis*, e.g. a BCG vaccination.

Animal tuberculosis is caused by *Mycobacterium bovis*, which is closely related to *M. tuberculosis* and within the tuberculosis complex. *M. bovis* is an important pathogen that can infect a range of hosts, including cattle and humans. Tuberculosis in cattle is a major

cause of economic loss and represents a significant cause of zoonotic infection. A number of strategies have been employed against bovine TB, but the approach has generally been based on government-organized programs by which animals deemed positive to defined screening test are slaughtered. The most common test used in cattle is Delayed-5 type hypersensitivity with PPD as antigen, but alternative in vitro assays are also developed. However, investigations have shown the both the in vivo and the in vitro tests have a relative low specificity, and the detection of false-positive is a significant economic problem (Pollock et al 2000). There is therefore a great need for a more specific diagnostic reagent, which can be used either *in vivo* or *in vitro* to detect *M. bovis* infections in
10 animals.

Summary of the invention

The invention is related to preventing, treating and detecting infections caused by species of the tuberculosis complex (*M. tuberculosis*, *M. bovis*, *M. africanum*) by the use of a polypeptide comprising a *M. tuberculosis* antigen or an immunogenic portion or other
15 variant thereof, or by the use of a DNA sequence encoding a *M. tuberculosis* antigen or an immunogenic portion or other variant thereof.

Detailed disclosure of the invention

The present invention discloses a substantially pure polypeptide, which comprises an amino acid sequence selected from

- 20 (a) Rv0284, Rv0285, Rv0455c, Rv0569, Rv1195, Rv1386, Rv3477, Rv3878, Rv3879c or MT3106.1;
- (b) an immunogenic portion, e.g. a T-cell epitope, of any one of the sequences in (a); and /or
- (c) an amino acid sequence analogue having at least 70% sequence identity to any
25 one of the sequences in (a) or (b) and at the same time being immunogenic.

Preferably, the amino acid sequence analogue has at least 80%, more preferred at least 90% and most preferred at least 95% sequence identity to any one of the sequences in (a) or (b).

30

The invention further discloses a fusion polypeptide, which comprises an amino acid sequence selected from

- (a) Rv0284, Rv0285, Rv0455c, Rv0569, Rv1195, Rv1386, Rv3477, Rv3878, Rv3879c or MT3106.1
- (b) an immunogenic portion, e.g. a T-cell epitope, of any one of the sequences in (a); and /or
- 5 (c) an amino acid sequence analogue having at least 70% sequence identity to any one of the sequences in (a) or (b) and at the same time being immunogenic; and at least one fusion partner.

Preferably, the fusion partner comprises a polypeptide fragment selected from

- 10 (a) a polypeptide fragment derived from a virulent mycobacterium, such as ESAT-6, MPB64, MPT64, TB10.4, CFP10, RD1-ORF5, RD1-ORF2, Rv1036, Ag85A, Ag85B, Ag85C, 19kDa lipoprotein, MPT32, MPB59 and alpha-crystallin;
- (b) a polypeptide according to the invention and defined above and/or
- (c) at least one immunogenic portion, e.g. a T-cell epitope, of any of such polypeptides in (a) or (b)

The invention further relates to a polypeptide, which comprises an amino acid sequence selected from

- 20 (a) Rv0284, Rv0285, Rv0455c, Rv0569, Rv1195, Rv1386, Rv3477, Rv3878, Rv3879c or MT3106.1
 - (b) an immunogenic portion, e.g. a T-cell epitope, of any one of the sequences in (a); and /or
 - (c) an amino acid sequence analogue having at least 70% sequence identity to any one of the sequences in (a) or (b) and at the same time being immunogenic;
- 25 which is lipidated so as to allow a self-adjuvating effect of the polypeptide.

Further, the invention relates to a polypeptide, which comprises an amino acid sequence selected from

- 30 (a) Rv0284, Rv0285, Rv0455c, Rv0569, Rv1195, Rv1386, Rv3477, Rv3878, Rv3879c or MT3106.1
 - (b) an immunogenic portion, e.g. a T-cell epitope, of any one of the sequences in (a); and /or
 - (c) an amino acid sequence analogue having at least 70% sequence identity to any one of the sequences in (a) or (b) and at the same time being immunogenic;
- 35 for use as a vaccine, as a pharmaceutical or as a diagnostic reagent.

In another embodiment, the invention relates to the use of a polypeptide as defined above for the preparation of a pharmaceutical composition for diagnosis, e.g. for diagnosis of tuberculosis caused by virulent mycobacteria, e.g. by *Mycobacterium tuberculosis*, *Mycobacterium africanum* or *Mycobacterium bovis*, and the use of a polypeptide as defined above for the preparation of a pharmaceutical composition, e.g. for the vaccination against infection caused by virulent mycobacteria, e.g. by *Mycobacterium tuberculosis*, *Mycobacterium africanum* or *Mycobacterium bovis*.

- 10 In a still further embodiment, the invention relates to an immunogenic composition comprising a polypeptide as defined above, preferably in the form of a vaccine or in the form of a skin test reagent.

In another embodiment, the invention relates to a nucleic acid fragment in isolated form
15 which

- (a) comprises a nucleic acid sequence which encodes a polypeptide as defined above, or comprises a nucleic acid sequence complementary thereto; or
- (b) has a length of at least 10 nucleotides and hybridizes readily under stringent hybridization conditions with a nucleotide sequence selected from Rv0284, Rv0285,
20 Rv0455c, Rv0569, Rv1195, Rv1386, Rv3477, Rv3878, Rv3879c or MT3106.1 nucleotide sequences or a sequence complementary thereto, or with a nucleotide sequence selected from a sequence in (a)

The nucleic acid fragment is preferably a DNA fragment. The fragment can be used as a
25 pharmaceutical.

In one embodiment, the invention relates to a vaccine comprising a nucleic acid fragment according to the invention, optionally inserted in a vector, the vaccine effecting *in vivo* expression of antigen by an animal, including a human being, to whom the vaccine has been
30 administered, the amount of expressed antigen being effective to confer substantially increased resistance to tuberculosis caused by virulent mycobacteria, e.g. by *Mycobacterium tuberculosis*, *Mycobacterium africanum* or *Mycobacterium bovis*, in an animal, including a human being.

In a further embodiment, the invention relates to the use of a nucleic acid fragment according to the invention for the preparation of a composition for the diagnosis of tuberculosis caused by virulent mycobacteria, e.g. by *Mycobacterium tuberculosis*, *Mycobacterium africanum* or *Mycobacterium bovis*, and the use of a nucleic acid fragment according

- .5 to the invention for the preparation of a pharmaceutical composition for the vaccination against tuberculosis caused by virulent mycobacteria, e.g. by *Mycobacterium tuberculosis*, *Mycobacterium africanum* or *Mycobacterium bovis*.

In a still further embodiment, the invention relates to a vaccine for immunizing an animal,

- 10 including a human being, against tuberculosis caused by virulent mycobacteria, e.g. by *Mycobacterium tuberculosis*, *Mycobacterium africanum* or *Mycobacterium bovis*, comprising as the effective component a non-pathogenic microorganism, wherein at least one copy of a DNA fragment comprising a DNA sequence encoding a polypeptide as defined above has been incorporated into the microorganism (e.g. placed on a plasmid or in the
15 genome) in a manner allowing the microorganism to express and optionally secrete the polypeptide.

In another embodiment, the invention relates to a replicable expression vector, which

comprises a nucleic acid fragment according to the invention, and a transformed cell har-
20 bouting at least one such vector.

In another embodiment, the invention relates to a method for producing a polypeptide as defined above, comprising

- (a) inserting a nucleic acid fragment according to the invention into a vector which is
25 able to replicate in a host cell, introducing the resulting recombinant vector into the host cell, culturing the host cell in a culture medium under conditions sufficient to effect expression of the polypeptide, and recovering the polypeptide from the host cell or culture medium;
- (b) isolating the polypeptide from a whole mycobacterium, e.g. *Mycobacterium tuberculosis*, *Mycobacterium africanum* or *Mycobacterium bovis*, from culture filtrate or
30 from lysates or fractions thereof; or
- (c) synthesizing the polypeptide e.g. by solid or liquid phase peptide synthesis.

The invention also relates to a method of diagnosing tuberculosis caused by virulent my-

- 35 cobacteria, e.g. by *Mycobacterium tuberculosis*, *Mycobacterium africanum* or *Myco-*

bacterium bovis, in an animal, including a human being, comprising intradermally injecting, in the animal, a polypeptide as defined above or an immunogenic composition as defined above, a positive skin response at the location of injection being indicative of the animal having tuberculosis, and a negative skin response at the location of injection being

5 indicative of the animal not having tuberculosis.

In another embodiment, the invention relates to a method for immunizing an animal, including a human being, against tuberculosis caused by virulent mycobacteria, e.g. by *Mycobacterium tuberculosis*, *Mycobacterium africanum* or *Mycobacterium bovis*, comprising

10 administering to the animal the polypeptide as defined above, the immunogenic composition according to the invention, or the vaccine according to the invention.

Another embodiment of the invention relates to a monoclonal or polyclonal antibody, which is specifically reacting with a polypeptide as defined above in an immuno assay, or

15 a specific binding fragment of said antibody. Preferably, said antibody is for use as a diagnostic reagent, e.g. for detection of mycobacterial antigens in sputum, urine or other body fluids of an infected animal, including a human being.

In a further embodiment the invention relates to a pharmaceutical composition which

20 comprises an immunologically responsive amount of at least one member selected from the group consisting of:

(a) a polypeptide selected from Rv0284, Rv0285, Rv0455c, Rv0569, Rv1195, Rv1386, Rv3477, Rv3878, Rv3879c or MT3106.1, or an immunogenic portion thereof;

25 (b) an amino acid sequence which has a sequence identity of at least 70% to any one of said polypeptides in (a) and is immunogenic;

(c) a fusion polypeptide comprising at least one polypeptide or amino acid sequence according to (a) or (b) and at least one fusion partner;

(d) a nucleic acid sequence which encodes a polypeptide or amino acid sequence

30 according to (a), (b) or (c);

(e) a nucleic acid sequence which is complementary to a sequence according to (d);

(f) a nucleic acid sequence which has a length of at least 10 nucleotides and which hybridizes under stringent conditions with a nucleic acid sequence according to (d) or (e); and

- (g) a non-pathogenic micro-organism which has incorporated (e.g. placed on a plasmid or in the genome) therein a nucleic acid sequence according to (d), (e) or (f) in a manner to permit expression of a polypeptide encoded thereby.
- 5 In a still further embodiment the invention relates to a method for stimulating an immunogenic response in an animal which comprises administering to said animal an immunologically stimulating amount of at least one member selected from the group consisting of:
- (a) a polypeptide selected from Rv0284, Rv0285, Rv0455c, Rv0569, Rv1195,
10 Rv1386, Rv3477, Rv3878, Rv3879c or MT3106.1, or an immunogenic portion thereof;
- (b) an amino acid sequence which has a sequence identity of at least 70% to any one of said polypeptides in (a) and is immunogenic;
- (c) a fusion polypeptide comprising at least one polypeptide or amino acid sequence
15 according to (a) or (b) and at least one fusion partner;
- (d) a nucleic acid sequence which encodes a polypeptide or amino acid sequence according to (a), (b) or (c);
- (e) a nucleic acid sequence which is complementary to a sequence according to (d);
- (f) a nucleic acid sequence which has a length of at least 10 nucleotides and which
20 hybridizes under stringent conditions with a nucleic acid sequence according to (d) or (e); and
- (g) a non-pathogenic micro-organism which has incorporated therein (e.g. placed on a plasmid or in the genome) a nucleic acid sequence according to (d), (e) or (f) in a manner to permit expression of a polypeptide encoded thereby.
- 25 The vaccine, immunogenic composition and pharmaceutical composition according to the invention can be used prophylactically in a subject not infected with a virulent mycobacterium; or therapeutically in a subject already infected with a virulent mycobacterium.
- 30 The invention also relates to a method for diagnosing previous or ongoing infection with a virulent mycobacterium, said method comprising
- (a) contacting a sample, e.g. a blood sample, with a composition comprising an antibody according to the invention, a nucleic acid fragment according to the invention and/or a polypeptide as defined above, or

- (b) contacting a sample, e.g. a blood sample comprising mononuclear cells (e.g. T-lymphocytes), with a composition comprising one or more polypeptides as defined above in order to detect a positive reaction, e.g. proliferation of the cells or release of cytokines such as IFN- γ .

5

Finally, the invention relates to a method of diagnosing *Mycobacterium tuberculosis* infection in a subject comprising:

- (a) contacting a polypeptide as defined above with a bodily fluid of the subject;
- (b) detecting binding of an antibody to said polypeptide, said binding being an indication that said subject is infected by *Mycobacterium tuberculosis* or is susceptible to *Mycobacterium tuberculosis* infection.

10

Definitions

The word "polypeptide" in the present invention should have its usual meaning. That is an amino acid chain of any length, including a full-length protein, oligopeptides, short peptides and fragments thereof, wherein the amino acid residues are linked by covalent peptide bonds.

The polypeptide may be chemically modified by being glycosylated, by being lipidated (e.g. by chemical lipidation with palmitoyloxy succinimide as described by Mowat et al. 1991 or with dodecanoyl chloride as described by Lustig et al. 1976), by comprising prosthetic groups, or by containing additional amino acids such as e.g. a his-tag or a signal peptide.

Each polypeptide may thus be characterised by specific amino acids and be encoded by specific nucleic acid sequences. It will be understood that such sequences include analogues and variants produced by recombinant or synthetic methods wherein such polypeptide sequences have been modified by substitution, insertion, addition or deletion of one or more amino acid residues in the recombinant polypeptide and still be immunogenic in any of the biological assays described herein. Substitutions are preferably "conservative". These are defined according to the following table. Amino acids in the same block in the second column and preferably in the same line in the third column may be substituted for each other. The amino acids in the third column are indicated in one-letter code.

ALIPHATIC	Non-polar	GAP
		ILV
	Polar-uncharged	CSTM
		NQ
AROMATIC	Polar-charged	DE
		KR
		HFWY

- A preferred polypeptide within the present invention is an immunogenic antigen from *M. tuberculosis*. Such antigen can for example be derived from *M. tuberculosis* and/or *M. tuberculosis* culture filtrate. Thus, a polypeptide comprising an immunogenic portion of one
- 5 of the above antigens may consist entirely of the immunogenic portion, or may contain additional sequences. The additional sequences may be derived from the native *M. tuberculosis* antigen or be heterologous and such sequences may, but need not, be immunogenic.
- 10 Each polypeptide is encoded by a specific nucleic acid sequence. It will be understood that such sequences include analogues and variants hereof wherein such nucleic acid sequences have been modified by substitution, insertion, addition or deletion of one or more nucleic acid. Substitutions are preferably silent substitutions in the codon usage which will not lead to any change in the amino acid sequence, but may be introduced to
- 15 enhance the expression of the protein.

- In the present context the term "substantially pure polypeptide fragment" means a polypeptide preparation which contains at most 5% by weight of other polypeptide material with which it is natively associated (lower percentages of other polypeptide material are
- 20 preferred, e.g. at most 4%, at most 3%, at most 2%, at most 1%, and at most ½%). It is preferred that the substantially pure polypeptide is at least 96% pure, i.e. that the polypeptide constitutes at least 96% by weight of total polypeptide material present in the preparation, and higher percentages are preferred, such as at least 97%, at least 98%, at least 99%, at least 99,25%, at least 99,5%, and at least 99,75%. It is especially preferred
- 25 that the polypeptide fragment is in "essentially pure form", i.e. that the polypeptide fragment is essentially free of any other antigen with which it is natively associated, i.e. free of

- any other antigen from bacteria belonging to the tuberculosis complex or a virulent mycobacterium. This can be accomplished by preparing the polypeptide fragment by means of recombinant methods in a non-mycobacterial host cell as will be described in detail below, or by synthesizing the polypeptide fragment by the well-known methods of solid or liquid 5 phase peptide synthesis, e.g. by the method described by Merrifield or variations thereof.

By the term "virulent mycobacterium" is understood a bacterium capable of causing the tuberculosis disease in an animal or in a human being. Examples of virulent mycobacteria are *M. tuberculosis*, *M. africanum*, and *M. bovis*. Examples of relevant animals are cattle, possums, badgers and kangaroos.

10

By "a TB patient" is understood an individual with culture or microscopically proven infection with virulent mycobacteria, and/or an individual clinically diagnosed with TB and who is responsive to anti-TB chemotherapy. Culture, microscopy and clinical diagnosis of TB are well known by any person skilled in the art.

15

By the term "PPD-positive individual" is understood an individual with a positive Mantoux test or an individual where PPD induces a positive *in vitro* recall response determined by release of IFN- γ .

- 20 By the term "delayed type hypersensitivity reaction" (DTH) is understood a T-cell mediated inflammatory response elicited after the injection of a polypeptide into, or application to, the skin, said inflammatory response appearing 72-96 hours after the polypeptide injection or application.
- 25 By the term "IFN- γ " is understood interferon-gamma. The measurement of IFN- γ is used as an indication of an immunological response.

- By the terms "nucleic acid fragment" and "nucleic acid sequence" are understood any nucleic acid molecule including DNA, RNA, LNA (locked nucleic acids), PNA, RNA, dsRNA 30 and RNA-DNA-hybrids. Also included are nucleic acid molecules comprising non-naturally occurring nucleosides. The term includes nucleic acid molecules of any length, e.g. from 10 to 10000 nucleotides, depending on the use. When the nucleic acid molecule is for use as a pharmaceutical, e.g. in DNA therapy, or for use in a method for producing a polypeptide according to the invention, a molecule encoding at least one epitope is preferably 35 used, having a length from about 18 to about 1000 nucleotides, the molecule being op-

- tionally inserted into a vector. When the nucleic acid molecule is used as a probe, as a primer or in antisense therapy, a molecule having a length of 10-100 is preferably used. According to the invention, other molecule lengths can be used, for instance a molecule having at least 12, 15, 21, 24, 27, 30, 33, 36, 39, 42, 50, 60, 70, 80, 90, 100, 200, 300,
- 5 400, 500 or 1000 nucleotides (or nucleotide derivatives), or a molecule having at most 10000, 5000, 4000, 3000, 2000, 1000, 700, 500, 400, 300, 200, 100, 50, 40, 30 or 20 nucleotides (or nucleotide derivatives). It should be understood that these numbers can be freely combined to produce ranges.
- 10 The term "stringent" when used in conjunction with hybridization conditions is as defined in the art, i.e. the hybridization is performed at a temperature not more than 15-20°C under the melting point T_m, cf. Sambrook et al, 1989, pages 11.45-11.49. Preferably, the conditions are "highly stringent", i.e. 5-10°C under the melting point T_m.
- 15 Throughout this specification, unless the context requires otherwise, the word "comprise", or variations thereof such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element or integer or group of elements or integers but not the exclusion of any other element or integer or group of elements or integers.
- 20 The term "sequence identity" indicates a quantitative measure of the degree of homology between two amino acid sequences of equal length or between two nucleotide sequences of equal length. If the two sequences to be compared are not of equal length, they must be aligned to best possible fit possible with the insertion of gaps or alternatively truncation at the ends of the protein sequences. The sequence identity can be calculated as
- 25
$$\frac{(N_{ref} - N_{dif})}{N_{ref}} \cdot 100$$
, wherein N_{dif} is the total number of non-identical residues in the two sequences when aligned and wherein N_{ref} is the number of residues in one of the sequences. Hence, the DNA sequence AGTCAGTC will have a sequence identity of 75% with the sequence AATCAATC (N_{dif}=2 and N_{ref}=8). A gap is counted as non-identity of the specific residue(s), i.e. the DNA sequence AGTGTC will have a sequence identity of 75% with the DNA se-
- 30 quence AGTCAGTC (N_{dif}=2 and N_{ref}=8). Sequence identity can alternatively be calculated by the BLAST program e.g. the BLASTP program (Pearson W. R. and D. J. Lipman (1988))(www.ncbi.nlm.nih.gov/cgi-bin/BLAST). In one aspect of the invention, alignment is performed with the sequence alignment method ClustalW with default parameters as described by Thompson J., et al 1994, available at <http://www2.ebi.ac.uk/clustalw/>.

A preferred minimum percentage of sequence identity is at least 80%, such as at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, and at least 99.5%.

- 5 In a preferred embodiment of the invention, the polypeptide comprises an immunogenic portion of the polypeptide, such as an epitope for a B-cell or T-cell. The immunogenic portion of a polypeptide is a part of the polypeptide, which elicits an immune response in an animal or a human being, and/or in a biological sample determined by any of the biological assays described herein. The immunogenic portion of a polypeptide may be a T-cell
10 epitope or a B-cell epitope. Immunogenic portions can be related to one or a few relatively small parts of the polypeptide, they can be scattered throughout the polypeptide sequence or be situated in specific parts of the polypeptide. For a few polypeptides epitopes have even been demonstrated to be scattered throughout the polypeptide covering the full sequence (Ravn et al 1999).

15

- In order to identify relevant T-cell epitopes which are recognised during an immune response, it is possible to use a "brute force" method: Since T-cell epitopes are linear, deletion mutants of the polypeptide will, if constructed systematically, reveal what regions of the polypeptide are essential in immune recognition, e.g. by subjecting these deletion
20 mutants e.g. to the IFN- γ assay described herein. Another method utilises overlapping oligopeptides for the detection of MHC class II epitopes, preferably synthetic, having a length of e.g. 20 amino acid residues derived from the polypeptide. These peptides can be tested in biological assays (e.g. the IFN- γ assay as described herein) and some of these will give a positive response (and thereby be immunogenic) as evidence for the
25 presence of a T cell epitope in the peptide. For the detection of MHC class I epitopes it is possible to predict peptides that will bind (Stryhn et al. 1996) and hereafter produce these peptides synthetic and test them in relevant biological assays e.g. the IFN- γ assay as described herein. The peptides preferably having a length of e.g. 8 to 11 amino acid residues derived from the polypeptide. B-cell epitopes can be determined by analysing the B
30 cell recognition to overlapping peptides covering the polypeptide of interest as e.g. described in Harboe et al 1998.

Although the minimum length of a T-cell epitope has been shown to be at least 6 amino acids, it is normal that such epitopes are constituted of longer stretches of amino acids.

- 35 Hence, it is preferred that the polypeptide fragment of the invention has a length of at

least 7 amino acid residues, such as at least 8, at least 9, at least 10, at least 12, at least 14, at least 16, at least 18, at least 20, at least 22, at least 24, and at least 30 amino acid residues. Hence, in important embodiments of the inventive method, it is preferred that the polypeptide fragment has a length of at most 50 amino acid residues, such as at most 5 40, 35, 30, 25, and 20 amino acid residues. It should be understood that these numbers can be freely combined to produce ranges.

It is expected that the peptides having a length of between 10 and 20 amino acid residues will prove to be most efficient as MHC class II epitopes and therefore especially preferred 10 lengths of the polypeptide fragment used in the inventive method are 18, such as 15, 14, 13, 12 and even 11 amino acid residues. It is expected that the peptides having a length of between 7 and 12 amino acid residues will prove to be most efficient as MHC class I epitopes and therefore especially preferred lengths of the polypeptide fragment used in the inventive method are 11, such as 10, 9, 8 and even 7 amino acid residues.

15

Immunogenic portions of polypeptides may be recognised by a broad part (high frequency) or by a minor part (low frequency) of the genetically heterogenic human population. In addition some immunogenic portions induce high immunological responses (dominant), whereas others induce lower, but still significant, responses (subdominant). High 20 frequency><low frequency can be related to the immunogenic portion binding to widely distributed MHC molecules (HLA type) or even by multiple MHC molecules (Kilgus et al. 1991, Sinigaglia et al 1988).

In the context of providing candidate molecules for a new vaccine against tuberculosis, 25 the subdominant epitopes are however as relevant as are the dominant epitopes since it has been shown (Olsen et al 2000) that such epitopes can induce protection regardless of being subdominant.

A common feature of the polypeptides of the invention is their capability to induce an immunological response as illustrated in the examples. It is understood that a variant of a 30 polypeptide of the invention produced by substitution, insertion, addition or deletion is also immunogenic determined by any of the assays described herein.

An immune individual is defined as a person or an animal, which has cleared or controlled 35 an infection with virulent mycobacteria or has received a vaccination with *M. bovis* BCG.

An immunogenic polypeptide is defined as a polypeptide that induces an immune response in a biological sample or an individual currently or previously infected with a virulent mycobacterium. The immune response may be monitored by one of the following 5 methods:

- An *in vitro* cellular response is determined by release of a relevant cytokine such as IFN- γ , from lymphocytes withdrawn from an animal or human being currently or previously infected with virulent mycobacteria, or by detection of proliferation of these T cells. The induction being performed by the addition of the polypeptide or the immunogenic portion to a suspension comprising from 1×10^5 cells to 3×10^5 cells per well. The cells being isolated from either the blood, the spleen, the liver or the lung and the addition of the polypeptide or the immunogenic portion resulting in a concentration of not more than 20 μg per ml suspension and the stimulation being performed from two to five days. For monitoring cell proliferation the cells are pulsed with radioactive labeled Thymidine and after 16-22 hours of incubation detecting the proliferation by liquid scintillation counting. A positive response being a response more than background plus two standard derivations. The release of IFN- γ can be determined by the ELISA method, which is well known to a person skilled in the art. A positive response being a response more than background plus two standard derivations. Other cytokines than IFN- γ could be relevant when monitoring the immunological response to the polypeptide, such as IL-12, TNF- α , IL-4, IL-5, IL-10, IL-6, TGF- β . Another and more sensitive method for determining the presence of a cytokine (e.g. IFN- γ) is the ELISPOT method where the cells isolated from either the blood, the spleen, the liver or the lung are diluted to a concentration of preferable of 1 to 4×10^6 cells /ml and incubated for 18-22 hrs in the presence of the polypeptide or the immunogenic portion resulting in a concentration of not more than 20 μg per ml. The cell suspensions are hereafter diluted to 1 to 2×10^6 / ml and transferred to Maxisorp plates coated with anti-IFN- γ and incubated for preferably 4 to 16 hours. The IFN- γ producing cells are determined by the use of labeled secondary anti-IFN- γ antibody and a relevant substrate giving rise to spots, which can be enumerated using a dissection microscope. It is also a possibility to determine the presence of mRNA coding for the relevant cytokine by the use of the PCR technique. Usually one or more cytokines will be measured

utilizing for example the PCR, ELISPOT or ELISA. It will be appreciated by a person skilled in the art that a significant increase or decrease in the amount of any of these cytokines induced by a specific polypeptide can be used in evaluation of the immunological activity of the polypeptide.

5

- An *in vitro* cellular response may also be determined by the use of T cell lines derived from an immune individual or an *M. tuberculosis* infected person where the T cell lines have been driven with either live mycobacteria, extracts from the bacterial cell or culture filtrate for 10 to 20 days with the addition of IL-2. The induction being performed by addition of not more than 20 μ g polypeptide per ml suspension to the T cell lines containing from 1×10^5 cells to 3×10^5 cells per well and incubation being performed from two to six days. The induction of IFN- γ or release of another relevant cytokine is detected by ELISA. The stimulation of T cells can also be monitored by detecting cell proliferation using radioactively labeled Thymidine as described above. For both assays a positive response being a response more than background plus two standard derivations.

- An *in vivo* cellular response which may be determined as a positive DTH response after intradermal injection or local application patch of at most 100 μ g of the polypeptide or the immunogenic portion to an individual who is clinically or subclinically infected with a virulent Mycobacterium, a positive response having a diameter of at least 5 mm 72-96 hours after the injection or application.

- An *in vitro* humoral response is determined by a specific antibody response in an immune or infected individual. The presence of antibodies may be determined by an ELISA technique or a Western blot where the polypeptide or the immunogenic portion is absorbed to either a nitrocellulose membrane or a polystyrene surface. The serum is preferably diluted in PBS from 1:10 to 1:100 and added to the absorbed polypeptide and the incubation being performed from 1 to 12 hours. By the use of labeled secondary antibodies the presence of specific antibodies can be determined by measuring the OD e.g. by ELISA where a positive response is a response of more than background plus two standard derivations or alternatively a visual response in a Western blot.

- Another relevant parameter is measurement of the protection in animal models induced after vaccination with the polypeptide in an adjuvant or after DNA vaccination. Suitable animal models include primates, guinea pigs or mice, which are challenged with an infection of a virulent Mycobacterium. Readout for induced protection could be decrease of the bacterial load in target organs compared to non-vaccinated animals, prolonged survival times compared to non-vaccinated animals and diminished weight loss compared to non-vaccinated animals.

5 In general, *M. tuberculosis* antigens, and DNA sequences encoding such antigens, may be prepared using any one of a variety of procedures. They may be purified as native proteins from the *M. tuberculosis* cell or culture filtrate by procedures such as those described above. Immunogenic antigens may also be produced recombinantly using a DNA sequence encoding the antigen, which has been inserted into an expression vector and expressed in an appropriate host. Examples of host cells are *E. coli*. The polypeptides or 10 immunogenic portion hereof can also be produced synthetically having fewer than about 100 amino acids, and generally fewer than 50 amino acids and may be generated using techniques well known to those ordinarily skilled in the art, such as commercially available solid-phase techniques where amino acids are sequentially added to a growing amino acid chain.

15

In the construction and preparation of plasmid DNA encoding the polypeptide as defined for DNA vaccination a host strain such as *E. coli* can be used. Plasmid DNA can then be prepared from overnight cultures of the host strain carrying the plasmid of interest, and purified using e.g. the Qiagen Giga -Plasmid column kit (Qiagen, Santa Clarita, CA, USA) 20 including an endotoxin removal step. It is essential that plasmid DNA used for DNA vaccination is endotoxin free.

The immunogenic polypeptides may also be produced as fusion proteins, by which methods superior characteristics of the polypeptide of the invention can be achieved. For instance, fusion partners that facilitate export of the polypeptide when produced recombinantly, fusion partners that facilitate purification of the polypeptide, and fusion partners which enhance the immunogenicity of the polypeptide fragment of the invention are all interesting possibilities. Therefore, the invention also pertains to a fusion polypeptide comprising at least one polypeptide or immunogenic portion defined above and at least 25 one fusion partner. The fusion partner can, in order to enhance immunogenicity, be an-

other polypeptide derived from *M. tuberculosis*, such as of a polypeptide fragment derived from a bacterium belonging to the tuberculosis complex, such as ESAT-6, TB10.4, CFP10, RD1-ORF5, RD1-ORF2, Rv1036, MPB64, MPT64, Ag85A, Ag85B (MPT59), MPB59, , Ag85C, 19kDa lipoprotein, MPT32 and alpha-crystallin, or at least one T-cell epitope of any of the above mentioned antigens ((Skjøt et al 2000; Danish Patent application PA 2000 00666; Danish Patent application PA 1999 01020; US patent application 09/0505,739; Rosenkrands et al 1998; Nagai et al 1991). The invention also pertains to a fusion polypeptide comprising mutual fusions of two or more of the polypeptides (or immunogenic portions thereof) of the invention.

10

Other fusion partners, which could enhance the immunogenicity of the product, are lymphokines such as IFN- γ , IL-2 and IL-12. In order to facilitate expression and/or purification, the fusion partner can e.g. be a bacterial fimbrial protein, e.g. the pilus components pilin and papA; protein A; the ZZ-peptide (ZZ-fusions are marketed by Pharmacia in Sweden); 15 the maltose binding protein; glutathione S-transferase; β -galactosidase; or poly-histidine. Fusion proteins can be produced recombinantly in a host cell, which could be *E. coli*, and it is a possibility to induce a linker region between the different fusion partners.

Other interesting fusion partners are polypeptides, which are lipidated so that the immunogenic polypeptide is presented in a suitable manner to the immune system. This effect is e.g. known from vaccines based on the *Borrelia burgdorferi* OspA polypeptide as described in e.g. WO 96/40718 A or vaccines based on the *Pseudomonas aeruginosa* OprI lipoprotein (Cote-Sierra J 1998). Another possibility is N-terminal fusion of a known signal sequence and an N-terminal cystein to the immunogenic polypeptide. Such a fusion results in lipidation of the immunogenic polypeptide at the N-terminal cystein, when produced in a suitable production host.

Another part of the invention pertains to a vaccine composition comprising a polypeptide (or at least one immunogenic portion thereof) or fusion polypeptide according to the invention. In order to ensure optimum performance of such a vaccine composition it is preferred that it comprises an immunologically and pharmaceutically acceptable carrier, vehicle or adjuvant.

An effective vaccine, wherein a polypeptide of the invention is recognized by the animal, 35 will in an animal model be able to decrease bacterial load in target organs, prolong sur-

vival times and/or diminish weight loss after challenge with a virulent Mycobacterium, compared to non-vaccinated animals.

Suitable carriers are selected from the group consisting of a polymer to which the peptide(s) is/are bound by hydrophobic non-covalent interaction, such as a plastic, e.g. polystyrene, or a polymer to which the polypeptide(s) is/are covalently bound, such as a polysaccharide, or a polypeptide, e.g. bovine serum albumin, ovalbumin or keyhole limpet haemocyanin. Suitable vehicles are selected from the group consisting of a diluent and a suspending agent. The adjuvant is preferably selected from the group consisting of di-
5 methylidioctadecylammonium bromide (DDA), Quil A, poly I:C, aluminium hydroxide, Freund's incomplete adjuvant, IFN- γ , IL-2, IL-12, monophosphoryl lipid A (MPL), Trehalose Dimycolate (TDM), Trehalose Dibehenate and muramyl dipeptide (MDP).

Preparation of vaccines which contain peptide sequences as active ingredients is generally well understood in the art, as exemplified by U.S. Patents 4,608,251; 4,601,903; 15 4,599,231 and 4,599,230, all incorporated herein by reference.

Other methods of achieving adjuvant effect for the vaccine include use of agents such as aluminum hydroxide or phosphate (alum), synthetic polymers of sugars (Carbopol), aggregation of the protein in the vaccine by heat treatment, aggregation by reactivating with pepsin treated (Fab) antibodies to albumin, mixture with bacterial cells such as C. parvum or endotoxins or lipopolysaccharide components of gram-negative bacteria, emulsion in physiologically acceptable oil vehicles such as mannide mono-oleate (Aracel A) or emulsion with 20 percent solution of a perfluorocarbon (Fluosol-DA) used as a block substitute
20 may also be employed. Other possibilities involve the use of immune modulating substances such as cytokines or synthetic IFN- γ inducers such as poly I:C in combination with the above-mentioned adjuvants.

Another interesting possibility for achieving adjuvant effect is to employ the technique described in Gosselin et al., 1992 (which is hereby incorporated by reference herein). In brief, a relevant antigen such as an antigen of the present invention can be conjugated to an antibody (or antigen binding antibody fragment) against the Fc γ receptors on monocytes/macrophages.

The vaccines are administered in a manner compatible with the dosage formulation, and in such amount as will be therapeutically effective and immunogenic. The quantity to be administered depends on the subject to be treated, including, e.g., the capacity of the individual's immune system to mount an immune response, and the degree of protection desired. Suitable dosage ranges are of the order of several hundred micrograms active ingredient per vaccination with a preferred range from about 0.1 µg to 1000 µg, such as in the range from about 1 µg to 300 µg, and especially in the range from about 10 µg to 50 µg. Suitable regimens for initial administration and booster shots are also variable but are typified by an initial administration followed by subsequent inoculations or other administrations.

The manner of application may be varied widely. Any of the conventional methods for administration of a vaccine are applicable. These are believed to include oral application on a solid physiologically acceptable base or in a physiologically acceptable dispersion, parenterally, by injection or the like. The dosage of the vaccine will depend on the route of administration and will vary according to the age of the person to be vaccinated and, to a lesser degree, the size of the person to be vaccinated.

The vaccines are conventionally administered parenterally, by injection, for example, either subcutaneously or intramuscularly. Additional formulations which are suitable for other modes of administration include suppositories and, in some cases, oral formulations. For suppositories, traditional binders and carriers may include, for example, polyalkalene glycols or triglycerides; such suppositories may be formed from mixtures containing the active ingredient in the range of 0.5% to 10%, preferably 1-2%. Oral formulations include such normally employed excipients as, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, and the like. These compositions take the form of solutions, suspensions, tablets, pills, capsules, sustained release formulations or powders and advantageously contain 10-95% of active ingredient, preferably 25-70%.

30

In many instances, it will be necessary to have multiple administrations of the vaccine. Especially, vaccines can be administered to prevent an infection with virulent mycobacteria and/or to treat established mycobacterial infection. When administered to prevent an infection, the vaccine is given prophylactically, before definitive clinical signs or symptoms of an infection are present.

Due to genetic variation, different individuals may react with immune responses of varying strength to the same polypeptide. Therefore, the vaccine according to the invention may comprise several different polypeptides in order to increase the immune response. The 5 vaccine may comprise two or more polypeptides or immunogenic portions, where all of the polypeptides are as defined above, or some but not all of the peptides may be derived from virulent mycobacteria. In the latter example, the polypeptides not necessarily fulfilling the criteria set forth above for polypeptides may either act due to their own immunogenicity or merely act as adjuvants.

10

The vaccine may comprise 1-20, such as 2-20 or even 3-20 different polypeptides or fusion polypeptides, such as 3-10 different polypeptides or fusion polypeptides.

The invention also pertains to a method for immunising an animal, including a human being, against TB caused by virulent mycobacteria, comprising administering to the animal 15 the polypeptide of the invention, or a vaccine composition of the invention as described above, or a living vaccine described above.

The invention also pertains to a method for producing an immunologic composition according to the invention, the method comprising preparing, synthesising or isolating a polypeptide according to the invention, and solubilizing or dispersing the polypeptide in a medium for a vaccine, and optionally adding other *M. tuberculosis* antigens and/or a carrier, vehicle and/or adjuvant substance.

25 The nucleic acid fragments of the invention may be used for effecting *in vivo* expression of antigens, i.e. the nucleic acid fragments may be used in so-called DNA vaccines as reviewed in Ulmer et al 1993, which is included by reference.

Hence, the invention also relates to a vaccine comprising a nucleic acid fragment according to the invention, the vaccine effecting *in vivo* expression of antigen by an animal, 30 including a human being, to whom the vaccine has been administered, the amount of expressed antigen being effective to confer substantially increased resistance to infections caused by virulent mycobacteria in an animal, including a human being.

The efficacy of such a DNA vaccine can possibly be enhanced by administering the gene encoding the expression product together with a DNA fragment encoding a polypeptide which has the capability of modulating an immune response.

- 5 One possibility for effectively activating a cellular immune response for a vaccine can be achieved by expressing the relevant antigen in a vaccine in a non-pathogenic microorganism or virus. Well-known examples of such microorganisms are *Mycobacterium bovis* BCG, *Salmonella* and *Pseudomona* and examples of viruses are *Vaccinia Virus* and *Adenovirus*.

10

- Therefore, another important aspect of the present invention is an improvement of the living BCG vaccine presently available, wherein one or more copies of a DNA sequence encoding one or more polypeptide as defined above has been incorporated into the genome of the micro-organism in a manner allowing the micro-organism to express and secrete 15 the polypeptide. The incorporation of more than one copy of a nucleotide sequence of the invention is contemplated to enhance the immune response

Another possibility is to integrate the DNA encoding the polypeptide according to the invention in an attenuated virus such as the vaccinia virus or Adenovirus (Rolph et al 1997).

- 20 The recombinant vaccinia virus is able to replicate within the cytoplasma of the infected host cell and the polypeptide of interest can therefore induce an immune response, which is envisioned to induce protection against TB.

- The invention also relates to the use of a polypeptide or nucleic acid of the invention for 25 use as therapeutic vaccines as have been described in the literature exemplified by D. Lowry (Lowry et al 1999). Antigens with therapeutic properties may be identified based on their ability to diminish the severity of *M. tuberculosis* infection in experimental animals or prevent reactivation of previous infection, when administered as a vaccine. The composition used for therapeutic vaccines can be prepared as described above for vaccines.

30

- The invention also relates to a method of diagnosing TB caused by a virulent mycobacterium in an animal, including a human being, comprising intradermally injecting, in the animal, a polypeptide according to the invention, a positive skin response at the location of injection being indicative of the animal having TB, and a negative skin response at the location of injection being indicative of the animal not having TB.

When diagnosis of previous or ongoing infection with virulent mycobacteria is the aim, a blood sample comprising mononuclear cells (*i.e.* T-lymphocytes) from a patient could be contacted with a sample of one or more polypeptides of the invention. This contacting can 5 be performed *in vitro* and a positive reaction could e.g. be proliferation of the T-cells or release of cytokines such as IFN- γ into the extracellular phase. It is also conceivable to contact a serum sample from a subject with a polypeptide of the invention, the demonstration of a binding between antibodies in the serum sample and the polypeptide being indicative of previous or ongoing infection.

10

- The invention therefore also relates to an *in vitro* method for diagnosing ongoing or previous sensitisation in an animal or a human being with a virulent mycobacterium, the method comprising providing a blood sample from the animal or human being, and contacting the sample from the animal with the polypeptide of the invention, a significant release 15 into the extracellular phase of at least one cytokine by mononuclear cells in the blood sample being indicative of the animal being sensitised. A positive response being a response more than release from a blood sample derived from a patient without the TB diagnosis plus two standard derivations. The invention also relates to the *in vitro* method for diagnosing ongoing or previous sensitisation in an animal or a human being with a 20 virulent mycobacterium, the method comprising providing a blood sample from the animal or human being, and by contacting the sample from the animal with the polypeptide of the invention demonstrating the presence of antibodies recognizing the polypeptide of the invention in the serum sample.
- 25 The immunogenic composition used for diagnosing may comprise 1-20, such as 2-20 or even 3-20 different polypeptides or fusion polypeptides, such as 3-10 different polypeptides or fusion polypeptides.

The nucleic acid probes encoding the polypeptide of the invention can be used in a variety 30 of diagnostic assays for detecting the presence of pathogenic organisms in a given sample. A method of determining the presence of mycobacterial nucleic acids in an animal, including a human being, or in a sample, comprising administering a nucleic acid fragment of the invention to the animal or incubating the sample with the nucleic acid fragment of the invention or a nucleic acid fragment complementary thereto, and detecting the presence 35 of hybridised nucleic acids resulting from the incubation (by using the hybridisation

assays which are well-known in the art), is also included in the invention. Such a method of diagnosing TB might involve the use of a composition comprising at least a part of a nucleotide sequence as defined above and detecting the presence of nucleotide sequences in a sample from the animal or human being to be tested which hybridise with
5 the nucleic acid fragment (or a complementary fragment) by the use of PCR technique.

A monoclonal or polyclonal antibody, which is specifically reacting with a polypeptide of the invention in an immuno assay, or a specific binding fragment of said antibody, is also a part of the invention. The antibodies can be produced by methods known to the person
10 skilled in the art. Polyclonal antibodies can be raised in a mammal, for example, by one or more injections of a polypeptide according to the present invention and, if desired, an adjuvant. The monoclonal antibodies according to the present invention may, for example, be produced by the hybridoma method first described by Kohler and Milstein (1975), or may be produced by recombinant DNA methods such as described in U.S. Pat. No.
15 4,816,567. The monoclonal antibodies may also be isolated from phage libraries generated using the techniques described by McCafferty et al (1990), for example. Methods for producing antibodies are described in the literature, e.g. in US 6,136,958.

A sample of a potentially infected organ may be contacted with such an antibody recognising a polypeptide of the invention. The demonstration of the reaction by means of methods well known in the art between the sample and the antibody will be indicative of an ongoing infection. It is of course also a possibility to demonstrate the presence of antimycobacterial antibodies in serum by contacting a serum sample from a subject with at least one of the polypeptide fragments of the invention and using well-known methods for
25 visualising the reaction between the antibody and antigen.

In diagnostics, an antibody, a nucleic acid fragment and/or a polypeptide of the invention can be used either alone, or as a constituent in a composition. Such compositions are known in the art, and comprise compositions in which the antibody, the nucleic acid fragment or the polypeptide of the invention is coupled, preferably covalently, to at least one other molecule, e.g. a label (e.g. radioactive or fluorescent) or a carrier molecule.

Concordance list

	Protein SEQ ID NO:	DNA SEQ ID NO:	Synonyms
Rv0284	2	1	
Rv0284ct	4	3	
Rv0285	6	5	
Rv0455c	8	7	TB13.7
Rv0569	10	9	TB9.5
Rv1195	12	11	
Rv1386	14	13	
Rv3477	16	15	
Rv3878	18	17	
ORF13A	20	19	
Rv3879c	22	21	
Rv0285-P1	23		
Rv0285-P2	24		
Rv0285-P3	25		
Rv0285-P4	26		
Rv0285-P5	27		
Rv0285-P6	28		
Rv0285-P7	29		
Rv0285-P8	30		
Rv0285-P9	31		
Rv0285-P10	32		
Rv1386-P1	33		
Rv1386-P2	34		
Rv1386-P3	35		
Rv1386-P4	36		
Rv1386-P5	37		
Rv1386-P6	38		
Rv1386-P7	39		
Rv1386-P8	40		
Rv1386-P9	41		
Rv1386-P10	42		
TB9.5-1	43		
TB9.5-2	44		
TB9.5-3	45		
TB9.5-4	46		
TB13.7-1	47		
TB13.7-2	48		
TB13.7-3	49		
TB13.7-4	50		

TB13.7-5	51	
MT3106.1	53	52
Rv0284-P1	54	
Rv0284-P2	55	
Rv0284-P3	56	
Rv0284-P4	57	
Rv0284-P5	58	
Rv0284-P6	59	
Rv0284-P7	60	
Rv0284-P8	61	
Rv0284-P9	62	
Rv0284-P10	63	
Rv0284-P11	64	
Rv0284-P12	65	
Rv0284-P13	66	
Rv0284-P14	67	
Rv0284-P15	68	
Rv0284-P16	69	
Rv0284-P17	70	
Rv0284-P18	71	
Rv0284-P19	72	
Rv0284-P20	73	
Rv0284-P21	74	
Rv0284-P22	75	
Rv0284-P23	76	
Rv0284-P24	77	
Rv0284-P25	78	
Rv0284-P26	79	
Rv0284-P27	80	
Rv0284-P28	81	
Rv0284-P29	82	
Rv0284-P30	83	
Rv0284-P31	84	
Rv0284-P32	85	
Rv0284-P33	86	
Rv0284-P34	87	
Rv0284-P35	88	
Rv0284-P36	89	
Rv0284-P37	90	
Rv0284-P38	91	
Rv0284-P39	92	

Rv0284-P40	93
Rv0284-P41	94
Rv0284-P42	95
Rv0284-P43	96
Rv0284-P44	97
Rv0284-P45	98
Rv0284-P46	99
Rv0284-P47	100
Rv0284-P48	101
Rv0284-P49	102
Rv0284-P50	103
Rv0284-P51	104
Rv0284-P52	105
Rv0284-P53	106
Rv0284-P54	107
Rv0284-P55	108
Rv0284-P56	109
Rv0284-P57	110
Rv0284-P58	111
Rv0284-P59	112
Rv0284-P60	113
Rv0284-P61	114
Rv0284-P62	115
Rv0284-P63	116
Rv0284-P64	117
Rv0284-P65	118
Rv0284-P66	119
Rv0284-P67	120
Rv0284-P68	121
Rv0284-P69	122
Rv3878-P1	123
Rv3878-P2	124
Rv3878-P3	125
Rv3878-P4	126
Rv3878-P5	127
Rv3878-P6	128
Rv3878-P7	129
Rv3878-P8	130
Rv3878-P9	131
Rv3878-P10	132
Rv3878-P11	133

Rv3878-P12	134
Rv3878-P13	135
Rv3878-P14	136
Rv3878-P15	137
Rv3878-P16	138
Rv3878-P17	139
Rv3878-P18	140
Rv3878-P19	141
Rv3878-P20	142
Rv3878-P21	143
Rv3878-P22	144
Rv3878-P23	145
MT3106.1-p1	146
MT3106.1-p2	147
MT3106.1-p3	148
MT3106.1-p4	149
MT3106.1-p5	150
MT3106.1-p6	151
MT3106.1-p7	152
MT3106.1-p8	153
MT3106.1-p9	154
MT3106.1-p10	155
MT3106.1-p11	156
Rv0284-F	157
Rv0284-R	158
Rv0285-F	159
Rv0285-R	160
Rv3878-F	161
Rv3878-R	162
ORF13A-F	163
ORF13A-R	164
Rv1195-F	165
Rv1195-R	166
Rv1386-F	167
Rv1386-R	168
Rv3477-F	169
Rv3477-R	170
TB9.5 15AA from sequencing	171
TB13.7 15AA from sequencing	172

Legends to figures

Figure 1: Stimulation of IFN- γ production by synthetic peptides in PBMC from PPD positive healthy donors. Single peptides were tested at concentrations of 10 μ g, 5 μ g and 2.5 μ g/ml in 200 μ l of cell culture. Pools of peptides were tested at 1 μ g, 0.5 μ g and 0.25 5 μ g/ml of each peptide. Results are presented as pg IFN- γ /ml of the maximum stimulation. Recombinant antigens were included for comparison.

Figure 2A: The antibody response of 48 TB patients to ORF13A evaluated by ELISA. The OD indicated is the mean of two wells coated with 1 μ g/ml ORF13A and the serum is diluted 1:100 in PBS.

Figure 2B: The antibody response of 15 BCG vaccinated healthy donors to ORF13A evaluated by ELISA. The OD indicated is the mean of two wells coated with 1 μ g/ml ORF13A and the serum is diluted 1:100 in PBS.

15

Figure 2C: The antibody response of 19 non BCG-vaccinated healthy donors to ORF13A evaluated by ELISA. The OD indicated is the mean of two wells coated with 1 μ g/ml ORF13A and the serum is diluted 1:100 in PBS.

20 **Figure 3:** Stimulation of T-cell proliferation by synthetic peptides derived from Rv3878. T-cell lines against STCF were derived from PBMC isolated from PPD positive donors. Peptides were tested at 10 μ g and 5 μ g/ml. Results are presented as cpm of the maximum stimulation. n.d = not determined.

Examples

25 **Example 1: Cloning and expression of Rv0284, Rv0285, Rv3878, Rv1195, Rv1386, Rv3477 and ORF13A**

The coding region of Rv0285, Rv3878, the 3'-part (380 bp) of Rv0284 and 5'-part of ORF13A (543 bp of Rv3879c) were amplified by PCR using following primer sets:

30

Rv0284-F: CTG AGA TCT CAG GTA CCG GAT TCG CCG
BglII

35

Rv0284-R: CTC CCA TGG TCA TGA CTG ACT CCC CTT
NcoI

Rv0285-F: CTG AGA TCT ATG ACG TTG CGA GTG GTT
BglII

5 **Rv0285-R:** CTC CCA TGG TCA GCC GCC CAC GAC CCC
NcoI

Rv3878-F: CTG AGA TCT GCT ACT GTT AAC AGA TCG
BglIII

10

Rv3878-R: CCG CTC GAG CTA CAA CGT TGT GGT TGT
XbaI

15

ORF13A-F: CCC AAG CTT ATG AGT ATT ACC AGG CCG
HindIII

ORF13A-R: CTC CCA TGG TCA CGA CTT CTG CTG AAG CAA
NcoI

20

PCR reactions contained 10 ng of *M. tuberculosis* H37Rv DNA in 1x low salt Taq⁺ buffer from Stratagene supplemented with 250 μM of each of the four nucleotides (Boehringer Mannheim), 0.5 mg/ml BSA (IgG technology), 1% DMSO (Merck), 5 pmoles of each primer and 0.5 unit Taq⁺ DNA polymerase (Stratagene) in 10 μl reaction volume. Reactions were initially heated to 94°C for 15 sec, followed by 30 cycles of 94°C for 30 sec, 55°C for 30 sec and 72°C for 90 sec, and finally by 72°C for 5 min.

30

The PCR fragments were cloned into the TA cloning vector pCR2.1 (Invitrogen) and then transferred to the pMCT3 expression vector at the restriction sites indicated by the primers above. The coding regions of Rv1195, Rv1386 and Rv3477 were amplified by PCR using the following primer sets:

Rv1195-F: gggg ACA AgT TTg TAc AAA AAA gCA ggC TTA gTgTCTTTCgTgATggCATACC
 Rv1195-R: gggg AC CAC TTT gTA CAA gAA AgC Tgg gTC CTA TTAgCTggCCgCCgC

35

Rv1386-F: gggg ACA AgT TTg TAc AAA AAA gCA ggC TTA gTgACgTTgCgAgTCgTTCC
 Rv1386-R: gggg AC CAC TTT gTA CAA gAA AgC Tgg gTC CTA TAgCCCACCgCTgAgATACg

Rv3477-F: gggg ACA AgT TTg TAc AAA AAA gCA ggC TTA gTgTCTTTCACTgCgCAACCG

40

Rv3477-R: gggg AC CAC TTT gTA CAA gAA AgC Tgg gTC CTA gCCggTgACCACAgCgTT

PCR reactions were carried out by Platinum® Tag DNA Polymerase (GIBCOBRL®) in 50 µl reaction volume containing 60 mM Tris-SO₄ (pH 8.9), 18 mM Ammonium Sulfate, 0.2 mM of each of the four nucleotides, 0.2 µM of each primer and 10 ng of M. tuberculosis H37Rv DNA. The reaction mixtures were initially heated to 95°C for 5 min, followed by 35 cycles

5 of 95°C for 45 sec, 60°C for 45 sec and 72°C for 2 min, and finally by 72°C for 15 min.

The PCR products were precipitated by PEG/MgCl₂, and then dissolved in 50 µl of TE buffer. DNA fragments were then cloned and expressed in Gateway™ Cloning system (GIBCOBRL®). First, to create Entry Clones, 5 µl of each DNA fragment was mixed with 1 µl of pDONR201, 2 µl of BP CLONASE Enzyme Mix and 2 µl of BP Reaction Buffer. The 10 recombination reactions were carried out at 25°C for 60 min. After degrading the Enzymes by Proteinase K at 37°C for 10 min, 5 µl of each sample was used to transform E. coli DH5α competent cells. The transformants were selected on LB plates containing 50 µg/ml kanamycin. Second, to create Expression clones, 2 µl of each Entry Clone DNA was mixed with 1 µl of the expression vector, pDest17, 2 µl LR reaction buffer and 2 µl LR 15 CLONASE Enzyme Mix in a total volume of 10 µl. After the recombination reaction at 25°C for 60 min and proteinase K treatment at 37°C for 10 min, 5 µl of the samples were used to transform E. coli BL21-SI competent cells. The transformants were selected on LBON (LB without NaCl) plates containing 100 µg/ml ampicillin. The resulting recombinant antigens carried 6-histidine residues at the N-terminal. All clones were confirmed by DNA 20 sequencing.

To express his-tagged recombinant antigens in pMCT3 vector, 100 ml of an overnight culture of XL-1 blue carrying the plasmid construct was added to 900 ml of LB-media containing 100 µg/ml ampicillin, grown at 37°C with shaking. 1 mM IPTG was added at 25 OD₆₀₀ = 0.4-0.6 and the culture was incubated for additional 3 - 16 hours before harvesting of cells.

To express his-tagged recombinant antigens in pDest17, BL21-SI cells were cultured in LBON medium at 30°C and the induction of recombinant antigen synthesis was achieved 30 by adding 0.3 M NaCl to the medium at OD600 = 0.4-0.6, and cells were harvested 3 hours later.

For purification, the cell pellet was resuspended in 20 ml of Sonication buffer (20 mM Tris-Cl, pH 8.0, 0.5 M NaCl, 10% Glycerol, 5 mM β-ME, 0.01% Tween 20 and 1 mM imida-

zole). Cells were lysed and DNA was digested by treating with lysozyme (0.1 mg/ml) and DNase I (2.5 µg/ml) at room temperature for 20 min with gentle agitation. The recombinant protein was brought to solution by adding 80 ml of Sonication Buffer containing 8 M urea and sonicated the sample 5 x 30 sec, with 30 sec pausing between the pulses.

- 5 After centrifugation, the lysate was applied to a 5 ml TALON column (Clonetech). The column was then washed with 25 ml of urea containing Sonication buffer, and the bound protein was eluted by imidazole steps (5, 10, 20, 40 and 100 mM) in the same buffer. The fractions were analyzed by silver stained SDS-PAGE, and recombinant protein containing fractions were pooled. Further purifications were achieved either by anion- and cation-
- 10 exchange chromatography on Hitrap columns (Pharmacia, Uppsala, Sweden) or by electroelution as described below: The pooled TALON fractions were dialyzed against 3 x 1 L of 10 mM Tris-Cl (pH 8.0), 0.15 M NaCl and 0.1% SDS. Two mg of TALON purified recombinant antigen was subjected to SDS-PAGE on a 16 x 16 cm gel. After separation, the recombinant antigen band was cut out and the protein was eluted by a Model 422
- 15 Electro-Eluter (Bio-Rad). SDS was removed from eluted protein by Chloroform/Methanol extraction.

Example 2: Biological activity of the recombinant antigens.

The purified recombinant proteins were screened for the ability to induce a T cell response measured as IFN- γ release and/or cell proliferation. A preliminary screening involved testing of the IFN- γ induction and/or cell proliferation of T cell lines generated from PPD positive donors. This test was followed by measuring the response in PBMC preparations obtained from TB patients, PPD positive as well as negative healthy donors.

Interferon- γ induction and cell proliferation of T cell lines:

- 25 **Human donors:** PBMC were obtained from healthy donors with a positive *in vitro* response to PPD.

T cell line preparation: T cell lines were prepared by culturing 5 x 10⁶ freshly isolated PBMC/ml with viable *M. tuberculosis* at a ratio of 5 bacteria per macrophage in a total volume of 1 ml. The cells were cultured in RPMI 1640 medium (Gibco, Grand Island, N.Y) supplemented with HEPES, and 10% heat-inactivated NHS. After 7 days in culture at 37°C and 5% CO₂, T cells were supplemented with 50 U/ml of r-IL-2 (Boehringer Mannheim) for approximately 7 days. Finally, in one experiment (Table 1), the T cell lines were

tested for reactivity against the recombinant antigens by stimulating $1\text{-}5 \times 10^5$ cells/ml with 5 µg/ml of PPD, 3 µg/ml of rRv0284ct (C-terminal part), 5 µg/ml of rRv0285, and 2.5 µg/ml of rRv3878 in the presence of 5×10^5 autologous antigen-presenting cells/ml. In another experiment (Table 1a), T cells were stimulated with 5 µg/ml and 1 µg/ml of each recombinant antigen indicated in the table. No ag and PHA were used as negative and positive controls, respectively. The supernatants were harvested after 4 days of culture and stored at -80°C until the presence of IFN-γ were analysed.

Cytokine analysis: Interferon-γ (IFN-γ) was detected with a standard sandwich ELISA technique using a commercially available pair of monoclonal antibodies (Endogen, MA, US) and used according to the manufacturer's instructions. Recombinant IFN-γ (Endogen, MA, US) was used as a standard. All data are means of duplicate wells and the variation between the wells did not exceed 10 % of the mean. Responses obtained with five T cell lines are shown in Table 1 and Table 1a.

15

T-cell proliferation assays: After removal of supernatant for IFN-γ assays, 0.5 µCi of [methyl-3H]thymidine were added to the same wells supplemented with 10% NHS in RPMI for another 16-20 hours. The cells were thereafter harvested with a Skatron cell harvester onto filter mats, dried, and immersed in scintillation fluid before reading the incorporation of thymidine on a beta liquid scintillation counter (Wallac). Results from 3 T cell lines are shown in Table 1b.

As shown in Table 1, high levels of IFN-γ release are observed after stimulation with the recombinant antigens ranging from 33% (rRv0284ct) to 83% (rRv3878) of the response seen after stimulation with PPD. The antigenicity of the recombinant antigens was confirmed by three additional T-cell lines as shown in Table 1a and Table 1b.

Table 1. Stimulation of two T cell lines with recombinant rRv0284ct, rRv0285, and rRv3878. Responses to PHA and PPD are shown for comparison. Results are presented 30 as pg IFN-γ/ml.

T cell line

Donor	No ag	PHA (1 µg/ml)	PPD (5 µg/ml)	rRv0284ct (3 µg/ml)	rRv0285 (5 µg/ml)	rRv3878 (2.5 µg/ml)
1	50	2975	2742	914	2019	1072
2	50	1482	803	352	548	667

Table 1a. Stimulation of three T cell lines with rRv0285 and rRv3878. Responses to PHA and PPD are shown for comparison. Results are presented as pg IFN- γ /ml of the maximum stimulation in the presence of either 5 μ g/ml or 1 μ g/ml of recombinant antigens.

T cell line

Donor	No ag	PHA (1 μ g/ml)	PPD (5 μ g/ml)	rRv0285	rRv3878
3	136	4467	2425	1189	504
4	2	1996	1175	626	413
5	4	5410	4490	2804	2034

5

Table 1b. Stimulation of T cell proliferation by rRv0285 and rRv3878. Results are presented as Stimulation Index (SI). The maximum stimulation in the presence of either 5 μ g/ml or 1 μ g/ml of recombinant antigens is given.

Donor	rRv0285	rRv3878
3	8.4	N.D
4	5.8	4.3
5	31.3	16.1

10

Interferon- γ release from PBMC isolated from human TB patients and PPD positive and negative healthy donors

Human donors: PBMC were obtained from healthy donors with a positive *in vitro* response to purified protein derivative (PPD) or non-vaccinated healthy donors with a negative *in vitro* response to PPD. PBMC were also obtained from TB patients with microscopy or culture proven infection. Blood samples were drawn from TB patients 0-6 months after diagnosis.

Lymphocyte preparations and cell culture: PBMC were freshly isolated by gradient centrifugation of heparinized blood on Lymphoprep (Nycomed, Oslo, Norway) and stored in liquid nitrogen until use. The cells were resuspended in complete RPMI 1640 medium (Gibco BRL, Life Technologies) supplemented with 1% penicillin/streptomycin (Gibco BRL, Life Technologies), 1% non-essential-amino acids (FLOW, ICN Biomedicals, CA, USA), and 10% heat-inactivated normal human AB serum (NHS). The viability and number of the cells were determined by Nigrosin staining. Cell cultures were established with 1.25×10^5 PBMCs in 100 μ l in microtitre plates (Nunc, Roskilde, Denmark) and stimulated with 5 μ g/ml PPD or rRv0284ct and rRv3878 in a final concentration of 2.5 and 5 μ g/ml, respectively; or with 2.5 and 10 μ g/ml of rRv0285, Rv1195, rRv1386 and Rv3477. No antigen (No ag) was used as a negative control, whereas phytohaemagglutinin (PHA) was

used as a positive control. Moreover, the response to a well-known TB-specific protein, ESAT-6, was included for comparison. Supernatants for the analysis of secreted cytokines were harvested after 5 days of culture, pooled, and stored at -80 °C until use.

5 **Cytokine analysis:** IFN- γ was detected as above. Responses obtained with PBMCs from 14 individual donors are shown in Table 2.

As shown in Table 2, stimulation of PBMC from TB patients as well as PPD positive donors with rRv0284ct and rRv3878 resulted in a marked release of IFN- γ with 55% of the 10 donors recognizing the recombinant antigens at a level of more than 500 pg/ml. As expected, none of the recombinant antigens gave rise to IFN- γ release in PPD negative donors. The effects of stimulating with rRv0285, rRv1386, rRv1195 and rRv3477 on IFN- γ release in PBMC are demonstrated in Table 2a.

Table 2. Stimulation of PBMCs from 4 TB patients, 7 PPD positive healthy donors, and 3 PPD negative healthy donors with recombinant antigen. Responses to PHA, PPD, and ESAT6 are shown for comparison. Results are given as pg IFN- γ /ml.

TB patients

Donor	No ag	PHA (1 μ g/ml)	PPD (5 μ g/ml)	ESAT-6 (5 μ g/ml)	rRv0284ct (2.5 μ g/ml)	rRv3878 (5 μ g/ml)
1	3	4541	4074	2154	809	3
2	92	3408	4891	611	236	2029
3	5	5282	4647	2827	308	149
4	10	4531	2077	38	140	287

5

PPD positive healthy donors

Donor	No ag	PHA (1 μ g/ml)	PPD (5 μ g/ml)	ESAT-6 (5 μ g/ml)	rRv0284ct (2.5 μ g/ml)	rRv3878 (5 μ g/ml)
1	74	5413	3339	0	382	77
2	14	5614	3852	198	1324	633
3	7	6165	5808	4	2951	2732
4	63	6532	6314	1567	3009	3482
5	43	4733	6195	1272	5166	2589
6	5	3809	2582	15	5	71
7	31	6716	2275	424	1449	832

PPD negative healthy donors

Donor	No ag	PHA (1 μ g/ml)	PPD (5 μ g/ml)	ESAT-6 (5 μ g/ml)	rRv0284ct (2.5 μ g/ml)	rRV3878 (5 μ g/ml)
1	0	3354	113	0	269	17
2	0	3803	563	0	22	0
3	0	3446	525	10	203	34

10

Table 2a. Stimulation of IFN- γ production by rRv0285, rRv1386, rRv1195 and rRv3477 in PBMC from PPD negative controls, PPD positive healthy donors as well as TB patients. TB10.4 was included for comparison.

Donor	No ag	PPD	Rv0285	Rv1386	Rv1195	Rv3477	TB10.4
PPD negative							
healthy donors¹⁾							
K150	12	265	0	5	2	3	0
K151	22	50	0	nd	nd	nd	10
K156	17	522	0	166	86	71	2
K159	27	155	1	16	12	19	3
K160	16	242	6	62	9	26	4
K161	35	510	2	40	23	33	0
K162	31	352	89	71	nd	0	9
TB-patients							
98-160	5	>5549	nd	2885	nd	nd	nd
99-203	0	2232	914	nd	nd	nd	903
99-208	2	4098	317	186	nd	11	8
00-199	11	2592	456	nd	nd	nd	3116
00-211	0	10633	2533	2862	1814	1243	4161
00-217	22	4140	124	57	nd	66	535
00-218	0	1578	21	28	nd	13	38
00-220	18	9476	77	106	437	34	3063
00-222	28	9824	2226	1071	226	44	3600
00-223	89	10412	2458	nd	nd	nd	4537
PPD positive							
healthy donors							
K119	0	7464	227	296	nd	111	585
K131	29	1730	1777	20	17	31	7
K147	86	4520	18	79	47	26	12
K148	52	8293	78	11	86	58	3843
K149	72	12730	932	243	nd	489	38
K152	96	6120	0	946	40	517	1303
K153	5	12391	2	467	nd	622	709
K155	5	9397	0	9	15	37	973
K167	105	15770	3531	1811	nd	nd	4881
k172	10	18811	21420	4	3717	10	110
K174	3	1443	492	44	56	17	160
KTB1	34	13748	3067	1307	nd	nd	9431
KTB2	23	8104*	391	nd	nd	nd	2237
KTB10	4	2394*	292	nd	nd	nd	46
L	46	7832*	949	nd	nd	nd	349
C	33	6538	303	3	255	116	5

¹⁾ IFN- γ median=13294 pg/ml on stimulation with PHA . * IFN- γ on stimulation with STCF

BMC from 6 additional TB patients were obtained, and the T-cell stimulatory effect of rRv1195 was also tested in these PBMCs. The results are shown in Table 2b.

Table 2b Stimulation of IFN- γ production by rRv1195 in PBMCs from six TB patients.

Donor	No ag	PPD	Rv1195
97-83	42	>3531	1060
97-138	13	>3366	231
98-149	256	>3449	2855
99-163	45	>2303	422
01-226	68	>3994	2133
PT36	342	1510	411

Together, these analyses using PBMC and T cell lines, respectively, indicate that rRv0284ct, rRv0285, rRv1386 and rRv3878 are highly biologically active and frequently
 5 recognized by PPD positive donors and TB patients. Though less frequently recognized by these donors rRv1195 and rRv3477 are additionally highly biologically active.
 As is expected, due to the genetical heterogeneity of the human population some of the recombinant antigens are recognized more frequently and to a higher level than others are.

10

Skin test reaction in TB infected guinea pigs

The skin test reactivity of the recombinant antigens was tested in *M. tuberculosis* infected guinea pigs. A group of 5 female outbred guinea pigs of the Dunkin Hartley strains (Møllegaard Breeding and Research Center A/S, Lille Skensved, Denmark) were infected by the aerosol route in an exposure chamber of a Glas-Col® Inhalation Exposure System, which was calibrated to deliver approximately 20-25 *M. tuberculosis* Erdman bacilli into the lungs of each animal. As a control, the skin test reactivity of uninfected guinea pigs was tested. Skin tests were performed 28 days after infection with injection of 5 µg of
 15 rRv0284ct, rRv0285, and rRv3878. As a positive control, the guinea pigs were sensitised with 10 tuberculin units (TU) of PPD (1TU = 0.02 µg) whereas injection of phosphate-buffered saline (PBS) was used as a negative control. Skin test responses (diameter of erythema) were read 24 h later by two experienced examinators and the results were expressed as the mean of the two readings. The variation between the two readings was
 20 less than 10%. Skin test responses larger than 5 mm were regarded as positive.
 25

As seen in Table 3, injection of rRv3878 induced a marked Delayed Type Hypersensitivity (DTH) reaction at the same level as after injection with PPD. rRv0284ct and rRv0285 resulted in a highly significant DTH reaction ($P < 0.005$; Tukey test). As expected, none of
 30 the antigens induced non-specific response in uninfected guinea pigs (Table 4).

Table 3. DTH erythema diameter (shown in mm) in guinea pigs aerosol infected with *M. tuberculosis* after stimulation with recombinant antigens.

Antigen ^a	Skin reaction (mm) ^b	SEM
PBS	3.10	0.30
PPD	13.10	1.18
rRv0284ct	8.40	0.45
rRv0285	7.00	1.08
rRv3878	14.56	1.05

^a The recombinant antigens were tested in a concentration of 5 µg, whereas 10 TU of PPD were used.

^b The skin reactions are measured in mm erythema 24 h after intradermal injection. The values are the mean of erythema diameter of five animals and the SEM are indicated. The values for rRv3878 are the mean of four animals.

Table 4. DTH erythema diameter (shown in mm) in non-infected guinea pigs after stimulation with recombinant antigens.

Antigen ^a	Skin reaction (mm) ^b	SEM
PBS	2.60	0.36
PPD	3.00	0.44
rRv0284ct	2.5	0.18
rRv0285	3.45	0.74
rRv3878	2.5	0.18

^a The recombinant antigens were tested in a concentration of 5 µg, whereas 10 TU of PPD were used.

^b The skin reactions are measured in mm erythema 24 h after intradermal injection. The values are the mean of erythema diameter of five animals and the SEM are indicated.

Example 3: Immunological response to synthetic polypeptides

5

Peptide synthesis: Ten overlapping peptides to Rv0285 and Rv1386 respectively, were synthesized. Synthetic polypeptides were purchased from Mimotopes Pty Ltd. The peptides were synthesized by Fmoc solid phase strategy. No purification steps were performed. Lyophilised peptides were stored dry until use.

10

Rv0285 peptides:

Rv0285-P1	TLRVVPEGLAAASAAVEA
Rv0285-P2	ASAAVEALTARLAAAHAS
15 Rv0285-P3	TARLAAAHASAAPVITAV
Rv0285-P4	AAPVITAVVPPAADPVSL
Rv0285-P5	PAADPVSLQTAAGFSAQG
Rv0285-P6	AAGFSAQGVHAAVTAEG
Rv0285-P7	HAAVTAEGVEELGRAGVG
20 Rv0285-P8	GVEELGRAGVGVGESGAS
Rv0285-P9	GVGESGASYLAGDAAAAAA
Rv0285-P10	SYLAGDAAAATYGVGG

Rv1386 peptides:

	Rv1386-P1	TLRVVPESLAGASAAIEA
5	Rv1386-P2	ASAAIEAVTARLAAAHA
	Rv1386-P3	TARLAAAHAAPFIAAV
	Rv1386-P4	AAPFIAAVIPPGSDSVS
	Rv1386-P5	PGSDSVSCNAVEFSVHG
	Rv1386-P6	AVEFSVHGSQHVAMAAQG
10	Rv1386-P7	HVAMAAQGVVEELGRSGVG
	Rv1386-P8	GVEELGRSGVGVAESGAS
	Rv1386-P9	GVAESGASYAARDALAAA
	Rv1386-P10	SYAARDALAAASYLSGGL

15 **PBMC culture and IFN- γ assay:** PBMC were isolated and cultured as described in Example 2. Single peptides were tested at concentrations of 10 μ g, 5 μ g and 2.5 μ g/ml in 200 μ l of cell culture. Pools of peptides were tested at 1 μ g, 0.5 μ g and 0.25 μ g/ml of each peptide. IFN- γ levels were measured by the method described in Example 2.

20 **PBMC recognition of peptides from Rv0285 and Rv1386**

The ability of these peptides to induce IFN- γ production in PBMC was assayed. The results from three PPD positive healthy donors (referred to as KTB1, KTB10 and K172, respectively) are shown in Fig.1. The pools of peptides from Rv0285 (referred to as Rv0285 p1 – Rv0285 p10) stimulated IFN- γ production in PBMC from all three donors. This is 25 consistent with the results obtained with recombinant Rv0285 (Table 2a and Fig.1). When tested singly, seven peptides were recognized by the three donors, indicating the presence of multiple immunogenic portions scattered through out the protein sequence of Rv0285.

30 The pools of peptides from Rv1386 and recombinant Rv1386 stimulated IFN- γ production in PBMC from two of the three donors. Four of the peptides were also positive when tested as single peptides. The synthetic peptides were also tested in PBMC from two PPD negative controls; as expected, no stimulation of IFN- γ production was detected for these donors (results not shown).

35

Example 3a: PBMC recognition of peptides derived from MT3106.1

A BLAST-P search of the GMT.pep database at TIGR CMR revealed an open reading frame which is highly related to Rv0285. This ORF is designated MT3106.1, and the pre-

dicted initiation codon is 33 codons upstream of the corresponding initiation codon in Rv0285. Amino acid sequence alignment revealed that the Rv0285-corresponding part of MT3106.1 has 80% sequence identity to the former, and a peptide fragment spanning residues 2 –29 on Rv0285 is 100% conserved on Mt3106.1. This segment of peptide 5 contains at least 2 distinct T-cell epitopes as demonstrated by the results in Fig. 1 (Rv0285-p1 and Rv0285-p2, respectively). Eleven additional overlapping peptides of MT3106.1 (MT3106.1-p1 - MT3106.1-p11, SEQ ID NO 146-156) were synthesized and analyzed for their ability to induce IFN- γ production in PBMCs from donor K172. Peptide MT3106.1-p7 was highly reactive and stimulated IFN- γ production to a level of 12079 10 pg/ml, which corresponds to 87% of the activity obtained with PPD.

PBMC from 6 additional TB patients were obtained, and the T-cell stimulatory effect of rRv1195 was also tested in these PBMCs. The results are shown in Table 2b.

15 **Example 3b. Recognition of synthetic peptides by T-cell lines derived from PBMC of PPD positive subjects.**

Non-overlapping peptides (Rv0284-p1 - Rv0284-p69, SEQ ID NO 54-122) were synthesized for the part of Rv0284 that was not included in rRv0284ct. Peptides were tested as 20 pools consisting of 2 or 3 peptides each. T-cell stimulatory effects were seen in a number of peptide pools. The largest effects on stimulation of IFN- γ release were obtained with peptide pools containing Rv0284-p3, Rv0284-p4, Rv0284-p7, Rv0284-p8, Rv0284-p9, Rv0284-p13, Rv0284-p17, Rv0284-p18, Rv0284-p19, Rv0284-p27, Rv0284-p37, Rv0284-p41, Rv0284-p42, Rv0284-p43, Rv0284-p47, Rv0284-p50, Rv0284-p51, 25 Rv0284-p52, and Rv0284-p53.

Twenty-three overlapping peptides were synthesised for Rv3878 (Rv3878-p1 - Rv3878-p23, SEQ ID NO 123-145). An initial screening of the peptides in four T-cell lines revealed a number of T-cell epitopes (Fig. 3).

30

Example 4: Identification of TB9.5 and TB13.7

Short-time culture filtrate (ST-CF) was produced from living *Mycobacterium tuberculosis* as previously described and used as an antigen source (Andersen, P. et al 1991). In brief, 35 ST-CF was produced by growing *M. tuberculosis* H37Rv (4×10^6 CFU/ml) on modified

Sauton medium in an incubator at 37 °C at gentle agitation for 7 days. The culture supernatant was steril-filtered and concentrated on a Amicon YM3 membrane. The culture filtrate was hereafter precipitation with 80 % ammonium sulphate and the precipitated proteins were removed by centrifugation and after washing resuspended in buffer containing

5 8 M urea, CHAPS 0.5% (w/v) and 5% glycerol. 250 mg of protein was separated on the Rotofor Isoelectrical Cell (Bio-Rad) in a pH gradient with 3% Biolyt 3/5 and 1% Biolyt 4/6. Fraction 3-8 were pooled, concentrated and buffer exchanged to PBS on a Centriprep concentrator with a 3 kDa cut off membrane. 100 ug of protein was separated by two-dimensional electrophoresis by applying the sample on immobilized pH 4-7 linear gradient

10 13 cm strips (Amersham Pharmacia Biotech) and the focusing was performed at 500 V for 1 hour, 1000 V at 1 hour followed by 2 hours at 8000 V in a IPGphor unit. The second dimension was performed in 10-20% SDS-PAGE gradient gels in the protean IIxi system (Bio-Rad). The proteins were transferred to a PVDF membrane which was stained for by Coomassie brilliant Blue and two spots was excised and subjected to N-terminal se-

15 quencing analysis by automated Edman degradation using a Procise 494 sequencer (Applied Biosystems) as described by the manufacturer.

Sequence analysis and peptide synthesis

The two spots were named TB9.5 and TB13.7. For each of the two protein spots a sequence of 15 amino acids was obtained.

- 20 For TB9.5: MKAKVGDILVIKGAT (SEQ ID NO 171)
For TB13.7: DSTEDFPIPXRMXAT (SEQ ID NO 172)
"X" denotes an amino acid, which could not be determined.

The two sequences were used for a homology search using the BLAST program on the

25 *M. tuberculosis* database: <http://genolist.pasteur.fr/TubercuList/>. For TB9.5 the 15 determined amino acids was 100% identical to the sequence of Rv0569, which is an 88 amino acids long protein. For TB13.7 the 13 determined amino acids was 100% identical to the sequence of Rv0455c. The 13 N-terminally determined amino acids starts at amino acids 31 in the predicted sequence of Rv0455c, indication the presence of a signal peptide,

30 which has been cleaved off. This is in agreement with the prediction of a signal peptide in Rv0455c by database analysis of the amino acids sequence using the program Signal P at <http://www.cbs.dtu.dk/services/SignalP/>, which also predicts the most likely cleavage site between position 30 and 31.

Overlapping peptides was produced for the mature version of each of the two proteins by Schafer-N, Copenhagen, Denmark as indicated below. The peptides were synthesized on polyamide resins using Fmoc-strategy and purified by reverse phase HPLC on C18-
5 columns in water/acetonitrile gradients containing 0.1%TFA (trifluoracetic acid). Purified peptides were lyophilized and stored dry until reconstitution in PBS.

TB9.5-1: MKAKVGDWLVIKGATIDQPDHRGLIIEVRS

TB9.5-2: HRGLIIEVRSSDGSPPYVVRWLETDHVATV

10 TB9.5-3: VRWLETDHVATVIPGPDAVVAATAEEQNAAD

TB9.5-4: VTAAEQNAADERAQHRGAVQSAILHARGT

TB13.7-1: DSTEDFPIPRRMIATTCDAEQYLA AVR DTS

TB13.7-2: QYLA A VRDTSPVYYQRYMIDFNNHANLQQQA

15 TB13.7-3: FNNHANLQQATINKAHWF FSLSPAERRDYS

TB13.7-4: LSPAERRDYSEHFYNGDPLTFAWVN HMKIF

TB13.7-5: FAWVN HMKIFFNNKGVVA KGTEVCNGY

Immunological activity of TB9.5 and TB13.7

The immunological relevance of the peptides in TB patients was tested by analysing the
20 ability of the peptides to induce an IFN- γ production or a cell proliferation on PBMC iso-
lated from human TB patients and PPD negative healthy controls (table 5 and table 7).
The TB9.5 peptides were in addition tested for ability to induce IFN- γ and cell proliferation
on T cell lines generated from TB patients driven by ST-CF or *M. tuberculosis* sonicate
(table 6). Lymphocyte preparation and T-cell lines generation were performed as de-
25 scribed in example 2.

Table 5: Stimulation of PBMC from three TB patients and three PPD negative healthy controls with pools of synthetic peptides from TB9.5 and TB13.7 in total of 10 ug/ml. 2.5 ug/ml of each peptide TB9.5-1, TB9.5-2, TB9.5-3 and TB9.5-4 were pooled and tested as TB9.5. 2 ug/ml of each peptide TB13.7-1, TB13.7-2, TB13.7-3, TB13.7-4 and TB13.7-5 were pooled and tested as TB13.7. The response to 5 ug/ml ST-CF is shown for comparison. Results are presented as pg IFN- γ /ml.

Antigen	TB patients			Healthy controls		
	PT1	PT2	PT3	H1	H2	H3
Control	0	0	0	9	10	0
ST-CF	4803	11810	3221	28	10	0
TB9.5 10ug/ml	38	59	479	39	0	2
TB9.5 2.5ug/ml	37	56	115	9	7	40
TB13.7 10ug/ml	160	36	29	5	15	13
TB13.7 2.5ug/ml	131	54	70	15	0	0

Pools of the peptides are tested on PBMC purified from human TB patients and healthy controls as seen in table 5. The pools of peptides from TB9.5 were recognized more frequently by TB patients than by the healthy controls. This demonstrates that a positive response is specific for TB patients. TB13.7 was also recognized more frequently by the 5 tested TB patients compared to the healthy controls. It is to be expected that not all of the patients recognized each of the peptide pools, due to the genetically heterogeneity of the human population.

Interestingly, it was not the same patient recognizing the two peptide pools indication that 10 the use of a combination of two peptide pools could be superior compared to using the single peptide pools.

The peptides from TB9.5 was in addition tested for ability to induce an IFN- γ response or cell proliferation on five T cell lines derived from TB patients (table 6). TB9.5-1 was positive in most of the tested T-cell lines demonstrating the presence of one or more broadly 15 recognized T cell epitope within this sequence (table 6). Furthermore, TB9.5-2, TB9.5-3 and TB9.5-4 were positive in at least one out of the five T cell lines tested demonstrating that these sequences also contains at least one T cell epitope. The presence of multiple

epitopes in the TB9.5 protein makes the full-length protein or peptides derived hereof an attractive candidate for a TB vaccine.

Tabel 6: Stimulation of five T cell lines derived from TB patients with synthetic overlapping peptides from TB9.5. Results are presented as pg IFN- γ /ml and cell proliferation. The peptides are tested in 1ug/ml and 10ug/ml and results are shown for the concentration given the highest response. The response to 5 μ g/ml ST-CF is shown for comparison.

Antigen	T-cell line 1		T-cell line 2		T-cell line 3		T-cell line 4		T-cell line 5	
	IFN- γ	CPM								
Control	133	1359	0	184	120	397	62	2550	9	333
ST-CF	4581	26296	3552	21239	2748	12118	2860	18624	4294	29736
TB9.5-1	1438	9116	407	3987	512	1749	42	2033	17	1252
TB9.5-2	3	919	341	3395	69	606	20	1718	10	322
TB9.5-3	26	1145	120	1859	88	537	49	2410	1	331
TB9.5-4	86	2556	519	3887	219	839	28	2860	3	1036
TB9.5-pool	208	3544	52	1825	127	831	6	1738	2	626

Table 7: Stimulation of PBMCs from two TB patients and two healthy controls with synthetic peptides from the TB13.7 protein. Responses to PPD are given for comparison. Control is stimulation without antigen. Results are given as pg IFN- γ /ml

Antigen/ conc.		TB patients		Healthy controls	
Control		PT1	PT2	H1	H2
PPD	5 μ g/ml	5549	1269	1570	11
13.7-1	10 μ g/ml	20	2	26	42
13.7-1	2.5 μ g/ml	6	1	23	47
13.7-2	10 μ g/ml	7	2	21	55
13.7-2	2.5 μ g/ml	5	3	21	49
13.7-3	10 μ g/ml	11	4	20	54
13.7-3	2.5 μ g/ml	10	2	28	45
13.7-4	10 μ g/ml	8	7	15	24
13.7-4	2.5 μ g/ml	8	6	16	30
13.7-5	10 μ g/ml	648	5	18	27
13.7-5	2.5 μ g/ml	205	7	22	29

The 13.7 peptides were tested on PBMC isolated from two TB patients and two healthy controls. As seen in table 7 one of the two TB patients recognized peptide TB13.7-5 while

no of the healthy controls recognized any of the peptides tested. This demonstrates that an epitope is presence in peptide TB13.7-5, but does not rule out the presence of epitopes in any of the other peptides. To demonstrate this it would be necessary to test a higher number of TB patients due to the genetically heterogeneity of the human population.

5

The expression of TB 9.5 is induced under low oxygen conditions

Immunogenic proteins may be identified by the means of their upregulation *in vivo* or in environments which reflects the *in vivo* situation. This may be different stress situations
10 such as low oxygen. To investigate the upregulation of *M. tuberculosis* proteins during low oxygen conditions the following experiments were performed: *M. tuberculosis* H37Rv (ATCC 27240) was cultured in Sauton medium enriched with 0.5 % sodium pyruvate and 0.5 % glucose. Sterile 10 ml (Nunc, Roskilde, Denmark) polystyrene tubes or 125 ml polycarbonate Erlenmeyer flasks (Corning, Acton, MA, USA) containing 6.7 ml or 20 ml of
15 medium, respectively, was inoculated with 2×10^6 bacteria per ml. Erlenmeyer flasks were placed in a standard 37°C shaking incubator (normal cultures), whereas tubes with tightly screwed caps (low oxygen cultures) were placed at 37°C under magnetic stirring at 100 rpm. After 3 h metabolic labelling was performed by addition of 10 µCi/ml of L-[³⁵S]-methionine and L-[³⁵S]cysteine (Redivue Promix, Amersham Pharmacia Biotech, Buck-
20 ingtonshire, United Kingdom). After 19 h, bacteria were harvested by centrifugation, and the medium was collected. The bacterial pellet was washed once in PBS, pH 7.4, and re-suspended in 300 µl of a suspension containing equal volumes of 0.1 mm glass beads and PBS, pH 7.4, added 0.1 % SDS and 1 mM PMSF. The bacteria were lysed for 5 min at maximum speed on a MS2 minishaker (IKA Works inc., Wilmington, NC). 20 µl of the
25 lysates was analysed by two-dimensional gel electrophoresis (2-D PAGE): Samples were applied to 13 cm IPG pH 4-7L strips (Amersham Pharmacia Biotech, Uppsala, Sweden) during rehydration according to the manufacturer's instructions. Focusing started at 500 V (1 h), was increased to 1000 V (1 h), and finally to 8000 V (2 h) in an IPGphor unit (Amersham Pharmacia Biotech). The second dimensional separation was performed in 10-20 %
30 SDS-PAGE gradient gels in the Protean Ixxi system (Bio-Rad, Richmond, CA, USA). The gel was blotted to PVDF membrane, and the membrane was exposed to Biomax MR film (Kodak, Rochester, NY, USA) for 3-21 days. The autoradiographs were scanned and analysed by the Phoretix 2D gel analysis software (Non Linear Dynamics, Newcastle upon Tyne, United Kingdom). Spots which showed more than two-fold induction under low
35 oxygen conditions compared to normal cultures were selected. A spot with observed

mass of approx. 12 kDa and pI of 6.3 was found to be induced under low oxygen conditions. For identification of this spot, 35 µl of the low oxygen lysate was analysed by 2-D PAGE as described above and the gel was silver stained. The relevant spot was excised and identified by MALDI-MS peptide mass fingerprinting. Four fragments corresponding to 5 the peptides 23-29, 30-40, 75-86 and 75-88 of TB9.5 (Rv0569) were matched, giving a sequence coverage of 36 % for this protein. This result demonstrates that the TB9.5 protein is upregulated under conditions that mimics the *in vivo* situation, which indicates that this protein may be a good vaccine candidate or a therapeutic vaccine candidate.

10 Example 5: ORF13A is a serological target in TB patients

To test the potential of ORF13A as a serological antigen, sera were collected from 48 TB patients (all proven culture positive for *M. tuberculosis*) and 15 healthy BCG vaccinated controls and 19 non-BCG vaccinated healthy controls. The sera were assayed for anti- 15 bodies recognizing the recombinantly produced ORF13A in an ELISA assay as follows: Each of the sera was absorbed with Promega *E. coli* extract (S37761) for 4 hours at room temperature and the supernatants collected after centrifugation. 1 µg/ml of ORF13A in Carbonatbuffer pH 9.6 were absorbed over night at 5 °C to a polystyrene plate (Maxisorp, Nunc). The plates were washed in PBS-0.05% Tween-20 and the sera applied in a dilution of 1:100. After 1 hour of incubation the plates were washed 3 times with PBS-0.05% 20 Tween-20 and 100 µl per well of peroxidase-conjugated Rabbit Anti-Human IgA, IgG, IgM was applied in a dilution of 1:8000. After 1 hour of incubation the plates were washed 3 times with PBS-0.05% Tween-20. 100 µl of substrate (TMB PLUS, Kem-En-Tec) was added per well and the reaction stopped after 30 min with 0.2 M Sulphuric acid and the 25 absorbance was read at 405 nm. The results are shown in figure 2A, 2B and 2C.

56% of the TB patients recognized ORF13A with an absorbance more than OD 0.3. The mean for all 48 patients was OD 0.44. In contrast only one BCG vaccinated individual recognized ORF13A slightly above the cutoff and three of the non BCG-vaccinated 30 healthy donors recognized ORF13A, only one significant above the cutoff. The mean for BCG vaccinated individuals were OD 0.18 and for non BCG-vaccinated OD 0.3.

Table 8: Serological responses to ORF13A and the 38kDa antigen evaluated by ELISA on 48 TB patients, 15 BCG vaccinated and 19 non BCG vaccinated individuals.

	TB patients		BCG vaccinated		Non BCG vaccinated	
Antigen	Percent (n) responders	Mean of OD	Percent (n) responders	Mean of OD	Percent (n) responders	Mean of OD
ORF13A	56% (27)	0.44	7% (1)	0.18	16% (3)	0.3
38 kDa	50% (24)	0.38	20% (3)	0.21	26% (5)	0.24

In table 8 the response to ORF13A is compared to an antigen which is known as one of the best serological antigens; the 38kDa phosphate binding proteins (Luashchenko, K. P., et al J Immunological Methods 242 (2000) 91-100). The two proteins were tested in part 5 allele on the same donors. The 38 kDa antigens is recognized by 50% of these TB patients and 20% of the BCG vaccinated and 26% of the non BCG-vaccinated in this study population. Thus ORF13A is recognized by more TB patients and by less of the healthy controls (both BCG vaccinated and non-vaccinated) than the 38 kDa antigen. This clearly demonstrates the potential of ORF13A as a serological antigen for the diagnosis of TB, 10 and demonstrates that ORF13A has the potential to differentiate between BCG vaccinated and *M. tuberculosis* infected individuals something, which is not possible with the current diagnostic reagent PPD. It is well known that the antibody repertoire of TB patients is very heterogeneous and it is therefore not likely that all patients will recognize the same mycobacterial antigen, as also demonstrated by these results. It is therefore most 15 likely that a serological kit for the diagnosis of *M. tuberculosis* infection will consist of more than one component and in this respect it will be obvious to combine ORF13A with other antigens, which are recognized by TB patients. This could be the 38 kDa antigens, but also other proteins could be included.

References

- Andersen, P. et al 1991. Infect. Immun. 59:1905-1910
- Andersen, P., and Heron, I. 1993 J. Immunol. Methods 161 29-39
- Brandt, L., et al. 2000 Infect. Immun. 68:2; 791-795.
- 5 Cole, S.T et al 1998 Nature 393: 537-544
- Cote-Sierra J, et al 1998, Gene Oct 9;221(1):25-34
- Danish Patent application PA 1999 01020 (WO 01/23388) "Tuberculosis vaccine and diagnostic based on the *Mycobacterium tuberculosis* esat-6 gene family".
- Danish Patent application PA 2000 00666 " Nucleic acid fragments and polypeptide
- 10 fragments derived from *M. tuberculosis*"
- Gosselin et al., (1992) J. Immunol. 149: 3477-3481
- Harboe, M., et al 1998 Infect. Immun. 66:2; 717-723
- Kilgus J et al, J Immunol. 1991 Jan 1;146(1):307-15
- Kohler and Milstein, Nature, 256:495 (1975)
- 15 Lowry, D.B. et al 1999, Nature 400: 269-71
- Luashchenko, K.P., et al 2000. J Immunological Methods 242: 91-100
- Lustig et al 1976, Cell Immunol 24(1):164-72
- McCafferty et al, Nature, 348:552-554 (1990)
- Merrifield, R. B. Fed. Proc. Am. Soc. Ex. Biol. 21: 412, 1962 and J. Am. Chem. Soc. 85:
- 20 2149, 1963
- Mowat et al 1991, Immunology 72(3):317-22
- Nagai et al 1991, Infect. Immun 59:1; 372-382
- Olsen A.W et al, Eur J Immunol. 2000 Jun; 30(6):1724-32
- Patent application US 09/0505,739 "Nucleic acid fragments and polypeptide fragments
- 25 derived from *M. tuberculosis*"
- Pearson W.R and D.J. Lipman (1988) PNAS USA 85:2444-2448
- Pollock, J., et al, 2000. The Veterinary record, 146:659-665
- Ravn, P. et al 1999. J.Infect.Dis. 179:637-645
- Rolph, M.S, and I. A. Ramshaw. 1997. Curr.Opin.Immunol.9:517-24
- 30 Rosenkrands, I., et al 1998, Infect. Immun 66:6; 2728-2735
- Sambrook et al Molecular Cloning; A laboratory manual, Cold Spring Harbor Laboratories, NY, 1989
- Sinigaglia F et al. Nature 1988 Dec 22-29;336(6201):778-80
- Skjøt, R.L.V., et al 2000, Infect. Immun 68:1; 214-220

- Stryhn, A., et al 1996 Eur. J. Immunol. 26:1911-1918
Thompson J., et al Nucleic Acids Res 1994 22:4673-4680
Ulmer J.B et al 1993, Curr. Opin. Invest. Drugs 2(9): 983-989

Claims

1. A substantially pure polypeptide, which comprises at least one amino acid sequence selected from the group consisting of:
 - 5 (a) an amino acid sequence selected from Rv0284, Rv0285, Rv0455c, Rv0569, Rv1195, Rv1386, Rv3477, Rv3878, Rv3879c or MT3106.1;
 - (b) an immunogenic portion of any one of the sequences in (a); and
 - (c) an amino acid sequence analogue having at least 70% sequence identity to any one of the sequences in (a) or (b) and at the same time being immunogenic.
- 10 2. A substantially pure polypeptide according to claim 1, wherein the amino acid sequence analogue has at least 80% sequence identity to any of the sequences in (a) or (b).
3. A fusion polypeptide, which comprises at least one amino acid sequence selected from
15 the group consisting of:
 - (a) an amino acid sequence selected from Rv0284, Rv0285, Rv0455c, Rv0569, Rv1195, Rv1386, Rv3477, Rv3878, Rv3879c or MT3106.1;
 - (b) an immunogenic portion of any one of the sequences in (a); and
 - (c) an amino acid sequence analogue having at least 70% sequence identity to any
20 one of the sequences in (a) or (b) and at the same time being immunogenic;
and at least one fusion partner.
4. A fusion polypeptide according to claim 3, wherein the fusion partner comprises a polypeptide fragment selected from the group consisting of:
 - 25 (a) a polypeptide fragment derived from a virulent mycobacterium;
 - (b) a polypeptide according to claim 1; and
 - (c) at least one immunogenic portion of any of such polypeptides in (a) or (b).
5. A polypeptide, which comprises at least one amino acid sequence selected from the
30 group consisting of:
 - (a) an amino acid sequence selected from Rv0284, Rv0285, Rv0455c, Rv0569, Rv1195, Rv1386, Rv3477, Rv3878, Rv3879c or MT3106.1;
 - (b) an immunogenic portion of any one of the sequences in (a); and
 - (c) an amino acid sequence analogue having at least 70% sequence identity to any
35 one of the sequences in (a) or (b) and at the same time being immunogenic;

which is lipidated so as to allow a self-adjuvating effect of the polypeptide.

6. A substantially pure polypeptide, which comprises at least one amino acid sequence selected from the group consisting of:

- 5 (a) an amino acid sequence selected from Rv0284, Rv0285, Rv0455c, Rv0569, Rv1195, Rv1386, Rv3477, Rv3878, Rv3879c or MT3106.1;
 - (b) an immunogenic portion of any one of the sequences in (a); and
 - (c) an amino acid sequence analogue having at least 70% sequence identity to any one of the sequences in (a) or (b) and at the same time being immunogenic;
- 10 for use as a vaccine, as a pharmaceutical or as a diagnostic reagent.

7. Use of a polypeptide according to any of the preceding claims for the preparation of a pharmaceutical composition for diagnosis of tuberculosis.

15 8. Use of a polypeptide according to any of claims 1-6 for the preparation of a pharmaceutical composition.

9. An immunogenic composition comprising at least one polypeptide according to any of claims 1-6.

20

10. An immunogenic composition according to claim 9, which is in the form of a vaccine.

11. An immunogenic composition according to claim 9, which is in the form of a skin test reagent.

25

12. A nucleic acid fragment in isolated form which

- (a) comprises at least one nucleic acid sequence which encodes a polypeptide as defined in any of claims 1-6, or comprises a nucleic acid sequence complementary thereto; and/or

30 (b) has a length of at least 10 nucleotides and hybridizes under stringent hybridization conditions with a nucleotide sequence selected from Rv0284, Rv0285, Rv0455c, Rv0569, Rv1195, Rv1386, Rv3477, Rv3878, Rv3879c or MT3106.1, or a nucleotide sequence complementary to any one of these sequences; or with a nucleotide sequence selected from a sequence in (a).

35

13. A nucleic acid fragment according to claim 12, which is a DNA fragment.
14. A nucleic acid fragment according to claim 12 or 13 for use as a pharmaceutical.
- 5 15. A vaccine comprising at least one nucleic acid fragment according to claim 12 or 13, optionally inserted in a vector, the vaccine effecting *in vivo* expression of antigen by an animal, including a human being, to whom the vaccine has been administered, the amount of expressed antigen being effective to confer substantially increased resistance to tuberculosis caused by virulent mycobacteria in an animal, including a human being.
10
16. Use of a nucleic acid fragment according to claim 12 or 13 for the preparation of a composition for the diagnosis of tuberculosis caused by virulent mycobacteria.
17. Use of a nucleic acid fragment according to claim 12 or 13 for the preparation of a
15 pharmaceutical composition for the vaccination against tuberculosis caused by virulent mycobacteria.
18. A vaccine for immunizing an animal, including a human being, against tuberculosis caused by virulent mycobacteria comprising as the effective component a non-pathogenic
20 microorganism, wherein at least one copy of a DNA fragment comprising a DNA sequence encoding a polypeptide according to any of claims 1-6 has been incorporated into the microorganism in a manner allowing the microorganism to express and optionally secrete the polypeptide.
- 25 19. A replicable expression vector, which comprises at least one nucleic acid fragment according to claim 12 or 13.
20. A transformed cell harbouring at least one vector according to claim 19.
- 30 21. A method for producing a polypeptide according to any of claims 1-6, comprising:
 - (a) inserting a nucleic acid fragment according to claim 12 or 13 into a vector which is able to replicate in a host cell, introducing the resulting recombinant vector into the host cell, culturing the host cell in a culture medium under conditions sufficient to effect expression of the polypeptide, and recovering the polypeptide from the
35 host cell or culture medium;

- (b) isolating the polypeptide from a whole mycobacterium from culture filtrate or from lysates or fractions thereof; or
- (c) synthesizing the polypeptide.

5 22. A method of diagnosing tuberculosis caused by virulent mycobacteria in an animal, including a human being, comprising intradermally injecting, in the animal, at least one polypeptide according to any of claims 1-6 or an immunogenic composition according to claim 9, a positive skin response at the location of injection being indicative of the animal having tuberculosis, and a negative skin response at the location of injection being indicative of the animal not having tuberculosis.

10 23. A method for immunising an animal, including a human being, against tuberculosis caused by virulent mycobacteria comprising administering to the animal at least one polypeptide according to any of claims 1-6, an immunogenic composition according to claim 9, 15 or a vaccine according to claim 18.

24. A monoclonal or polyclonal antibody, which is specifically reacting with a polypeptide according to any of claims 1-6 in an immuno assay, or a specific binding fragment of said antibody.

20 25. A monoclonal or polyclonal antibody, which is specifically reacting with a polypeptide according to any of claims 1-6 in an immuno assay, or a specific binding fragment of said antibody for use as a diagnostic reagent.

25 26. A pharmaceutical composition which comprises an immunologically responsive amount of at least one member selected from the group consisting of:

(a) a polypeptide selected from Rv0284, Rv0285, Rv0455c, Rv0569, Rv1195, Rv1386, Rv3477, Rv3878, Rv3879c or MT3106.1, or an immunogenic portion thereof;

30 (b) an amino acid sequence which has a sequence identity of at least 70% to any one of said polypeptides in (a) and is immunogenic;

(c) a fusion polypeptide comprising at least one polypeptide or amino acid sequence according to (a) or (b) and at least one fusion partner;

(d) a nucleic acid sequence which encodes a polypeptide or amino acid sequence according to (a), (b) or (c);

35

- (e) a nucleic acid sequence which is complementary to a sequence according to (d);
 - (f) a nucleic acid sequence which has a length of at least 10 nucleotides and which hybridizes under stringent conditions with a nucleic acid sequence according to (d) or (e); and
- 5 (g) a non-pathogenic micro-organism which has incorporated therein a nucleic acid sequence according to (d), (e) or (f) in a manner to permit expression of a polypeptide encoded thereby.

27. A method for stimulating an immunogenic response in an animal which comprises
10 administering to said animal an immunologically stimulating amount of at least one member selected from the group consisting of:

- (a) a polypeptide selected from Rv0284, Rv0285, Rv0455c, Rv0569, Rv1195, Rv1386, Rv3477, Rv3878, Rv3879c or MT3106.1, or an immunogenic portion thereof;
 - 15 (b) an amino acid sequence which has a sequence identity of at least 70% to any one of said polypeptides in (a) and is immunogenic;
 - (c) a fusion polypeptide comprising at least one polypeptide or amino acid sequence according to (a) or (b) and at least one fusion partner;
 - (d) a nucleic acid sequence which encodes a polypeptide or amino acid sequence
20 according to (a), (b) or (c);
 - (e) a nucleic acid sequence which is complementary to a sequence according to (d);
 - (f) a nucleic acid sequence which has a length of at least 10 nucleotides and which hybridizes under stringent conditions with a nucleic acid sequence according to (d) or (e); and
- 25 (g) a non-pathogenic micro-organism which has incorporated therein a nucleic acid sequence according to (d), (e) or (f) in a manner to permit expression of a polypeptide encoded thereby.

28. Vaccine according to claim 15 or 18, immunogenic composition according to claim 10
30 or pharmaceutical composition according to claim 26, characterized in that said vaccine/immunogenic composition/pharmaceutical composition can be used prophylactically in a subject not infected with a virulent mycobacterium; or therapeutically in a subject already infected with a virulent mycobacterium.

29. A method for diagnosing previous or ongoing infection with a virulent mycobacterium, said method comprising:

- (a) contacting a sample with a composition comprising at least one antibody according to claim 24 or 25, at least one nucleic acid fragment according to any of claims 12-14 and/or at least one polypeptide according to any of claims 1-6; or
- (b) contacting a sample with a composition comprising at least one polypeptide according to any of claims 1-6 in order to detect a positive reaction.

30. A method of diagnosing *Mycobacterium tuberculosis* infection in a subject comprising:

- 10 (a) contacting at least one polypeptide according to any of the claims 1-6 with a bodily fluid of the subject;
- (b) detecting binding of an antibody to said polypeptide, said binding being an indication that said subject is infected by *Mycobacterium tuberculosis* or is susceptible to *Mycobacterium tuberculosis* infection.

1 / 6




Figure 1

2/6






Figure 1 - continued

3/6

Figure 2A




4/6

Figure 2B

5/6

Figure 2C



6/6




Figure 3

SEQUENCE LISTING

5 <110> Statens Serum Institut
 10 <120> M. tuberculosis Antigens
 15 <130> 22030PC01
 20 <160> 172
 25 <170> FastSEQ for Windows Version 3.0
 30 <210> 1
 35 <211> 3990
 40 <212> DNA
 45 <213> Mycobacterium tuberculosis
 50 <220>
 55 <221> CDS
 60 <222> (1)...(3990)
 65 <400> 1
 Val Ser Arg Leu Ile Phe Glu Ala Arg Arg Arg Leu Ala Pro Pro Ser
 70 1 5 10 15 48
 75 agc cac cag ggc acc atc atc atc gag gcg cct ccc gag ctg cct cgg
 80 Ser His Gln Gly Thr Ile Ile Glu Ala Pro Pro Glu Leu Pro Arg
 85 20 25 30 96
 90 gtg atc cca ccg tca ctg cta cga cga gcg ctg cct tat ctg atc ggg
 95 Val Ile Pro Pro Ser Leu Leu Arg Arg Ala Leu Pro Tyr Leu Ile Gly
 100 35 40 45 144
 105 atc ctc atc gtg ggg atg atc gtg gcg ctg gtc gcc acc ggg atg cgg
 110 Ile Leu Ile Val Gly Met Ile Val Ala Leu Val Ala Thr Gly Met Arg
 115 50 55 60 192
 120 gtg att tct ccg cag acg ttg ttc ttc cca ttt gtg ctg ctg ttg gcg
 125 Val Ile Ser Pro Gln Thr Leu Phe Phe Pro Phe Val Leu Leu Leu Ala
 130 65 70 75 80 240
 135 gcc acc gcg ctc tac cgc ggc aac gac aag aag atg cgc acc gag gag
 140 Ala Thr Ala Leu Tyr Arg Gly Asn Asp Lys Lys Met Arg Thr Glu Glu
 145 85 90 95 288
 150 gtc gac gcc gaa cgg gcc gac tac cta cgt tac cta tcg gtg gtg cgg
 155 Val Asp Ala Glu Arg Ala Asp Tyr Leu Arg Tyr Leu Ser Val Val Arg
 160 100 105 110 336
 165 gac aac att cgg gcc cag gcc gag cag cgg gcc agc gcg ttg tgg
 170 Asp Asn Ile Arg Ala Gln Ala Ala Glu Gln Arg Ala Ser Ala Leu Trp
 175 115 120 125 384
 180 tct cat cct gac ccc acg gcg ttg gcg tcg gtg ccg ggg tca cgt cgc
 185 Ser His Pro Asp Pro Thr Ala Leu Ala Ser Val Pro Gly Ser Arg Arg
 190 130 135 140 432
 195 caa tgg gag cgt gac ccc cac gac ccc gac ttt ttg gtg ttg cgg gcc
 200 Gln Trp Glu Arg Asp Pro His Asp Pro Asp Phe Leu Val Leu Arg Ala
 205 145 150 155 480
 210 160

	ggc cgg cac acg gta ccg ctg gct act acg ctg cga gtc aac gac acc Gly Arg His Thr Val Pro Leu Ala Thr Thr Leu Arg Val Asn Asp Thr 165 170 175	528
5	gcc gag atc gac ctg gaa ccg gtg tcg cac agt gca tta cgc agc Ala Asp Glu Ile Asp Leu Glu Pro Val Ser His Ser Ala Leu Arg Ser 180 185 190	576
10	ctg ctc gac acc cag cgc agc att ggc gac gtg ccg acc ggg atc gac Leu Leu Asp Thr Gln Arg Ser Ile Gly Asp Val Pro Thr Gly Ile Asp 195 200 205	624
15	ctg acc aag gtt tcg ccg atc acc gtg ctg ggg gag cgc gca cag gtg Leu Thr Lys Val Ser Pro Ile Thr Val Leu Gly Glu Arg Ala Gln Val 210 215 220	672
20	cgc gcg gtg tta cgc gcc tgg atc gct cag gcg gtg acc tgg cac gac Arg Ala Val Leu Arg Ala Trp Ile Ala Gln Ala Val Thr Trp His Asp 225 230 235 240	720
25	ccg acg gtg ctc ggg gtg gcg ctg gcc gcg cgt gat ctg gag ggt cgc Pro Thr Val Leu Gly Val Ala Leu Ala Ala Arg Asp Leu Glu Gly Arg 245 250 255	768
30	gat tgg aac tgg ctg aag tgg tta ccg cac gtg gac att ccc ggc cgc Asp Trp Asn Trp Leu Lys Trp Leu Pro His Val Asp Ile Pro Gly Arg 260 265 270	816
35	ctc atc gcg ctg ggg ccc gtc ctg gca gac cgc ccg gcg ttt acc Leu Ile Ala Leu Leu Gly Pro Val Leu Ala Asp Arg Pro Ala Phe Thr 290 295 300	912
40	ggg cag cca aca gat gcg ttg cgg cac ttg ctg atc gtc gtc gat gac Gly Gln Pro Thr Asp Ala Leu Arg His Leu Leu Ile Val Val Asp Asp 305 310 315 320	960
45	ccg gac tac gac ctg ggc gca tcg ccg ctg gcg gtg ggc cgc gcg ggt Pro Asp Tyr Asp Leu Gly Ala Ser Pro Leu Ala Val Gly Arg Ala Gly 325 330 335	1008
50	gtc acc gtc gtg cac tgc tcg gcc agt gcg ccg cac cgg gaa cag tat Val Thr Val Val His Cys Ser Ala Ser Ala Pro His Arg Glu Gln Tyr 340 345 350	1056
55	tcg gat ccg gaa aag ccg atc ctg cgg gtg gct cac ggc gct atc gaa Ser Asp Pro Glu Lys Pro Ile Leu Arg Val Ala His Gly Ala Ile Glu 355 360 365	1104
60	cgc tgg cag aca ggc ggc tgg cag ccc tac atc gac gcc gcc gac caa Arg Trp Gln Thr Gly Gly Trp Gln Pro Tyr Ile Asp Ala Ala Asp Gln 370 375 380	1152
65	tcc agc gct gat gag gcc gcc cac ctg gcg cgc cga ctg tcg cgg tgg Phe Ser Ala Asp Glu Ala Ala His Leu Ala Arg Arg Leu Ser Arg Trp 385 390 395 400	1200
	gac tcc aac ccc acc cat gcc ggg ctg cgc tcg gcg gcc act cgc ggc Asp Ser Asn Pro Thr His Ala Gly Leu Arg Ser Ala Ala Thr Arg Gly 405 410 415	1248
	gcg agt ttc acc aca ctg ctg ggc atc gag gac gca tcc cga ctg gat	1296

	Ala Ser Phe Thr Thr Leu Leu Gly Ile Glu Asp Ala Ser Arg Leu Asp			
	420	425	430	
5	gtg ccc gcg ctg tgg gcg ccg cga cga cgc gac gag gag tta cgc gtg Val Pro Ala Leu Trp Ala Pro Arg Arg Arg Asp Glu Glu Leu Arg Val		1344	
	435	440	445	
10	ccg atc ggt gtc act ggc acc ggc gag ccg ctg atg ttc gac ctc aaa Pro Ile Gly Val Thr Gly Thr Gly Glu Pro Leu Met Phe Asp Leu Lys		1392	
	450	455	460	
15	gac gaa gcc gag ggc ggg atg ggc ccg cac ggg ctg atg atc ggc atg Asp Glu Ala Glu Gly Gly Met Gly Pro His Gly Leu Met Ile Gly Met		1440	
	465	470	475	480
20	acc ggt tcg ggc aag tcg cag act ttg atg tcg att ctg ttg tcg ctg Thr Gly Ser Gly Lys Ser Gln Thr Leu Met Ser Ile Leu Leu Ser Leu		1488	
	485	490	495	
25	ttg acc aca cac tcc gcg gag cgg ctc atc gtc atc tac gcc gac ttc Leu Thr Thr His Ser Ala Glu Arg Leu Ile Val Ile Tyr Ala Asp Phe		1536	
	500	505	510	
30	aag ggt gag gcc ggc gcc gac agt ttc cga gat ttc ccg cag gtg gtt Lys Gly Glu Ala Gly Ala Asp Ser Phe Arg Asp Phe Pro Gln Val Val		1584	
	515	520	525	
35	gcg gtg atc tcg aat atg gcc gag aag aag tcg ttg gct gat cgg ttc Ala Val Ile Ser Asn Met Ala Glu Lys Lys Ser Leu Ala Asp Arg Phe		1632	
	530	535	540	
40	gcc gac acg ctg cgc ggc gag gtg gct cgt cgc gag atg ctg ctg cgt Ala Asp Thr Leu Arg Gly Glu Val Ala Arg Arg Glu Met Leu Leu Arg		1680	
	545	550	555	560
45	565	570	575	
50	gag gcc ggc cgc aag gtc cag ggc agc gcg ttc aac tcg gtg ctc gag Glu Ala Gly Arg Lys Val Gln Gly Ser Ala Phe Asn Ser Val Leu Glu		1728	
	580	585	590	
55	tat gaa aac gcc atc gcc gca ggg cat agc ctg ccc atc ccg aca Tyr Glu Asn Ala Ile Ala Gly His Ser Leu Pro Pro Ile Pro Thr		1776	
	595	600	605	
60	ctg ttc gtg gtc gcc gac gag ttc acc ttg atg ctg gcc gat cac ccg Leu Phe Val Val Ala Asp Glu Phe Thr Leu Met Leu Ala Asp His Pro		1824	
	610	615	620	
65	gaa tac gcg gag ctg ttc gac tat gtg gcc cgc aag ggt cgc tcg ttt Glu Tyr Ala Glu Leu Phe Asp Tyr Val Ala Arg Lys Gly Arg Ser Phe		1872	
	625	630	635	640
70	cgc atc cac atc cta ttc gcg tcc cag aca ctg gac gtg ggc aag atc Arg Ile His Ile Leu Phe Ala Ser Gln Thr Leu Asp Val Gly Lys Ile		1920	
	645	650	655	
75	aaa gac atc gac aag aac acc gcc tat cgg att ggg ctg aaa gtg gcc Lys Asp Ile Asp Lys Asn Thr Ala Tyr Arg Ile Gly Leu Lys Val Ala		1968	
	660	665	670	
80	atc gag tcg ggc aaa gaa cac aaa ggc gtg ggc ttt ttg gtg ccc gcg Ile Glu Ser Gly Lys Glu His Lys Gly Val Gly Phe Leu Val Pro Ala		2016	
	675	680	685	

	ccc ggt gcc acc ccg ata agg ttc cgc agc acc tat gtc gac ggg atc Pro Gly Ala Thr Pro Ile Arg Phe Arg Ser Thr Tyr Val Asp Gly Ile 690 695 700	2112
5	tat gaa ccg ccg cag acg gct aaa gcc gtt gtc gtg caa tcc gtt ccg Tyr Glu Pro Pro Gln Thr Ala Lys Ala Val Val Val Gln Ser Val Pro 705 710 715 720	2160
10	gag ccc aag ctg ttc acc gcc gcc gtc gaa ccg gat ccg ggc acg Glu Pro Lys Leu Phe Thr Ala Ala Val Glu Pro Asp Pro Gly Thr 725 730 735	2208
15	gtg atc gcc gat act gac gaa caa gaa ccc gcc gac cca cca cgc aaa Val Ile Ala Asp Thr Asp Glu Gln Glu Pro Ala Asp Pro Pro Arg Lys 740 745 750	2256
20	ctg atc gcc acc atc ggc gaa caa ctg gcc cgc tac ggt ccg cgg gcg Leu Ile Ala Thr Ile Gly Glu Gln Leu Ala Arg Tyr Gly Pro Arg Ala 755 760 765	2304
25	ccg cag ttg tgg ctg ccg cca ctc gac gaa acg atc cca ctg agc gcg Pro Gln Leu Trp Leu Pro Pro Leu Asp Glu Thr Ile Pro Leu Ser Ala 770 775 780	2352
30	gcg ttg gcc cgc gcc ggg gtc ggc ccc cgg cag tgg cgc tgg ccg ctg Ala Leu Ala Arg Ala Gly Val Gly Pro Arg Gln Trp Arg Trp Pro Leu 785 790 795 800	2400
35	ggg gag atc gac agg ccc ttc gag atg cgg cgc gac ccg ttg gtg ttt Gly Glu Ile Asp Arg Pro Phe Glu Met Arg Arg Asp Pro Leu Val Phe 805 810 815	2448
40	gac gct agg tcg tcg gcc gga aat atg gtg atc cac ggc ggc ccc aag Asp Ala Arg Ser Ser Ala Gly Asn Met Val Ile His Gly Pro Lys 820 825 830	2496
45	tcc ggc aaa tcc act gcg ctg cag aca ttc atc ctc tca gct gct agc Ser Gly Lys Ser Thr Ala Leu Gln Thr Phe Ile Leu Ser Ala Ala Ser 835 840 845	2544
50	ctg cac tcg ccg cac gag gtt agc ttc tat tgc ctg gac tac ggc ggt Leu His Ser Pro His Glu Val Ser Phe Tyr Cys Leu Asp Tyr Gly Gly 850 855 860	2592
55	ggg cag ctg cgg gcg cta cag gat cta gcg cac gtc ggc agt gtc gcc Gly Gln Leu Arg Ala Leu Gln Asp Leu Ala His Val Gly Ser Val Ala 865 870 875 880	2640
60	tca gcg ctg gaa ccc gaa cgc atc cgc cgc acc ttc ggc gag ctc gag Ser Ala Leu Glu Pro Glu Arg Ile Arg Arg Thr Phe Gly Glu Leu Glu 885 890 895	2688
65	caa ctg ctg ttg tcc cgg cag cag cgg gaa gta ttc cgt gac ccg ggt Gln Leu Leu Ser Arg Gln Gln Arg Glu Val Phe Arg Asp Arg Gly 900 905 910	2736
70	gct aat ggc tcg acc ccc gac gac ggg ttc ggt gag gtg ttc ctg gtc Ala Asn Gly Ser Thr Pro Asp Asp Gly Phe Gly Glu Val Phe Leu Val 915 920 925	2784
75	atc gac aat ctc tat ggc ttc ggc cgc gat aac acc gat cag ttc aac Ile Asp Asn Leu Tyr Gly Phe Gly Arg Asp Asn Thr Asp Gln Phe Asn 930 935 940	2832
80	acc cgt aat ccg ttg ctg gcc agg gta acc gaa ctg gtc aac gtg ggc	2880

	Thr Arg Asn Pro Leu Leu Ala Arg Val Thr Glu Leu Val Asn Val Gly			
945	950	955	960	
5	ctt gcc tac ggg atc cac gtg atc att acc acg ccg agc tgg ctg gaa Leu Ala Tyr Gly Ile His Val Ile Ile Thr Thr Pro Ser Trp Leu Glu	2928		
	965	970	975	
10	gtg ccg ttg gcg atg cgc gac ggg ctc ggg ctg cgt ctc gag ctg cga Val Pro Leu Ala Met Arg Asp Gly Leu Gly Leu Arg Leu Glu Leu Arg	2976		
	980	985	990	
15	ctg cac gac gcg cgc gac agc aac gtg cgg gtg gtc ggc gcc ctg cgc Leu His Asp Ala Arg Asp Ser Asn Val Arg Val Val Gly Ala Leu Arg	3024		
	995	1000	1005	
20	cgc ccg gcc gac gcc gtc ccg cac gac cag ccc ggc cgc gga ctg acc Arg Pro Ala Asp Ala Val Pro His Asp Gln Pro Gly Arg Gly Leu Thr	3072		
	1010	1015	1020	
25	atg gcc gcc gag cac ttc ctg ttc gcg gct cca gaa ctg gac gcg caa Met Ala Ala Glu His Phe Leu Phe Ala Ala Pro Glu Leu Asp Ala Gln	3120		
	1025	1030	1035	1040
30	aca aac ccg gtg gcc gcg atc aac gcc cgc tac ccc ggc atg gcg gct Thr Asn Pro Val Ala Ala Ile Asn Ala Arg Tyr Pro Gly Met Ala Ala	3168		
	1045	1050	1055	
35	ccc ccg gtt cgg ttg ttg ccc acc aac ctt gcg ccg cac gcc gtc ggc Pro Pro Val Arg Leu Leu Pro Thr Asn Leu Ala Pro His Ala Val Gly	3216		
	1060	1065	1070	
40	gaa ctg tat cgg ggt ccc gac caa ctg gtg att ggc cag cgc gaa gaa Glu Leu Tyr Arg Gly Pro Asp Gln Leu Val Ile Gly Gln Arg Glu Glu	3264		
	1075	1080	1085	
45	gac ctg gcg ccg gtg ata ctc gac ctc gcc gcc aac ccg ctg ctg atg Asp Leu Ala Pro Val Ile Leu Asp Leu Ala Ala Asn Pro Leu Leu Met	3312		
	1090	1095	1100	
50	gtg ttc ggc gat gcc agg tca gga aag acg acg ctg ctg cgc cac atc Val Phe Gly Asp Ala Arg Ser Gly Lys Thr Thr Leu Leu Arg His Ile	3360		
	1105	1110	1115	1120
55	atc cgc acc gtc cgc gag cac tcc acc gcc gac cgg gtc gcg ttc acc Ile Arg Thr Val Arg Glu His Ser Thr Ala Asp Arg Val Ala Phe Thr	3408		
	1125	1130	1135	
60	gtg ctg gac cgc cgg cta cac ctg gtc gac gaa cca ctg ttc ccc gac Val Leu Asp Arg Arg Leu His Leu Val Asp Glu Pro Leu Phe Pro Asp	3456		
	1140	1145	1150	
65	aac gag tac acc gcc aac atc gat cgg atc atc ccg gcg atg ctc ggg Asn Glu Tyr Thr Ala Asn Ile Asp Arg Ile Ile Pro Ala Met Leu Gly	3504		
	1155	1160	1165	
	ctg gcc aac ctc atc gag gcg cgc cgg ccg gcc ggg atg tct gcg Leu Ala Asn Leu Ile Glu Ala Arg Arg Pro Pro Ala Gly Met Ser Ala	3552		
	1170	1175	1180	
70	gcc gag ctg tcc cgc tgg acc ttt gcc ggg cac acc cac tac ctg atc Ala Glu Leu Ser Arg Trp Thr Phe Ala Gly His Thr His Tyr Leu Ile	3600		
	1185	1190	1195	1200
75	atc gac gac gtc gac cag gta ccg gat tcg ccg gcg atg acc ggt ccc Ile Asp Asp Val Asp Gln Val Pro Asp Ser Pro Ala Met Thr Gly Pro	3648		
	1205	1210	1215	

	tac atc gga cag cgg ccg tgg acc ccg ctg atc ggt ctc ctg gcc cag Tyr Ile Gly Gln Arg Pro Trp Thr Pro Leu Ile Gly Leu Leu Ala Gln 1220 1225 1230	3696
5	gcc ggc gac ttg ggg cta ccg gtg att gtc acc ggg cgt gcc act gga Ala Gly Asp Leu Gly Leu Arg Val Ile Val Thr Gly Arg Ala Thr Gly 1235 1240 1245	3744
10	tcg gcg cac ctg ctg atg aca agt ccg ttg ctg cgc ccg ttc aac gac Ser Ala His Leu Leu Met Thr Ser Pro Leu Leu Arg Arg Phe Asn Asp 1250 1255 1260	3792
15	ctg cag gcg acc acg ctg atg ttg gca ggc aat ccg gcc gac agc ggc Leu Gln Ala Thr Thr Leu Met Leu Ala Gly Asn Pro Ala Asp Ser Gly 1265 1270 1275 1280	3840
20	aag att cgc ggt gag cgg ttt gcc cga ttg cct gct gga cga gca att Lys Ile Arg Gly Glu Arg Phe Ala Arg Leu Pro Ala Gly Arg Ala Ile 1285 1290 1295	3888
25	ctg ttg acc gac agt gat agt cca acc tac gtg cag ttg atc aac ccg Leu Leu Thr Asp Ser Asp Ser Pro Thr Tyr Val Gln Leu Ile Asn Pro 1300 1305 1310	3936
30	ctg gtc gat gcg gcc gcg gtt tct ggt gaa acc caa cag aag ggg agt Leu Val Asp Ala Ala Val Ser Gly Glu Thr Gln Gln Lys Gly Ser 1315 1320 1325	3984
35	cag tca Gln Ser 1330	3990
40	<210> 2 <211> 1330 <212> PRT <213> Mycobacterium tuberculosis	
45	<400> 2 Val Ser Arg Leu Ile Phe Glu Ala Arg Arg Leu Ala Pro Pro Ser 1 5 10 15 Ser His Gln Gly Thr Ile Ile Ile Glu Ala Pro Pro Glu Leu Pro Arg 20 25 30	
50	Val Ile Pro Pro Ser Leu Leu Arg Arg Ala Leu Pro Tyr Leu Ile Gly 35 40 45 Ile Leu Ile Val Gly Met Ile Val Ala Leu Val Ala Thr Gly Met Arg 50 55 60	
55	Val Ile Ser Pro Gln Thr Leu Phe Phe Pro Phe Val Leu Leu Ala 65 70 75 80 Ala Thr Ala Leu Tyr Arg Gly Asn Asp Lys Lys Met Arg Thr Glu Glu 85 90 95	
60	Val Asp Ala Glu Arg Ala Asp Tyr Leu Arg Tyr Leu Ser Val Val Arg 100 105 110	
65	Asp Asn Ile Arg Ala Gln Ala Ala Glu Gln Arg Ala Ser Ala Leu Trp 115 120 125 Ser His Pro Asp Pro Thr Ala Leu Ala Ser Val Pro Gly Ser Arg Arg 130 135 140	
70	Gln Trp Glu Arg Asp Pro His Asp Pro Asp Phe Leu Val Leu Arg Ala 145 150 155 160 Gly Arg His Thr Val Pro Leu Ala Thr Thr Leu Arg Val Asn Asp Thr 165 170 175	
75	Ala Asp Glu Ile Asp Leu Glu Pro Val Ser His Ser Ala Leu Arg Ser 180 185 190	
80	Leu Leu Asp Thr Gln Arg Ser Ile Gly Asp Val Pro Thr Gly Ile Asp 195 200 205	

Leu Thr Lys Val Ser Pro Ile Thr Val Leu Gly Glu Arg Ala Gln Val
 210 215 220
 Arg Ala Val Leu Arg Ala Trp Ile Ala Gln Ala Val Thr Trp His Asp
 225 230 235 240
 5 Pro Thr Val Leu Gly Val Ala Leu Ala Ala Arg Asp Leu Glu Gly Arg
 245 250 255
 Asp Trp Asn Trp Leu Lys Trp Leu Pro His Val Asp Ile Pro Gly Arg
 260 265 270
 10 Leu Asp Ala Leu Gly Pro Ala Arg Asn Leu Ser Thr Asp Pro Asp Glu
 275 280 285
 Leu Ile Ala Leu Leu Gly Pro Val Leu Ala Asp Arg Pro Ala Phe Thr
 290 295 300
 Gly Gln Pro Thr Asp Ala Leu Arg His Leu Leu Ile Val Val Asp Asp
 305 310 315 320
 15 Pro Asp Tyr Asp Leu Gly Ala Ser Pro Leu Ala Val Gly Arg Ala Gly
 325 330 335
 Val Thr Val Val His Cys Ser Ala Ser Ala Pro His Arg Glu Gln Tyr
 340 345 350
 Ser Asp Pro Glu Lys Pro Ile Leu Arg Val Ala His Gly Ala Ile Glu
 20 355 360 365
 Arg Trp Gln Thr Gly Gly Trp Gln Pro Tyr Ile Asp Ala Ala Asp Gln
 370 375 380
 Phe Ser Ala Asp Glu Ala Ala His Leu Ala Arg Arg Leu Ser Arg Trp
 385 390 395 400
 25 Asp Ser Asn Pro Thr His Ala Gly Leu Arg Ser Ala Ala Thr Arg Gly
 405 410 415
 Ala Ser Phe Thr Thr Leu Leu Gly Ile Glu Asp Ala Ser Arg Leu Asp
 420 425 430
 Val Pro Ala Leu Trp Ala Pro Arg Arg Arg Asp Glu Glu Leu Arg Val
 30 435 440 445
 Pro Ile Gly Val Thr Gly Thr Gly Glu Pro Leu Met Phe Asp Leu Lys
 450 455 460
 Asp Glu Ala Glu Gly Gly Met Gly Pro His Gly Leu Met Ile Gly Met
 465 470 475 480
 35 Thr Gly Ser Gly Lys Ser Gln Thr Leu Met Ser Ile Leu Leu Ser Leu
 485 490 495
 Leu Thr Thr His Ser Ala Glu Arg Leu Ile Val Ile Tyr Ala Asp Phe
 500 505 510
 Lys Gly Glu Ala Gly Ala Asp Ser Phe Arg Asp Phe Pro Gln Val Val
 40 515 520 525
 Ala Val Ile Ser Asn Met Ala Glu Lys Lys Ser Leu Ala Asp Arg Phe
 530 535 540
 Ala Asp Thr Leu Arg Gly Glu Val Ala Arg Arg Glu Met Leu Leu Arg
 545 550 555 560
 45 Glu Ala Gly Arg Lys Val Gln Gly Ser Ala Phe Asn Ser Val Leu Glu
 565 570 575
 Tyr Glu Asn Ala Ile Ala Ala Gly His Ser Leu Pro Pro Ile Pro Thr
 580 585 590
 Leu Phe Val Val Ala Asp Glu Phe Thr Leu Met Leu Ala Asp His Pro
 50 595 600 605
 Glu Tyr Ala Glu Leu Phe Asp Tyr Val Ala Arg Lys Gly Arg Ser Phe
 610 615 620
 Arg Ile His Ile Leu Phe Ala Ser Gln Thr Leu Asp Val Gly Lys Ile
 625 630 635 640
 55 Lys Asp Ile Asp Lys Asn Thr Ala Tyr Arg Ile Gly Leu Lys Val Ala
 645 650 655
 Ser Pro Ser Val Ser Arg Gln Ile Ile Gly Val Glu Asp Ala Tyr His
 660 665 670
 Ile Glu Ser Gly Lys Glu His Lys Gly Val Gly Phe Leu Val Pro Ala
 60 675 680 685
 Pro Gly Ala Thr Pro Ile Arg Phe Arg Ser Thr Tyr Val Asp Gly Ile
 690 695 700
 Tyr Glu Pro Pro Gln Thr Ala Lys Ala Val Val Val Gln Ser Val Pro
 705 710 715 720
 65 Glu Pro Lys Leu Phe Thr Ala Ala Ala Val Glu Pro Asp Pro Gly Thr
 725 730 735

Val Ile Ala Asp Thr Asp Glu Gln Glu Pro Ala Asp Pro Pro Arg Lys
 740 745 750
 Leu Ile Ala Thr Ile Gly Glu Gln Leu Ala Arg Tyr Gly Pro Arg Ala
 755 760 765
 5 Pro Gln Leu Trp Leu Pro Pro Leu Asp Glu Thr Ile Pro Leu Ser Ala
 770 775 780
 Ala Leu Ala Arg Ala Gly Val Gly Pro Arg Gln Trp Arg Trp Pro Leu
 785 790 795 800
 10 Gly Glu Ile Asp Arg Pro Phe Glu Met Arg Arg Asp Pro Leu Val Phe
 805 810 815
 Asp Ala Arg Ser Ser Ala Gly Asn Met Val Ile His Gly Gly Pro Lys
 820 825 830
 Ser Gly Lys Ser Thr Ala Leu Gln Thr Phe Ile Leu Ser Ala Ala Ser
 835 840 845
 15 Leu His Ser Pro His Glu Val Ser Phe Tyr Cys Leu Asp Tyr Gly Gly
 850 855 860
 Gly Gln Leu Arg Ala Leu Gln Asp Leu Ala His Val Gly Ser Val Ala
 865 870 875 880
 20 Ser Ala Leu Glu Pro Glu Arg Ile Arg Arg Thr Phe Gly Glu Leu Glu
 885 890 895
 Gln Leu Leu Ser Arg Gln Gln Arg Glu Val Phe Arg Asp Arg Gly
 900 905 910
 Ala Asn Gly Ser Thr Pro Asp Asp Gly Phe Gly Glu Val Phe Leu Val
 915 920 925
 25 Ile Asp Asn Leu Tyr Gly Phe Gly Arg Asp Asn Thr Asp Gln Phe Asn
 930 935 940
 Thr Arg Asn Pro Leu Leu Ala Arg Val Thr Glu Leu Val Asn Val Gly
 945 950 955 960
 30 Leu Ala Tyr Gly Ile His Val Ile Ile Thr Thr Pro Ser Trp Leu Glu
 965 970 975
 Val Pro Leu Ala Met Arg Asp Gly Leu Gly Leu Arg Leu Glu Leu Arg
 980 985 990
 Leu His Asp Ala Arg Asp Ser Asn Val Arg Val Val Gly Ala Leu Arg
 995 1000 1005
 35 Arg Pro Ala Asp Ala Val Pro His Asp Gln Pro Gly Arg Gly Leu Thr
 1010 1015 1020
 Met Ala Ala Glu His Phe Leu Phe Ala Ala Pro Glu Leu Asp Ala Gln
 1025 1030 1035 1040
 40 Thr Asn Pro Val Ala Ala Ile Asn Ala Arg Tyr Pro Gly Met Ala Ala
 1045 1050 1055
 Pro Pro Val Arg Leu Leu Pro Thr Asn Leu Ala Pro His Ala Val Gly
 1060 1065 1070
 Glu Leu Tyr Arg Gly Pro Asp Gln Leu Val Ile Gly Gln Arg Glu Glu
 1075 1080 1085
 45 Asp Leu Ala Pro Val Ile Leu Asp Leu Ala Ala Asn Pro Leu Leu Met
 1090 1095 1100
 Val Phe Gly Asp Ala Arg Ser Gly Lys Thr Thr Leu Leu Arg His Ile
 1105 1110 1115 1120
 Ile Arg Thr Val Arg Glu His Ser Thr Ala Asp Arg Val Ala Phe Thr
 50 1125 1130 1135
 Val Leu Asp Arg Arg Leu His Leu Val Asp Glu Pro Leu Phe Pro Asp
 1140 1145 1150
 Asn Glu Tyr Thr Ala Asn Ile Asp Arg Ile Ile Pro Ala Met Leu Gly
 1155 1160 1165
 55 Leu Ala Asn Leu Ile Glu Ala Arg Arg Pro Pro Ala Gly Met Ser Ala
 1170 1175 1180
 Ala Glu Leu Ser Arg Trp Thr Phe Ala Gly His Thr His Tyr Leu Ile
 1185 1190 1195 1200
 60 Ile Asp Asp Val Asp Gln Val Pro Asp Ser Pro Ala Met Thr Gly Pro
 1205 1210 1215
 Tyr Ile Gly Gln Arg Pro Trp Thr Pro Leu Ile Gly Leu Leu Ala Gln
 1220 1225 1230
 Ala Gly Asp Leu Gly Leu Arg Val Ile Val Thr Gly Arg Ala Thr Gly
 1235 1240 1245
 65 Ser Ala His Leu Leu Met Thr Ser Pro Leu Leu Arg Arg Phe Asn Asp
 1250 1255 1260

Leu Gln Ala Thr Thr Leu Met Leu Ala Gly Asn Pro Ala Asp Ser Gly
 1265 1270 1275 1280
 Lys Ile Arg Gly Glu Arg Phe Ala Arg Leu Pro Ala Gly Arg Ala Ile
 1285 1290 1295
 5 Leu Leu Thr Asp Ser Asp Ser Pro Thr Tyr Val Gln Leu Ile Asn Pro
 1300 1305 1310
 Leu Val Asp Ala Ala Ala Val Ser Gly Glu Thr Gln Gln Lys Gly Ser
 1315 1320 1325
 Gln Ser
 10 1330

 <210> 3
 <211> 375
 <212> DNA
 15 <213> Mycobacterium tuberculosis

 <220>
 <221> CDS
 <222> (1)...(375)

 20 <400> 3
 cag gta ccg gat tcg ccg gcg atg acc ggt ccc tac atc gga cag cgg 48
 Gln Val Pro Asp Ser Pro Ala Met Thr Gly Pro Tyr Ile Gly Gln Arg
 1 5 10 15

 25 ccg tgg acc ccg ctg atc ggt ctc ctg gcc cag gcc ggc gac ttg ggg 96
 Pro Trp Thr Pro Leu Ile Gly Leu Leu Ala Gln Ala Gly Asp Leu Gly
 20 25 30

 30 cta ccg gtg att gtc acc ggg cgt gcc act gga tcg gcg cac ctg ctg 144
 Leu Arg Val Ile Val Thr Gly Arg Ala Thr Gly Ser Ala His Leu Leu
 35 40 45

 35 atg aca agt ccg ttg ctg cgc ccg ttc aac gac ctg cag gcg acc acg 192
 Met Thr Ser Pro Leu Leu Arg Arg Phe Asn Asp Leu Gln Ala Thr Thr
 50 55 60

 40 ctg atg ttg gca ggc aat ccg gcc gac agc ggc aag att cgc ggt gag 240
 Leu Met Leu Ala Gly Asn Pro Ala Asp Ser Gly Lys Ile Arg Gly Glu
 65 70 75 80

 45 ccg ttt gcc cga ttg cct gct gga cga gca att ctg ttg acc gac agt 288
 Arg Phe Ala Arg Leu Pro Ala Gly Arg Ala Ile Leu Leu Thr Asp Ser
 85 90 95

 50 gat agt cca acc tac gtg cag ttg atc aac ccg ctg gtc gat gcg gcc 336
 Asp Ser Pro Thr Tyr Val Gln Leu Ile Asn Pro Leu Val Asp Ala Ala
 100 105 110

 55 gcg gtt tct ggt gaa acc caa cag aag ggg agt cag tca 375
 Ala Val Ser Gly Glu Thr Gln Gln Lys Gly Ser Gln Ser
 115 120 125

 60 <210> 4
 <211> 125
 <212> PRT
 <213> Mycobacterium tuberculosis

 65 <400> 4
 Gln Val Pro Asp Ser Pro Ala Met Thr Gly Pro Tyr Ile Gly Gln Arg
 1 5 10 15
 Pro Trp Thr Pro Leu Ile Gly Leu Leu Ala Gln Ala Gly Asp Leu Gly
 20 25 30
 65 Leu Arg Val Ile Val Thr Gly Arg Ala Thr Gly Ser Ala His Leu Leu
 35 40 45

Met Thr Ser Pro Leu Leu Arg Arg Phe Asn Asp Leu Gln Ala Thr Thr
 50 55 60
 Leu Met Leu Ala Gly Asn Pro Ala Asp Ser Gly Lys Ile Arg Gly Glu
 65 70 75 80
 5 Arg Phe Ala Arg Leu Pro Ala Gly Arg Ala Ile Leu Leu Thr Asp Ser
 85 90 95
 Asp Ser Pro Thr Tyr Val Gln Leu Ile Asn Pro Leu Val Asp Ala Ala
 100 105 110
 10 Ala Val Ser Gly Glu Thr Gln Gln Lys Gly Ser Gln Ser
 115 120 125

15 <210> 5
 <211> 306
 <212> DNA
 <213> Mycobacterium tuberculosis

20 <220>
 <221> CDS
 <222> (1)...(306)

25 <400> 5
 atg acg ttg cga gtg gtt ccg gag ggg ctg gcc gca gcc agc gct gcg 48
 Met Thr Leu Arg Val Val Pro Glu Gly Leu Ala Ala Ala Ser Ala Ala
 1 5 10 15

30 gtg gaa gcg ctg acg gcg cgg ttg gcc gcc gcg cat gcg agc gca gcg 96
 Val Glu Ala Leu Thr Ala Arg Leu Ala Ala Ala His Ala Ser Ala Ala
 20 25 30

35 ccg gtg att acc gcg gta gtg ccg ccg gcg gat ccg gtc tcg ctg 144
 Pro Val Ile Thr Ala Val Val Pro Pro Ala Ala Asp Pro Val Ser Leu
 35 40 45

40 cag acc gcg gcc ggg ttc agt gca cag ggc gtc gag cac gcg gtc gtc 192
 Gln Thr Ala Ala Gly Phe Ser Ala Gln Gly Val Glu His Ala Val Val
 50 55 60

45 acc gcc gaa ggt gtc gaa gag ctg gga cgc gcc ggc gtt ggt gtc ggc 240
 Thr Ala Glu Gly Val Glu Glu Leu Gly Arg Ala Gly Val Gly Val Gly
 65 70 75 80

50 gaa tcc ggc gcc agc tac ctg gcc ggt gat gcg gcc gcc gcc gct acg 288
 Glu Ser Gly Ala Ser Tyr Leu Ala Gly Asp Ala Ala Ala Ala Thr
 85 90 95

55 tac ggg gtc gtg ggc ggc 306
 Tyr Gly Val Val Gly Gly
 100

60 <210> 6
 <211> 102
 <212> PRT
 <213> Mycobacterium tuberculosis

65 Met Thr Leu Arg Val Val Pro Glu Gly Leu Ala Ala Ala Ser Ala Ala
 1 5 10 15
 Val Glu Ala Leu Thr Ala Arg Leu Ala Ala Ala His Ala Ser Ala Ala
 20 25 30
 Pro Val Ile Thr Ala Val Val Pro Pro Ala Ala Asp Pro Val Ser Leu
 35 40 45
 Gln Thr Ala Ala Gly Phe Ser Ala Gln Gly Val Glu His Ala Val Val
 50 55 60
 70 75 80

Glu Ser Gly Ala Ser Tyr Leu Ala Gly Asp Ala Ala Ala Ala Ala Thr
 85 90 95
 Tyr Gly Val Val Gly Gly
 100
5
 <210> 7
 <211> 444
 <212> DNA
 <213> Mycobacterium tuberculosis
10
 <220>
 <221> CDS
 <222> (1)...(444)
15
 <400> 7
 atg tct cgg ctg agt tcc atc ctg cgt gcc ggc gca ttt ctg gtt 48
 Met Ser Arg Leu Ser Ser Ile Leu Arg Ala Gly Ala Ala Phe Leu Val
 1 5 10 15
20
 ctc ggc atc gcc gct gcg aca ttt cca caa agc gcg gca gcc gac tcc 96
 Leu Gly Ile Ala Ala Ala Thr Phe Pro Gln Ser Ala Ala Asp Ser
 20 25 30
25
 acg gaa gac ttt cca ata cct cgc cgg atg atc gca acc acc tgc gac 144
 Thr Glu Asp Phe Pro Ile Pro Arg Arg Met Ile Ala Thr Thr Cys Asp
 35 40 45

 gcc gaa caa tat ctg gcg gcg gtg cgg gat acc agt ccg gtg tac tac 192
 Ala Glu Gln Tyr Leu Ala Ala Val Arg Asp Thr Ser Pro Val Tyr Tyr
 50 55 60
30
 cag cgg tac atg atc gac ttc aac aac cat gca aac ctt cag caa gcg 240
 Gln Arg Tyr Met Ile Asp Phe Asn Asn His Ala Asn Leu Gln Gln Ala
 65 70 75 80
35
 acg atc aac aag gcg cac tgg ttc ttc tcg ctg tca ccg gcg gag cgc 288
 Thr Ile Asn Lys Ala His Trp Phe Phe Ser Leu Ser Pro Ala Glu Arg
 85 90 95
40
 cga gac tac tcc gaa cac ttt tac aat ggc gat ccg ctg acg ttt gcc 336
 Arg Asp Tyr Ser Glu His Phe Tyr Asn Gly Asp Pro Leu Thr Phe Ala
 100 105 110

45
 tgg gtc aat cac atg aaa atc ttc ttc aac aac aag ggc gtc gtc gct 384
 Trp Val Asn His Met Lys Ile Phe Phe Asn Asn Lys Gly Val Val Ala
 115 120 125

50
 aaa ggg acc gag gtg tgc aat gga tac cca gcc ggc gac atg tcg gtg 432
 Lys Gly Thr Glu Val Cys Asn Gly Tyr Pro Ala Gly Asp Met Ser Val
 130 135 140

 tgg aac tgg gcc 444
 Trp Asn Trp Ala
 145
55
 <210> 8
 <211> 148
 <212> PRT
60
 <213> Mycobacterium tuberculosis

 <400> 8
 Met Ser Arg Leu Ser Ser Ile Leu Arg Ala Gly Ala Ala Phe Leu Val
 1 5 10 15
65
 Leu Gly Ile Ala Ala Ala Thr Phe Pro Gln Ser Ala Ala Asp Ser
 20 25 30

Thr Glu Asp Phe Pro Ile Pro Arg Arg Met Ile Ala Thr Thr Cys Asp
 35 40 45
 Ala Glu Gln Tyr Leu Ala Ala Val Arg Asp Thr Ser Pro Val Tyr Tyr
 50 55 60
 5 Gln Arg Tyr Met Ile Asp Phe Asn Asn His Ala Asn Leu Gln Gln Ala
 65 70 75 80
 Thr Ile Asn Lys Ala His Trp Phe Phe Ser Leu Ser Pro Ala Glu Arg
 85 90 95
 Arg Asp Tyr Ser Glu His Phe Tyr Asn Gly Asp Pro Leu Thr Phe Ala
 100 105 110
 Trp Val Asn His Met Lys Ile Phe Phe Asn Asn Lys Gly Val Val Ala
 115 120 125
 Lys Gly Thr Glu Val Cys Asn Gly Tyr Pro Ala Gly Asp Met Ser Val
 130 135 140
 15 Trp Asn Trp Ala
 145

<210> 9
 <211> 264
 20 <212> DNA
 <213> *Mycobacterium tuberculosis*

<220>
 <221> CDS
 25 <222> (1)...(264)

<400> 9
 atg aag gca aag gtc ggg gac tgg ctg gtg atc aaa ggc gcg acg ata 48
 Met Lys Ala Lys Val Gly Asp Trp Leu Val Ile Lys Gly Ala Thr Ile
 30 1 5 10 15

gat caa ccg gac cac cga ggg ttg att att gag gtg cgc tca tcc gat 96
 Asp Gln Pro Asp His Arg Gly Leu Ile Ile Glu Val Arg Ser Ser Asp
 20 25 30

35 ggt tcg ccg ccg tat gtg gtg cgc tgg ctc gag acc gac cat gtg gcg 144
 Gly Ser Pro Pro Tyr Val Val Arg Trp Leu Glu Thr Asp His Val Ala
 35 40 45

40 acg gtg att ccg ggt ccg gat gcg gtc gtg gtc act gcg gag gag cag 192
 Thr Val Ile Pro Gly Pro Asp Ala Val Val Thr Ala Glu Glu Gln
 50 55 60

45 aat gcg gcc gac gag cgg gcg cag cat cgg ttc ggc gcg gtt cag tcg 240
 Asn Ala Ala Asp Glu Arg Ala Gln His Arg Phe Gly Ala Val Gln Ser
 65 70 75 80

50 gcg atc ctc cat gcc agg gga acg 264
 Ala Ile Leu His Ala Arg Gly Thr
 85

<210> 10
 <211> 88
 55 <212> PRT
 <213> *Mycobacterium tuberculosis*

<400> 10
 60 Met Lys Ala Lys Val Gly Asp Trp Leu Val Ile Lys Gly Ala Thr Ile
 1 5 10 15
 Asp Gln Pro Asp His Arg Gly Leu Ile Ile Glu Val Arg Ser Ser Asp
 20 25 30
 Gly Ser Pro Pro Tyr Val Val Arg Trp Leu Glu Thr Asp His Val Ala
 35 40 45
 65 Thr Val Ile Pro Gly Pro Asp Ala Val Val Thr Ala Glu Glu Gln
 50 55 60

Asn Ala Ala Asp Glu Arg Ala Gln His Arg Phe Gly Ala Val Gln Ser
 65 70 75 80
 Ala Ile Leu His Ala Arg Gly Thr
 85

5 <210> 11
 <211> 297
 <212> DNA
 <213> Mycobacterium tuberculosis

10 <220>
 <221> CDS
 <222> (1)...(297)

15 <400> 11
 gtg tct ttc gtg atg gca tac cca gag atg ttg gcg gcg gct gac 48
 Val Ser Phe Val Met Ala Tyr Pro Glu Met Leu Ala Ala Ala Asp
 1 5 10 15

20 acc ctg cag agc atc ggt gct acc act gtg gct agc aat gcc gct gcg 96
 Thr Leu Gln Ser Ile Gly Ala Thr Thr Val Ala Ser Asn Ala Ala Ala
 20 25 30

25 gcg gcc ccg acg act ggg gtg gtg ccc ccc gct gcc gat gag gtg tcg 144
 Ala Ala Pro Thr Thr Gly Val Val Pro Pro Ala Ala Asp Glu Val Ser
 35 40 45

30 gcg ctg act gcg gac ttc gcc gca cat gcg gcg atg tat cag tcc 192
 Ala Leu Thr Ala Ala His Phe Ala Ala His Ala Ala Met Tyr Gln Ser
 50 55 60

35 gtg agc gct cgg gct gct gcg att cat gac cag ttc gtg gcc acc ctt 240
 Val Ser Ala Arg Ala Ala Ile His Asp Gln Phe Val Ala Thr Leu
 65 70 75 80

40 gcc agc agc gcc agc tcg tat gcg gcc act gaa gtc gcc aat gcg gcg 288
 Ala Ser Ser Ala Ser Tyr Ala Ala Thr Glu Val Ala Asn Ala Ala
 85 90 95

45 <210> 12
 <211> 99
 <212> PRT
 <213> Mycobacterium tuberculosis

50 <400> 12
 Val Ser Phe Val Met Ala Tyr Pro Glu Met Leu Ala Ala Ala Asp
 1 5 10 15
 Thr Leu Gln Ser Ile Gly Ala Thr Thr Val Ala Ser Asn Ala Ala
 20 25 30

55 Ala Ala Pro Thr Thr Gly Val Val Pro Pro Ala Ala Asp Glu Val Ser
 35 40 45
 Ala Leu Thr Ala Ala His Phe Ala Ala His Ala Ala Met Tyr Gln Ser
 50 55 60

60 Val Ser Ala Arg Ala Ala Ile His Asp Gln Phe Val Ala Thr Leu
 65 70 75 80
 Ala Ser Ser Ala Ser Ser Tyr Ala Ala Thr Glu Val Ala Asn Ala Ala
 85 90 95

65 Ala Ala Ser
 <210> 13

<211> 306
 <212> DNA
 <213> Mycobacterium tuberculosis

5 <220>
 <221> CDS
 <222> (1)...(306)

10 <400> 13
 gtg acg ttg cga gtc gtt ccc gaa agc ctg gca ggc gcc agc gct gcc 48
 Val Thr Leu Arg Val Val Pro Glu Ser Leu Ala Gly Ala Ser Ala Ala
 1 5 10 15

15 atc gaa gca gtg acc gct cgc ctg gcc ggc cac gcc gcg gac 96
 Ile Glu Ala Val Thr Ala Arg Leu Ala Ala His Ala Ala Ala Ala
 20 25 30

20 ccg ttt atc gcg gcg gtc atc ccg cct ggg tcc gac tcg gtt tcg gtg 144
 Pro Phe Ile Ala Ala Val Ile Pro Pro Gly Ser Asp Ser Val Ser Val
 35 40 45

25 tgc aac gcc gtt gag ttc agc gtt cac ggt agt cag cat gtg gca atg 192
 Cys Asn Ala Val Glu Phe Ser Val His Gly Ser Gln His Val Ala Met
 50 55 60

30 gcc gct cag ggg gtt gag ctc ggc cgc tcg ggg gtc ggg gtg gcc 240
 Ala Ala Gln Gly Val Glu Leu Gly Arg Ser Gly Val Gly Val Ala
 65 70 75 80

35 tat ctc agc ggt ggg cta 306
 Tyr Leu Ser Gly Gly Leu
 100

40 <210> 14
 <211> 102
 <212> PRT
 <213> Mycobacterium tuberculosis

45 <400> 14
 Val Thr Leu Arg Val Val Pro Glu Ser Leu Ala Gly Ala Ser Ala Ala
 1 5 10 15
 Ile Glu Ala Val Thr Ala Arg Leu Ala Ala His Ala Ala Ala Ala
 20 25 30

50 Pro Phe Ile Ala Ala Val Ile Pro Pro Gly Ser Asp Ser Val Ser Val
 35 40 45
 Cys Asn Ala Val Glu Phe Ser Val His Gly Ser Gln His Val Ala Met
 50 55 60
 Ala Ala Gln Gly Val Glu Leu Gly Arg Ser Gly Val Gly Val Ala
 65 70 75 80

55 Glu Ser Gly Ala Ser Tyr Ala Ala Arg Asp Ala Leu Ala Ala Ser
 85 90 95
 Tyr Leu Ser Gly Gly Leu
 100

60 <210> 15
 <211> 294
 <212> DNA
 <213> Mycobacterium tuberculosis

65 <220>
 <221> CDS

<222> (1)...(294)

	<400> 15		
5	gtg tct ttc act gcg caa ccg gag atg ttg gcg gcc gcg gct ggc gaa Val Ser Phe Thr Ala Gln Pro Glu Met Leu Ala Ala Ala Gly Glu 1 5 10 15		48
10	ctt cgt tcc ctg ggg gca acg ctg aag gct agc aat gcc gcc gca gcc Leu Arg Ser Leu Gly Ala Thr Leu Lys Ala Ser Asn Ala Ala Ala 20 25 30		96
15	gtg ccg acg act ggg gtg gtg ccc ccg gct gcc gac gag gtg tcg ctg Val Pro Thr Thr Gly Val Val Pro Pro Ala Ala Asp Glu Val Ser Leu 35 40 45		144
20	ctg ctt gcc aca caa ttc cgt acg cat gcg gcg acg tat cag acg gcc Leu Leu Ala Thr Gln Phe Arg Thr His Ala Ala Thr Tyr Gln Thr Ala 50 55 60		192
25	acc agc gct agt tca tat gcg gac acc gag gcc aac gct gtg gtc Thr Ser Ala Ser Ser Tyr Ala Asp Thr Glu Ala Ala Asn Ala Val Val 85 90 95		288
30	acc ggc Thr Gly		294
35	<210> 16 <211> 98 <212> PRT <213> Mycobacterium tuberculosis		
40	<400> 16 Val Ser Phe Thr Ala Gln Pro Glu Met Leu Ala Ala Ala Gly Glu 1 5 10 15 Leu Arg Ser Leu Gly Ala Thr Leu Lys Ala Ser Asn Ala Ala Ala 20 25 30		
45	Val Pro Thr Thr Gly Val Val Pro Pro Ala Ala Asp Glu Val Ser Leu 35 40 45 Leu Leu Ala Thr Gln Phe Arg Thr His Ala Ala Thr Tyr Gln Thr Ala 50 55 60 Ser Ala Lys Ala Ala Val Ile His Glu Gln Phe Val Thr Thr Leu Ala 65 70 75 80		
50	Thr Ser Ala Ser Ser Tyr Ala Asp Thr Glu Ala Ala Asn Ala Val Val 85 90 95 Thr Gly		
55	<210> 17 <211> 840 <212> DNA <213> Mycobacterium tuberculosis		
60	<220> <221> CDS <222> (1)...(840)		
65	<400> 17 atg gct gaa ccg ttg gcc gtc gat ccc acc ggc ttg agc gca gcg gcc Met Ala Glu Pro Leu Ala Val Asp Pro Thr Gly Leu Ser Ala Ala 1 5 10 15		48

	gct gaa ttg gcc ggc ctc gtt ttt ccg cag cct ccg gcg ccc atc gct Ala Lys Leu Ala Gly Leu Val Phe Pro Gln Pro Pro Ala Pro Ile Ala 20 25 30	96
5	gtc agc gga acg gat tcg gtg gta gca gca atc aac gag acc atg cca Val Ser Gly Thr Asp Ser Val Val Ala Ala Ile Asn Glu Thr Met Pro 35 40 45	144
10	agc atc gaa tcg ctg gtc agt gac ggg ctg ccc ggc gtg aaa gcc gcc Ser Ile Glu Ser Leu Val Ser Asp Gly Leu Pro Gly Val Lys Ala Ala 50 55 60	192
15	ctg act cga aca gca tcc aac atg aac gct gct gac gtc tat gct Leu Thr Arg Thr Ala Ser Asn Met Asn Ala Ala Asp Val Tyr Ala 65 70 75 80	240
20	aag acc gat cag tca ctg gga acc agt ttg agc cag tat gca ttc ggc Lys Thr Asp Gln Ser Leu Gly Thr Ser Leu Ser Gln Tyr Ala Phe Gly 85 90 95	288
25	tcg tcg ggc gaa ggc ctg gct ggc gtc gcc tcg gtc ggt ggt cag cca Ser Ser Gly Glu Gly Leu Ala Gly Val Ala Ser Val Gly Gly Gln Pro 100 105 110	336
30	agt cag gct acc cag ctg ctg agc aca ccc gtg tca cag gtc acg acc Ser Gln Ala Thr Gln Leu Leu Ser Thr Pro Val Ser Gln Val Thr Thr 115 120 125	384
35	cag ctc ggc gag acg gcc gct gag ctg gca ccc cgt gtt gtt gcc acg Gln Leu Gly Glu Thr Ala Ala Glu Leu Ala Pro Arg Val Val Ala Thr 130 135 140	432
40	gtg ccg caa ctc gtt cag ctg gct ccg cac gcc gtt cag atg tcg caa Val Pro Gln Leu Val Gln Leu Ala Pro His Ala Val Gln Met Ser Gln 145 150 155 160	480
45	aac gca tcc ccc atc gct cag acg atc agt caa acc gcc caa cag gcc Asn Ala Ser Pro Ile Ala Gln Thr Ile Ser Gln Thr Ala Gln Gln Ala 165 170 175	528
50	gcc cag agc gct cag ggc ggc agc ggc cca atg ccc gca cag ctt gcc Ala Gln Ser Ala Gln Gly Gly Ser Gly Pro Met Pro Ala Gln Leu Ala 180 185 190	576
55	agc gct gaa aaa ccg gcc acc gag caa gct gag ccg gtc cac gaa gtg Ser Ala Glu Lys Pro Ala Thr Glu Gln Ala Glu Pro Val His Glu Val 195 200 205	624
60	aca aac gac gat cag ggc gac cag ggc gac gtg cag ccg gcc gag gtc Thr Asn Asp Asp Gln Gly Asp Gln Gly Asp Val Gln Pro Ala Glu Val 210 215 220	672
65	gtt gcc gct gca cgt gac gaa ggc ggc gca tca ccg ggc cag cag Val Ala Ala Ala Arg Asp Glu Gly Ala Gly Ala Ser Pro Gly Gln Gln 225 230 235 240	720
70	ccc ggc ggg ggc gtt ccc gct ctt gca gca atg gat acc gga gcc ggt gcc Pro Gly Gly Val Pro Ala Gln Ala Met Asp Thr Gly Ala Gly Ala 245 250 255	768
75	cgc cca gct gct agt ccg ctg gct gcc ccc gtc gat ccg tcg act ccg Arg Pro Ala Ala Ser Pro Leu Ala Ala Pro Val Asp Pro Ser Thr Pro 260 265 270	816
80	gca ccc tca aca acc aca acg ttg	840

Ala Pro Ser Thr Thr Thr Thr Leu
275 280

5 <210> 18
<211> 280
<212> PRT
<213> Mycobacterium tuberculosis

10 <400> 18
Met Ala Glu Pro Leu Ala Val Asp Pro Thr Gly Leu Ser Ala Ala Ala
1 5 10 15
Ala Lys Leu Ala Gly Leu Val Phe Pro Gln Pro Pro Ala Pro Ile Ala
20 25 30
15 Val Ser Gly Thr Asp Ser Val Val Ala Ala Ile Asn Glu Thr Met Pro
35 40 45
Ser Ile Glu Ser Leu Val Ser Asp Gly Leu Pro Gly Val Lys Ala Ala
50 55 60
Leu Thr Arg Thr Ala Ser Asn Met Asn Ala Ala Ala Asp Val Tyr Ala
65 70 75 80
Lys Thr Asp Gln Ser Leu Gly Thr Ser Leu Ser Gln Tyr Ala Phe Gly
85 90 95
Ser Ser Gly Glu Gly Leu Ala Gly Val Ala Ser Val Gly Gly Gln Pro
100 105 110
25 Ser Gln Ala Thr Gln Leu Leu Ser Thr Pro Val Ser Gln Val Thr Thr
115 120 125
Gln Leu Gly Glu Thr Ala Ala Glu Leu Ala Pro Arg Val Val Ala Thr
130 135 140
Val Pro Gln Leu Val Gln Leu Ala Pro His Ala Val Gln Met Ser Gln
145 150 155 160
Asn Ala Ser Pro Ile Ala Gln Thr Ile Ser Gln Thr Ala Gln Gln Ala
165 170 175
Ala Gln Ser Ala Gln Gly Gly Ser Gly Pro Met Pro Ala Gln Leu Ala
180 185 190
35 Ser Ala Glu Lys Pro Ala Thr Glu Gln Ala Glu Pro Val His Glu Val
195 200 205
Thr Asn Asp Asp Gln Gly Asp Gln Gly Asp Val Gln Pro Ala Glu Val
210 215 220
40 Val Ala Ala Ala Arg Asp Glu Gly Ala Gly Ala Ser Pro Gly Gln Gln
225 230 235 240
Pro Gly Gly Val Pro Ala Gln Ala Met Asp Thr Gly Ala Gly Ala
245 250 255
Arg Pro Ala Ala Ser Pro Leu Ala Ala Pro Val Asp Pro Ser Thr Pro
260 265 270
45 Ala Pro Ser Thr Thr Thr Thr Leu
275 280

50 <210> 19
<211> 543
<212> DNA
<213> Mycobacterium tuberculosis

55 <220>
<221> CDS
<222> (1)...(543)

60 <400> 19
atg agt att acc agg ccg acg ggc agc tat gcc aga cag atg ctg gat 48
Met Ser Ile Thr Arg Pro Thr Gly Ser Tyr Ala Arg Gln Met Leu Asp
1 5 10 15

65 ccg ggc ggc tgg ttg gaa gcc gat gaa gac act ttc tat gac ccg gcc 96
Pro Gly Gly Trp Val Glu Ala Asp Glu Asp Thr Phe Tyr Asp Arg Ala
20 25 30

cag gaa tat agc cag gtt ttg caa agg gtc acc gat gta ttg gac acc 144

Gln	Glu	Tyr	Ser	Gln	Val	Leu	Gln	Arg	Val	Thr	Asp	Val	Leu	Asp	Thr		
35				35		40			40			45					
5	tgc	cgc	cag	cag	aaa	ggc	cac	gtc	ttc	gaa	ggc	ggc	cta	tgg	tcc	ggc	192
	Cys	Arg	Gln	Gln	Lys	Gly	His	Val	Phe	Glu	Gly	Gly	Leu	Trp	Ser	Gly	
	50				55				55			60					
10	ggc	gcc	gcc	aat	gct	gcc	aac	ggc	gcc	ctg	ggt	gca	aac	atc	aat	caa	240
	Gly	Ala	Ala	Asn	Ala	Ala	Asn	Gly	Ala	Leu	Gly	Ala	Asn	Ile	Asn	Gln	
	65				70				75			80					
15	ttg	atg	acg	ctg	cag	gat	tat	ctc	gcc	acg	gtg	att	acc	tgg	cac	agg	288
	Leu	Met	Thr	Leu	Gln	Asp	Tyr	Leu	Ala	Thr	Val	Ile	Thr	Trp	His	Arg	
	85				90				95								
20	cat	att	gcc	ggg	ttg	att	gag	caa	gct	aaa	tcc	gat	atc	ggc	aat	aat	336
	His	Ile	Ala	Gly	Leu	Ile	Glu	Gln	Ala	Lys	Ser	Asp	Ile	Gly	Asn	Asn	
	100				105				105			110					
25	gtg	gat	ggc	gct	caa	cgg	gag	atc	gat	atc	ctg	gag	aat	gac	cct	agc	384
	Val	Asp	Gly	Ala	Gln	Arg	Glu	Ile	Asp	Ile	Leu	Glu	Asn	Asp	Pro	Ser	
	115				120				125								
30	ctg	gat	gct	gat	gag	cgc	cat	acc	gcc	atc	aat	tca	ttg	gtc	acg	ggc	432
	Leu	Asp	Ala	Asp	Glu	Arg	His	Thr	Ala	Ile	Asn	Ser	Leu	Val	Thr	Ala	
	130				135				140								
35	acg	cat	ggg	gcc	aat	gtc	agt	ctg	gtc	gcc	gag	acc	gct	gag	cgg	gtg	480
	Thr	His	Gly	Ala	Asn	Val	Ser	Leu	Val	Ala	Glu	Thr	Ala	Glu	Arg	Val	
	145				150				155			160					
40	ctg	gaa	tcc	aag	aat	tgg	aaa	cct	ccg	aag	aac	gca	ctc	gag	gat	ttg	528
	Leu	Glu	Ser	Lys	Asn	Trp	Lys	Pro	Pro	Lys	Asn	Ala	Leu	Glu	Asp	Leu	
	165				170				175								
45	ctt	cag	cag	aag	tcg												543
	Leu	Gln	Gln	Lys	Ser												
	180																
50	<210>	20															
	<211>	181															
	<212>	PRT															
	<213>	Mycobacterium	tuberculosis														
55	<400>	20															
	Met	Ser	Ile	Thr	Arg	Pro	Thr	Gly	Ser	Tyr	Ala	Arg	Gln	Met	Leu	Asp	
	1		5		10						15						
60	Pro	Gly	Gly	Trp	Val	Glu	Ala	Asp	Glu	Asp	Thr	Phe	Tyr	Asp	Arg	Ala	
	20			25		30											
65	Gln	Glu	Tyr	Ser	Gln	Val	Leu	Gln	Arg	Val	Thr	Asp	Val	Leu	Asp	Thr	
	35		40		45												
70	Cys	Arg	Gln	Gln	Lys	Gly	His	Val	Phe	Glu	Gly	Gly	Leu	Trp	Ser	Gly	
	50		55		60												
75	Gly	Ala	Ala	Asn	Ala	Ala	Asn	Gly	Ala	Leu	Gly	Ala	Asn	Ile	Asn	Gln	
	65		70		75									80			
80	Leu	Met	Thr	Leu	Gln	Asp	Tyr	Leu	Ala	Thr	Val	Ile	Thr	Trp	His	Arg	
	85			90					95								
85	His	Ile	Ala	Gly	Leu	Ile	Glu	Gln	Ala	Lys	Ser	Asp	Ile	Gly	Asn	Asn	
	100		105		110												
90	Val	Asp	Gly	Ala	Gln	Arg	Glu	Ile	Asp	Ile	Leu	Glu	Asn	Asp	Pro	Ser	
	115		120		125												
95	Leu	Asp	Ala	Asp	Glu	Arg	His	Thr	Ala	Ile	Asn	Ser	Leu	Val	Thr	Ala	
	130		135		140												
100	Thr	His	Gly	Ala	Asn	Val	Ser	Leu	Val	Ala	Glu	Thr	Ala	Glu	Arg	Val	
	145			150					155			160					

Leu Glu Ser Lys Asn Trp Lys Pro Pro Lys Asn Ala Leu Glu Asp Leu
 165 170 175
 Leu Gln Gln Lys Ser
 180
 5 <210> 21
 <211> 2187
 <212> DNA
 <213> *Mycobacterium tuberculosis*
 10 <220>
 <221> CDS
 <222> (1)...(2187)
 15 <400> 21
 atg agt att acc agg ccg acg ggc agc tat gcc aga cag atg ctg gat 48
 Met Ser Ile Thr Arg Pro Thr Gly Ser Tyr Ala Arg Gln Met Leu Asp
 1 5 10 15
 20 ccg ggc ggc tgg gtg gaa gcc gat gaa gac act ttc tat gac ccg gcc 96
 Pro Gly Gly Trp Val Glu Ala Asp Glu Asp Thr Phe Tyr Asp Arg Ala
 20 25 30
 25 cag gaa tat agc cag gtt ttg caa agg gtc acc gat gta ttg gac acc 144
 Gln Glu Tyr Ser Gln Val Leu Gln Arg Val Thr Asp Val Leu Asp Thr
 35 40 45
 30 tgc cgc cag cag aaa ggc cac gtc ttc gaa ggc ggc cta tgg tcc ggc 192
 Cys Arg Gln Gln Lys Gly His Val Phe Glu Gly Leu Trp Ser Gly
 50 55 60
 35 ggc gcc gcc aat gct gcc aac ggc gcc ctg ggt gca aac atc aat caa 240
 Gly Ala Ala Asn Ala Ala Asn Gly Ala Leu Gly Ala Asn Ile Asn Gln
 65 70 75 80
 40 ttg atg acg ctg cag gat tat ctc gcc acg gtg att acc tgg cac agg 288
 Leu Met Thr Leu Gln Asp Tyr Leu Ala Thr Val Ile Thr Trp His Arg
 85 90 95
 45 cat att gcc ggg ttg att gag caa gct aaa tcc gat atc ggc aat aat 336
 His Ile Ala Gly Leu Ile Glu Gln Ala Lys Ser Asp Ile Gly Asn Asn
 100 105 110
 50 gtg gat ggc gct caa cgg gag atc gat atc ctg gag aat gac cct agc 384
 Val Asp Gly Ala Gln Arg Glu Ile Asp Ile Leu Glu Asn Asp Pro Ser
 115 120 125
 55 ctg gat gct gat gag cgc cat acc gcc atc aat tca ttg gtc acg gcg 432
 Leu Asp Ala Asp Glu Arg His Thr Ala Ile Asn Ser Leu Val Thr Ala
 130 135 140
 60 acg cat ggg gcc aat gtc agt ctg gtc gcc gag acc gct gag cgg gtg 480
 Thr His Gly Ala Asn Val Ser Leu Val Ala Glu Thr Ala Glu Arg Val
 145 150 155 160
 55 ctg gaa tcc aag aat tgg aaa cct ccc aag aac gca ctc gag gat ttg 528
 Leu Glu Ser Lys Asn Trp Lys Pro Pro Lys Asn Ala Leu Glu Asp Leu
 165 170 175
 60 ctt cag cag aag tcg ccc cca gac gtg cct acc ctg gtc gtg 576
 Leu Gln Gln Lys Ser Pro Pro Pro Pro Asp Val Pro Thr Leu Val Val
 180 185 190
 65 cca tcc ccg ggc aca ccc ggc aca ccc gga acc ccg atc acc ccg gga 624
 Pro Ser Pro Gly Thr Pro Gly Thr Pro Gly Thr Pro Ile Thr Pro Gly
 195 200 205

	acc ccg atc acc ccg gga acc cca atc aca ccc atc ccg gga gcg ccg Thr Pro Ile Thr Pro Gly Thr Pro Ile Thr Pro Ile Pro Gly Ala Pro	672	
210	215	220	
5			
	gta act ccg atc aca cca acg ccc ggc act ccc gtc acg ccg gtg acc Val Thr Pro Ile Thr Pro Thr Pro Gly Thr Pro Val Thr Pro Val Thr	720	
225	230	235	240
10	ccg ggc aag ccg gtc acc ccg gtg acc ccg gtc aaa ccg ggc aca cca Pro Gly Lys Pro Val Thr Pro Val Thr Pro Val Lys Pro Gly Thr Pro	768	
245	250	255	
15	ggc gag cca acc ccg atc acg ccg gtc acc ccc ccg gtc gcc ccg gcc Gly Glu Pro Thr Pro Ile Thr Pro Val Thr Pro Pro Val Ala Pro Ala	816	
260	265	270	
20	aca ccg gca acc ccg gcc acg ccc gtt acc cca gct ccc gct cca cac Thr Pro Ala Thr Pro Ala Thr Pro Val Thr Pro Ala Pro Ala Pro His	864	
275	280	285	
25	ccg cag ccg gct ccg gca ccg gcg cca tcg cct ggg ccc cag ccg gtt Pro Gln Pro Ala Pro Ala Pro Ser Pro Gly Pro Gln Pro Val	912	
290	295	300	
	aca ccg gcc act ccc ggt ccg tct ggt cca gca aca ccg ggc acc cca Thr Pro Ala Thr Pro Gly Pro Ser Gly Pro Ala Thr Pro Gly Thr Pro	960	
305	310	315	320
30	ggg ggc gag ccg gcg ccg cac gtc aaa ccc gcg gcg ttg gcg gag caa Gly Gly Glu Pro Ala Pro His Val Lys Pro Ala Ala Leu Ala Glu Gln	1008	
325	330	335	
35	cct ggt gtg ccg ggc cag cat gcg ggc ggg ggg acg cag tcg ggg cct Pro Gly Val Pro Gly Gln His Ala Gly Gly Thr Gln Ser Gly Pro	1056	
340	345	350	
40	gcc cat gcg gac gaa tcc gcc gcg tcg gtg acg ccg gct gcg gcg tcc Ala His Ala Asp Glu Ser Ala Ala Ser Val Thr Pro Ala Ala Ala Ser	1104	
355	360	365	
45	ggt gtc ccg ggc gca ccg gcg gcg gcc gcc gcg ccg agc ggt acc acc gcc Gly Val Pro Gly Ala Arg Ala Ala Ala Ala Pro Ser Gly Thr Ala	1152	
370	375	380	
	gtg gga gcg ggc gcg cgt tcg agc gtg ggt acg gcc gcg gcc tcg ggc Val Gly Ala Gly Ala Arg Ser Ser Val Gly Thr Ala Ala Ala Ser Gly	1200	
385	390	395	400
50	gct ggg tcg cat gct gcc act ggg ccg gcg ccg gtg gct acc tcg gac Ala Gly Ser His Ala Ala Thr Gly Arg Ala Pro Val Ala Thr Ser Asp	1248	
405	410	415	
55	aag gcg gca ccg agc acg ccg gcg gcc tcg gcg ccg acg gca cct Lys Ala Ala Ala Pro Ser Thr Arg Ala Ala Ser Ala Arg Thr Ala Pro	1296	
420	425	430	
60	cct gcc ccg ccg tcg acc gat cac atc gac aaa ccc gat cgc agc Pro Ala Arg Pro Pro Ser Thr Asp His Ile Asp Lys Pro Asp Arg Ser	1344	
435	440	445	
	gag tct gca gat gac ggt acg ccg gtg tcg atg atc ccg gtg tcg gcg Glu Ser Ala Asp Asp Gly Thr Pro Val Ser Met Ile Pro Val Ser Ala	1392	
450	455	460	
65	gct cggt gca ccg ccg gac gcc gcc act gca gct gcc agc gcc ccg cag	1440	

	Ala Arg Ala Ala Arg Asp Ala Ala Thr Ala Ala Ala Ser Ala Arg Gln			
465	470	475	480	
5	cgt ggc cgc ggt gat gcg ctg cgg ttg gcg cga cgc atc gcg gcg gcg Arg Gly Arg Gly Asp Ala Leu Arg Leu Ala Arg Arg Ile Ala Ala Ala		1488	
	485	490	495	
10	ctc aac gcg tcc gac aac aac gcg ggc gac tac ggg ttc ttc tgg atc Leu Asn Ala Ser Asp Asn Asn Ala Gly Asp Tyr Gly Phe Phe Trp Ile		1536	
	500	505	510	
15	acc gcg gtg acc acc gac ggt tcc atc gtc gtg gcc aac agc tat ggg Thr Ala Val Thr Thr Asp Gly Ser Ile Val Val Ala Asn Ser Tyr Gly		1584	
	515	520	525	
20	ctg gcc tac ata ccc gac ggg atg gaa ttg ccg aat aag gtg tac ttg Leu Ala Tyr Ile Pro Asp Gly Met Glu Leu Pro Asn Lys Val Tyr Leu		1632	
	530	535	540	
25	gcc agc gcg gat cac gca atc ccg gtt gac gaa att gca cgc tgt gcc Ala Ser Ala Asp His Ala Ile Pro Val Asp Glu Ile Ala Arg Cys Ala		1680	
	545	550	555	560
30	acc tac ccg gtt ttg gcc gtg caa gcc tgg gcg gct ttc cac gac atg Thr Tyr Pro Val Leu Ala Val Gln Ala Trp Ala Ala Phe His Asp Met		1728	
	565	570	575	
35	acg ctg cgg gcg gtg atc ggt acc gcg gag cag ttg gcc agt tcg gat Thr Leu Arg Ala Val Ile Gly Thr Ala Glu Gln Leu Ala Ser Ser Asp		1776	
	580	585	590	
40	ccc ggt gtg gcc aag att gtg ctg gag cca gat gac att ccg gag agc Pro Gly Val Ala Lys Ile Val Leu Glu Pro Asp Asp Ile Pro Glu Ser		1824	
	595	600	605	
45	ggc aaa atg acg ggc cgg tcg cgg ctg gag gtc gtc gac ccc tcg gcg Gly Lys Met Thr Gly Arg Ser Arg Leu Glu Val Val Asp Pro Ser Ala		1872	
	610	615	620	
50	gag gct cag ctg gcc gac act acc gat cag cgt ttg ctc gac ttg ttg Ala Ala Gln Leu Ala Asp Thr Thr Asp Gln Arg Leu Leu Asp Leu Leu		1920	
	625	630	635	640
55	ccg ccg gcg cgg gtg gat gtc aat cca ccg ggc gat gag cgg cac atg Pro Pro Ala Pro Val Asp Val Asn Pro Pro Gly Asp Glu Arg His Met		1968	
	645	650	655	
60	ctg tgg ttc gag ctg atg aag ccc atg acc agc acc gct acc ggc cgc Leu Trp Phe Glu Leu Met Lys Pro Met Thr Ser Thr Ala Thr Gly Arg		2016	
	660	665	670	
65	gag gcc gct cat ctg cgg gcg ttc cgg gcc tac gct gcc cac tca cag Glu Ala Ala His Leu Arg Ala Phe Arg Ala Tyr Ala Ala His Ser Gln		2064	
	675	680	685	
70	gag att gcc ctg cac caa gcg cac act gcg act gac gcg gcc gtc cag Glu Ile Ala Leu His Gln Ala His Thr Ala Thr Asp Ala Ala Val Gln		2112	
	690	695	700	
75	cgt gtg gcc gtc gcg gac tgg ctg tac tgg caa tac gtc acc ggg ttg Arg Val Ala Val Ala Asp Trp Leu Tyr Trp Gln Tyr Val Thr Gly Leu		2160	
	705	710	715	720
80	ctc gac cgg gcc ctg gcc gca tgc Leu Asp Arg Ala Leu Ala Ala Cys		2187	
	725			

5 <210> 22
 <211> 729
 <212> PRT
 <213> *Mycobacterium tuberculosis*
 10 <400> 22
 Met Ser Ile Thr Arg Pro Thr Gly Ser Tyr Ala Arg Gln Met Leu Asp
 1 5 10 15
 Pro Gly Gly Trp Val Glu Ala Asp Glu Asp Thr Phe Tyr Asp Arg Ala
 20 25 30
 Gln Glu Tyr Ser Gln Val Leu Gln Arg Val Thr Asp Val Leu Asp Thr
 35 40 45
 15 Cys Arg Gln Gln Lys Gly His Val Phe Glu Gly Leu Trp Ser Gly
 50 55 60
 Gly Ala Ala Asn Ala Ala Asn Gly Ala Leu Gly Ala Asn Ile Asn Gln
 65 70 75 80
 Leu Met Thr Leu Gln Asp Tyr Leu Ala Thr Val Ile Thr Trp His Arg
 20 85 90 95
 His Ile Ala Gly Leu Ile Glu Gln Ala Lys Ser Asp Ile Gly Asn Asn
 100 105 110
 Val Asp Gly Ala Gln Arg Glu Ile Asp Ile Leu Glu Asn Asp Pro Ser
 115 120 125
 25 Leu Asp Ala Asp Glu Arg His Thr Ala Ile Asn Ser Leu Val Thr Ala
 130 135 140
 Thr His Gly Ala Asn Val Ser Leu Val Ala Glu Thr Ala Glu Arg Val
 145 150 155 160
 30 Leu Glu Ser Lys Asn Trp Lys Pro Pro Lys Asn Ala Leu Glu Asp Leu
 165 170 175
 Leu Gln Gln Lys Ser Pro Pro Pro Asp Val Pro Thr Leu Val Val
 180 185 190
 Pro Ser Pro Gly Thr Pro Gly Thr Pro Gly Thr Pro Ile Thr Pro Gly
 195 200 205
 35 Thr Pro Ile Thr Pro Gly Thr Pro Ile Thr Pro Ile Pro Gly Ala Pro
 210 215 220
 Val Thr Pro Ile Thr Pro Thr Pro Gly Thr Pro Val Thr Pro Val Thr
 225 230 235 240
 40 Pro Gly Lys Pro Val Thr Pro Val Thr Pro Val Lys Pro Gly Thr Pro
 245 250 255
 Gly Glu Pro Thr Pro Ile Thr Pro Val Thr Pro Pro Val Ala Pro Ala
 260 265 270
 Thr Pro Ala Thr Pro Ala Thr Pro Val Thr Pro Ala Pro Ala Pro His
 275 280 285
 45 Pro Gln Pro Ala Pro Ala Pro Ala Pro Ser Pro Gly Pro Gln Pro Val
 290 295 300
 Thr Pro Ala Thr Pro Gly Pro Ser Gly Pro Ala Thr Pro Gly Thr Pro
 305 310 315 320
 50 Gly Gly Glu Pro Ala Pro His Val Lys Pro Ala Ala Leu Ala Glu Gln
 325 330 335
 Pro Gly Val Pro Gly Gln His Ala Gly Gly Gly Thr Gln Ser Gly Pro
 340 345 350
 Ala His Ala Asp Glu Ser Ala Ala Ser Val Thr Pro Ala Ala Ala Ser
 355 360 365
 55 Gly Val Pro Gly Ala Arg Ala Ala Ala Ala Pro Ser Gly Thr Ala
 370 375 380
 Val Gly Ala Gly Ala Arg Ser Ser Val Gly Thr Ala Ala Ala Ser Gly
 385 390 395 400
 60 Ala Gly Ser His Ala Ala Thr Gly Arg Ala Pro Val Ala Thr Ser Asp
 405 410 415
 Lys Ala Ala Ala Pro Ser Thr Arg Ala Ala Ser Ala Arg Thr Ala Pro
 420 425 430
 Pro Ala Arg Pro Pro Ser Thr Asp His Ile Asp Lys Pro Asp Arg Ser
 435 440 445
 65 Glu Ser Ala Asp Asp Gly Thr Pro Val Ser Met Ile Pro Val Ser Ala
 450 455 460

Ala Arg Ala Ala Arg Asp Ala Ala Thr Ala Ala Ser Ala Arg Gln
 465 470 475 480
 Arg Gly Arg Gly Asp Ala Leu Arg Leu Ala Arg Arg Ile Ala Ala Ala
 485 490 495
 5 Leu Asn Ala Ser Asp Asn Asn Ala Gly Asp Tyr Gly Phe Phe Trp Ile
 500 505 510
 Thr Ala Val Thr Thr Asp Gly Ser Ile Val Val Ala Asn Ser Tyr Gly
 515 520 525
 10 Leu Ala Tyr Ile Pro Asp Gly Met Glu Leu Pro Asn Lys Val Tyr Leu
 530 535 540
 Ala Ser Ala Asp His Ala Ile Pro Val Asp Glu Ile Ala Arg Cys Ala
 545 550 555 560
 Thr Tyr Pro Val Leu Ala Val Gln Ala Trp Ala Ala Phe His Asp Met
 565 570 575
 15 Thr Leu Arg Ala Val Ile Gly Thr Ala Glu Gln Leu Ala Ser Ser Asp
 580 585 590
 Pro Gly Val Ala Lys Ile Val Leu Glu Pro Asp Asp Ile Pro Glu Ser
 595 600 605
 Gly Lys Met Thr Gly Arg Ser Arg Leu Glu Val Val Asp Pro Ser Ala
 610 615 620
 Ala Ala Gln Leu Ala Asp Thr Thr Asp Gln Arg Leu Leu Asp Leu Leu
 625 630 635 640
 Pro Pro Ala Pro Val Asp Val Asn Pro Pro Gly Asp Glu Arg His Met
 645 650 655
 25 Leu Trp Phe Glu Leu Met Lys Pro Met Thr Ser Thr Ala Thr Gly Arg
 660 665 670
 Glu Ala Ala His Leu Arg Ala Phe Arg Ala Tyr Ala Ala His Ser Gln
 675 680 685
 30 Glu Ile Ala Leu His Gln Ala His Thr Ala Thr Asp Ala Ala Val Gln
 690 695 700
 Arg Val Ala Val Ala Asp Trp Leu Tyr Trp Gln Tyr Val Thr Gly Leu
 705 710 715 720
 Leu Asp Arg Ala Leu Ala Ala Ala Cys
 725
 35
 <210> 23
 <211> 18
 <212> PRT
 <213> Mycobacterium tuberculosis
 40
 <400> 23
 Thr Leu Arg Val Val Pro Glu Gly Leu Ala Ala Ala Ser Ala Ala Val
 1 5 10 15
 Glu Ala
 45
 <210> 24
 <211> 18
 <212> PRT
 <213> Mycobacterium tuberculosis
 50
 <400> 24
 Ala Ser Ala Ala Val Glu Ala Leu Thr Ala Arg Leu Ala Ala Ala His
 1 5 10 15
 55 Ala Ser
 60
 <210> 25
 <211> 18
 <212> PRT
 <213> Mycobacterium tuberculosis
 65
 <400> 25
 Thr Ala Arg Leu Ala Ala Ala His Ala Ser Ala Ala Pro Val Ile Thr
 1 5 10 15
 Ala Val

5 <210> 26
 <211> 18
 <212> PRT
 <213> *Mycobacterium tuberculosis*

10 <400> 26
 Ala Ala Pro Val Ile Thr Ala Val Val Pro Pro Ala Ala Asp Pro Val
 1 5 10 15
 Ser Leu

15 <210> 27
 <211> 18
 <212> PRT
 <213> *Mycobacterium tuberculosis*

20 <400> 27
 Pro Ala Ala Asp Pro Val Ser Leu Gln Thr Ala Ala Gly Phe Ser Ala
 1 5 10 15
 Gln Gly

25 <210> 28
 <211> 18
 <212> PRT
 <213> *Mycobacterium tuberculosis*

30 <400> 28
 Ala Ala Gly Phe Ser Ala Gln Gly Val Glu His Ala Val Val Thr Ala
 1 5 10 15
 Glu Gly

35 <210> 29
 <211> 18
 <212> PRT
 <213> *Mycobacterium tuberculosis*

40 <400> 29
 His Ala Val Val Thr Ala Glu Gly Val Glu Glu Leu Gly Arg Ala Gly
 1 5 10 15
 Val Gly

45 <210> 30
 <211> 18
 <212> PRT
 <213> *Mycobacterium tuberculosis*

50 <400> 30
 Gly Val Glu Glu Leu Gly Arg Ala Gly Val Gly Val Gly Glu Ser Gly
 1 5 10 15

55 55 Ala Ser

60 <210> 31
 <211> 18
 <212> PRT
 <213> *Mycobacterium tuberculosis*

65 <400> 31
 Gly Val Gly Glu Ser Gly Ala Ser Tyr Leu Ala Gly Asp Ala Ala Ala
 1 5 10 15
 Ala Ala

5 <210> 32
 <211> 18
 <212> PRT
 <213> *Mycobacterium tuberculosis*

10 <400> 32
 Ser Tyr Leu Ala Gly Asp Ala Ala Ala Ala Thr Tyr Gly Val Val
 1 5 10 15
 Gly Gly

15 <210> 33
 <211> 18
 <212> PRT
 <213> *Mycobacterium tuberculosis*

20 <400> 33
 Thr Leu Arg Val Val Pro Glu Ser Leu Ala Gly Ala Ser Ala Ala Ile
 1 5 10 15
 Glu Ala

25 <210> 34
 <211> 18
 <212> PRT
 <213> *Mycobacterium tuberculosis*

30 <400> 34
 Ala Ser Ala Ala Ile Glu Ala Val Thr Ala Arg Leu Ala Ala Ala His
 1 5 10 15
 Ala Ala

35 <210> 35
 <211> 18
 <212> PRT
 <213> *Mycobacterium tuberculosis*

40 <400> 35
 Thr Ala Arg Leu Ala Ala Ala His Ala Ala Ala Ala Pro Phe Ile Ala
 1 5 10 15
 Ala Val

45 <210> 36
 <211> 18
 <212> PRT
 <213> *Mycobacterium tuberculosis*

50 <400> 36
 Ala Ala Pro Phe Ile Ala Ala Val Ile Pro Pro Gly Ser Asp Ser Val
 1 5 10 15
 55 Ser Val

60 <210> 37
 <211> 18
 <212> PRT
 <213> *Mycobacterium tuberculosis*

65 <400> 37
 Pro Gly Ser Asp Ser Val Ser Val Cys Asn Ala Val Glu Phe Ser Val
 1 5 10 15
 His Gly

5 <210> 38
 <211> 18
 <212> PRT
 <213> **Mycobacterium tuberculosis**

10 <400> 38
Ala Val Glu Phe Ser Val His Gly Ser Gln His Val Ala Met Ala Ala
1 5 10 15
Gln Gly

15 <210> 39
 <211> 18
 <212> PRT
 <213> **Mycobacterium tuberculosis**

20 <400> 39
His Val Ala Met Ala Ala Gln Gly Val Glu Glu Leu Gly Arg Ser Gly
1 5 10 15
Val Gly

25 <210> 40
 <211> 18
 <212> PRT
 <213> **Mycobacterium tuberculosis**

30 <400> 40
Gly Val Glu Glu Leu Gly Arg Ser Gly Val Gly Val Ala Glu Ser Gly
1 5 10 15
Ala Ser

35 <210> 41
 <211> 18
 <212> PRT
 <213> **Mycobacterium tuberculosis**

40 <400> 41
Gly Val Ala Glu Ser Gly Ala Ser Tyr Ala Ala Arg Asp Ala Leu Ala
1 5 10 15
Ala Ala

45 <210> 42
 <211> 18
 <212> PRT
 <213> **Mycobacterium tuberculosis**

50 <400> 42
Ser Tyr Ala Ala Arg Asp Ala Leu Ala Ala Ser Tyr Leu Ser Gly
1 5 10 15
55 Gly Leu

60 <210> 43
 <211> 30
 <212> PRT
 <213> **Mycobacterium tuberculosis**

65 <400> 43
Met Lys Ala Lys Val Gly Asp Trp Leu Val Ile Lys Gly Ala Thr Ile
1 5 10 15
Asp Gln Pro Asp His Arg Gly Leu Ile Ile Glu Val Arg Ser

	20	25	30													
	<210> 44															
5	<211> 30															
	<212> PRT															
	<213> Mycobacterium tuberculosis															
	<400> 44															
10	His	Arg	Gly	Leu	Ile	Ile	Glu	Val	Arg	Ser	Ser	Asp	Gly	Ser	Pro	Pro
	1			5				10							15	
	Tyr	Val	Val	Arg	Trp	Leu	Glu	Thr	Asp	His	Val	Ala	Thr	Val		
					20			25						30		
15	<210> 45															
	<211> 30															
	<212> PRT															
	<213> Mycobacterium tuberculosis															
	<400> 45															
20	Val	Arg	Trp	Leu	Glu	Thr	Asp	His	Val	Ala	Thr	Val	Ile	Pro	Gly	Pro
	1			5				10						15		
	Asp	Ala	Val	Val	Val	Thr	Ala	Glu	Glu	Gln	Asn	Ala	Ala	Asp		
					20			25						30		
25	<210> 46															
	<211> 30															
	<212> PRT															
	<213> Mycobacterium tuberculosis															
30	<400> 46															
	Val	Thr	Ala	Glu	Glu	Gln	Asn	Ala	Ala	Asp	Glu	Arg	Ala	Gln	His	Arg
	1			5				10						15		
	Phe	Gly	Ala	Val	Gln	Ser	Ala	Ile	Leu	His	Ala	Arg	Gly	Thr		
				20				25						30		
35	<210> 47															
	<211> 30															
	<212> PRT															
	<213> Mycobacterium tuberculosis															
40	<400> 47															
	Asp	Ser	Thr	Glu	Asp	Phe	Pro	Ile	Pro	Arg	Arg	Met	Ile	Ala	Thr	Thr
	1			5				10						15		
	Cys	Asp	Ala	Glu	Gln	Tyr	Leu	Ala	Ala	Val	Arg	Asp	Thr	Ser		
45				20				25						30		
	<210> 48															
	<211> 30															
	<212> PRT															
50	<213> Mycobacterium tuberculosis															
	<400> 48															
	Gln	Tyr	Leu	Ala	Ala	Val	Arg	Asp	Thr	Ser	Pro	Val	Tyr	Tyr	Gln	Arg
	1			5				10						15		
55	Tyr	Met	Ile	Asp	Phe	Asn	Asn	His	Ala	Asn	Leu	Gln	Gln	Ala		
				20				25						30		
	<210> 49															
	<211> 30															
	<212> PRT															
60	<213> Mycobacterium tuberculosis															
	<400> 49															
65	Phe	Asn	Asn	His	Ala	Asn	Leu	Gln	Gln	Ala	Thr	Ile	Asn	Lys	Ala	His
	1			5				10						15		
	Trp	Phe	Phe	Ser	Leu	Ser	Pro	Ala	Glu	Arg	Arg	Asp	Tyr	Ser		

	20	25	30	
	<210> 50			
	<211> 30			
5	<212> PRT			
	<213> Mycobacterium tuberculosis			
	 <400> 50			
10	Leu Ser Pro Ala Glu Arg Arg Asp Tyr Ser Glu His Phe Tyr Asn Gly			
	1	5	10	15
	Asp Pro Leu Thr Phe Ala Trp Val Asn His Met Lys Ile Phe			
	20	25	30	
	 <210> 51			
15	<211> 27			
	<212> PRT			
	<213> Mycobacterium tuberculosis			
	 <400> 51			
20	Phe Ala Trp Val Asn His Met Lys Ile Phe Phe Asn Asn Lys Gly Val			
	1	5	10	15
	Val Ala Lys Gly Thr Glu Val Cys Asn Gly Tyr			
	20	25		
25	<210> 52			
	<211> 411			
	<212> DNA			
	<213> Mycobacterium tuberculosis			
30	<220>			
	<221> CDS			
	<222> (1)...(411)			
	 <400> 52			
35	atg tca aga cag gcg tca aga cag gtg tca ata att cgc tcc gct ggt			48
	Met Ser Arg Gln Ala Ser Arg Gln Val Ser Ile Ile Arg Ser Ala Gly			
	1	5	10	15
	 gac ggt aac cgg tcg tgc ggg tgt gtg acg cct aag gaa gga gtg tgg			
40	Asp Gly Asn Arg Ser Cys Gly Cys Val Thr Pro Lys Glu Gly Val Trp			96
	20	25	30	
	 gtg gtg acg ctg aga gtg gtt cct gag ggt ttg gcg gcc gcc agt gcg			
	Val Val Thr Leu Arg Val Val Pro Glu Gly Leu Ala Ala Ser Ala			144
45	35	40	45	
	 gcg gtg gag gcg ttg acc gca cgg ctg gcc gca cac gct ggc gcg			
	Ala Val Glu Ala Leu Thr Ala Arg Leu Ala Ala His Ala Gly Ala			192
	50	55	60	
50	 gcg ccg gcg att acg gcg gtg gtg gcg ccg gcg gat ccg gtg tcg			
	Ala Pro Ala Ile Thr Ala Val Val Ala Pro Ala Ala Asp Pro Val Ser			240
	65	70	75	80
55	 ttg cag agt gcg gtg ggg ttt acg gcc tta ggt agc gag cat gcg gcg			
	Leu Gln Ser Ala Val Gly Phe Ser Ala Leu Gly Ser Glu His Ala Ala			288
	85	90	95	
	 atc gcg ggc gaa ggg gtc gag gag ctg ggt cgt tcc ggg gtc gct gtg			
60	Ile Ala Gly Glu Gly Val Glu Leu Gly Arg Ser Gly Val Ala Val			336
	100	105	110	
	 ggt gag tct ggg atc ggt tat gcc gcc ggt gat gcg gtg gcg gcg gcg			
65	Gly Glu Ser Gly Ile Gly Tyr Ala Ala Gly Asp Ala Val Ala Ala			384
	115	120	125	

acg tat ctg gtt tcg ggt ggg tcg ttg
 Thr Tyr Leu Val Ser Gly Gly Ser Leu
 130 135

411

5

<210> 53
 <211> 137
 <212> PRT
 <213> Mycobacterium tuberculosis

10

<400> 53
 Met Ser Arg Gln Ala Ser Arg Gln Val Ser Ile Ile Arg Ser Ala Gly
 1 5 10 15
 Asp Gly Asn Arg Ser Cys Gly Cys Val Thr Pro Lys Glu Gly Val Trp
 15 20 25 30
 Val Val Thr Leu Arg Val Val Pro Glu Gly Leu Ala Ala Ala Ser Ala
 \35 40 45
 Ala Val Glu Ala Leu Thr Ala Arg Leu Ala Ala His Ala Gly Ala
 50 55 60
 20 Ala Pro Ala Ile Thr Ala Val Val Ala Pro Ala Ala Asp Pro Val Ser
 65 70 75 80
 Leu Gln Ser Ala Val Gly Phe Ser Ala Leu Gly Ser Glu His Ala Ala
 85 90 95
 Ile Ala Gly Glu Gly Val Glu Glu Leu Gly Arg Ser Gly Val Ala Val
 25 100 105 110
 Gly Glu Ser Gly Ile Gly Tyr Ala Ala Gly Asp Ala Val Ala Ala Ala
 115 120 125
 Thr Tyr Leu Val Ser Gly Gly Ser Leu
 130 135

30

<210> 54
 <211> 20
 <212> PRT
 <213> Mycobacterium tuberculosis

35

<400> 54
 Ser Arg Leu Ile Phe Glu Ala Arg Arg Arg Leu Ala Pro Pro Ser Ser
 1 5 10 15
 His Gln Gly Thr

40

20
 <210> 55
 <211> 20
 <212> PRT
 <213> Mycobacterium tuberculosis

45

<400> 55
 Ile Ile Ile Glu Ala Pro Pro Glu Leu Pro Arg Val Ile Pro Pro Ser
 1 5 10 15
 50 Leu Leu Arg Arg

20

55

<210> 56
 <211> 20
 <212> PRT
 <213> Mycobacterium tuberculosis

60

<400> 56
 Ala Leu Pro Tyr Leu Ile Gly Ile Leu Ile Val Gly Met Ile Val Ala
 1 5 10 15
 Leu Val Ala Thr

20

65

<210> 57
 <211> 20
 <212> PRT

<213> Mycobacterium tuberculosis

<400> 57

5 Gly Met Arg Val Ile Ser Pro Gln Thr Leu Phe Phe Pro Phe Val Leu
1 5 10 15
Leu Leu Ala Ala
20

10 <210> 58
<211> 20
<212> PRT
<213> Mycobacterium tuberculosis

15 <400> 58

15 Thr Ala Leu Tyr Arg Gly Asn Asp Lys Lys Met Arg Thr Glu Glu Val
1 5 10 15
Asp Ala Glu Arg
20

20 <210> 59
<211> 20
<212> PRT
<213> Mycobacterium tuberculosis

25 <400> 59

Ala Asp Tyr Leu Arg Tyr Leu Ser Val Val Arg Asp Asn Ile Arg Ala
1 5 10 15
Gln Ala Ala Glu
20

30 <210> 60
<211> 20
<212> PRT
<213> Mycobacterium tuberculosis

35 <400> 60

Gln Arg Ala Ser Ala Leu Trp Ser His Pro Asp Pro Thr Ala Leu Ala
1 5 10 15
Ser Val Pro Gly
20

40 <210> 61
<211> 20
<212> PRT
<213> Mycobacterium tuberculosis

45 <400> 61

Ser Arg Arg Gln Trp Glu Arg Asp Pro His Asp Pro Asp Phe Leu Val
1 5 10 15
Leu Arg Ala Gly
20

50 <210> 62
<211> 20
<212> PRT
<213> Mycobacterium tuberculosis

55 <400> 62

Arg His Thr Val Pro Leu Ala Thr Thr Leu Arg Val Asn Asp Thr Ala
1 5 10 15
Asp Glu Ile Asp
20

60 <210> 63
<211> 20
<212> PRT

<213> Mycobacterium tuberculosis

<400> 63

5 Leu Glu Pro Val Ser His Ser Ala Leu Arg Ser Leu Leu Asp Thr Gln
1 5 10 15
Arg Ser Ile Gly
20

10 <210> 64
<211> 20
<212> PRT
<213> Mycobacterium tuberculosis

15 <400> 64

15 Asp Val Pro Thr Gly Ile Asp Leu Thr Lys Val Ser Pro Ile Thr Val
1 5 10 15
Leu Gly Glu Arg
20

20 <210> 65
<211> 20
<212> PRT
<213> Mycobacterium tuberculosis

25 <400> 65

Ala Gln Val Arg Ala Val Leu Arg Ala Trp Ile Ala Gln Ala Val Thr
1 5 10 15
Trp His Asp Pro
20

30 <210> 66
<211> 20
<212> PRT
<213> Mycobacterium tuberculosis

35 <400> 66

Thr Val Leu Gly Val Ala Leu Ala Ala Arg Asp Leu Glu Gly Arg Asp
1 5 10 15
Trp Asn Trp Leu
20

40 <210> 67
<211> 20
<212> PRT
<213> Mycobacterium tuberculosis

45 <400> 67

Lys Trp Leu Pro His Val Asp Ile Pro Gly Arg Leu Asp Ala Leu Gly
1 5 10 15
50 Pro Ala Arg Asn
20

55 <210> 68
<211> 20
<212> PRT
<213> Mycobacterium tuberculosis

60 <400> 68

Leu Ser Thr Asp Pro Asp Glu Leu Ile Ala Leu Leu Gly Pro Val Leu
1 5 10 15
Ala Asp Arg Pro
20

65 <210> 69
<211> 20
<212> PRT

<213> Mycobacterium tuberculosis
 <400> 69
 Ala Phe Thr Gly Gln Pro Thr Asp Ala Leu Arg His Leu Leu Ile Val
 5 1 5 10 15
 Val Asp Asp Pro
 20
 10 <210> 70
 <211> 20
 <212> PRT
 <213> Mycobacterium tuberculosis
 <400> 70
 15 Asp Tyr Asp Leu Gly Ala Ser Pro Leu Ala Val Gly Arg Ala Gly Val
 1 5 10 15
 Thr Val Val His
 20
 20 <210> 71
 <211> 20
 <212> PRT
 <213> Mycobacterium tuberculosis
 <400> 71
 Cys Ser Ala Ser Ala Pro His Arg Glu Gln Tyr Ser Asp Pro Glu Lys
 1 5 10 15
 Pro Ile Leu Arg
 20
 30 <210> 72
 <211> 20
 <212> PRT
 <213> Mycobacterium tuberculosis
 <400> 72
 Val Ala His Gly Ala Ile Glu Arg Trp Gln Thr Gly Gly Trp Gln Pro
 1 5 10 15
 Tyr Ile Asp Ala
 20
 <210> 73
 <211> 20
 <212> PRT
 <213> Mycobacterium tuberculosis
 <400> 73
 Ala Asp Gln Phe Ser Ala Asp Glu Ala Ala His Leu Ala Arg Arg Leu
 1 5 10 15
 50 Ser Arg Trp Asp
 20
 <210> 74
 <211> 20
 <212> PRT
 <213> Mycobacterium tuberculosis
 <400> 74
 60 Ser Asn Pro Thr His Ala Gly Leu Arg Ser Ala Ala Thr Arg Gly Ala
 1 5 10 15
 Ser Phe Thr Thr
 20
 <210> 75
 <211> 20
 <212> PRT

<213> Mycobacterium tuberculosis

<400> 75

5 Leu Leu Gly Ile Glu Asp Ala Ser Arg Leu Asp Val Pro Ala Leu Trp
1 5 10 15
Ala Pro Arg Arg
20

10 <210> 76
<211> 20
<212> PRT
<213> Mycobacterium tuberculosis

<400> 76

15 Arg Asp Glu Glu Leu Arg Val Pro Ile Gly Val Thr Gly Thr Gly Glu
1 5 10 15
Pro Leu Met Phe
20

20 <210> 77
<211> 20
<212> PRT
<213> Mycobacterium tuberculosis

25 <400> 77

Asp Leu Lys Asp Glu Ala Glu Gly Gly Met Gly Pro His Gly Leu Met
1 5 10 15
Ile Gly Met Thr
20

30 <210> 78
<211> 20
<212> PRT
<213> Mycobacterium tuberculosis

35 <400> 78

Gly Ser Gly Lys Ser Gln Thr Leu Met Ser Ile Leu Leu Ser Leu Leu
1 5 10 15
Thr Thr His Ser
20

40 <210> 79
<211> 20
<212> PRT
<213> Mycobacterium tuberculosis

<400> 79

Ala Glu Arg Leu Ile Val Ile Tyr Ala Asp Phe Lys Gly Glu Ala Gly
1 5 10 15
50 Ala Asp Ser Phe
20

55 <210> 80
<211> 20
<212> PRT
<213> Mycobacterium tuberculosis

<400> 80

60 Arg Asp Phe Pro Gln Val Val Ala Val Ile Ser Asn Met Ala Glu Lys
1 5 10 15
Lys Ser Leu Ala
20

65 <210> 81
<211> 20
<212> PRT

<213> Mycobacterium tuberculosis

<400> 81
 5 Asp Arg Phe Ala Asp Thr Leu Arg Gly Glu Val Ala Arg Arg Glu Met
 1 5 10 15
 Leu Leu Arg Glu
 20

10 <210> 82
 <211> 20
 <212> PRT
 <213> Mycobacterium tuberculosis

15 <400> 82
 15 Ala Gly Arg Lys Val Gln Gly Ser Ala Phe Asn Ser Val Leu Glu Tyr
 1 5 10 15
 Glu Asn Ala Ile
 20

20 <210> 83
 <211> 20
 <212> PRT
 <213> Mycobacterium tuberculosis

25 <400> 83
 15 Ala Ala Gly His Ser Leu Pro Pro Ile Pro Thr Leu Phe Val Val Ala
 1 5 10 15
 Asp Glu Phe Thr
 20

30 <210> 84
 <211> 20
 <212> PRT
 <213> Mycobacterium tuberculosis

35 <400> 84
 15 Leu Met Leu Ala Asp His Pro Glu Tyr Ala Glu Leu Phe Asp Tyr Val
 1 5 10 15
 Ala Arg Lys Gly
 20

40 <210> 85
 <211> 20
 <212> PRT
 <213> Mycobacterium tuberculosis

45 <400> 85
 15 Arg Ser Phe Arg Ile His Ile Leu Phe Ala Ser Gln Thr Leu Asp Val
 1 5 10 15
 Gly Lys Ile Lys
 20

50 <210> 86
 <211> 20
 <212> PRT
 <213> Mycobacterium tuberculosis

55 <400> 86
 15 Asp Ile Asp Lys Asn Thr Ala Tyr Arg Ile Gly Leu Lys Val Ala Ser
 1 5 10 15
 Pro Ser Val Ser
 20

60 <210> 87
 <211> 20
 <212> PRT

<213> Mycobacterium tuberculosis

5 Arg Gln Ile Ile Gly Val Glu Asp Ala Tyr His Ile Glu Ser Gly Lys
 1 5 10 15
 Glu His Lys Gly
 20

10 <210> 88
 <211> 20
 <212> PRT
 <213> Mycobacterium tuberculosis

15 <400> 88
 Val Gly Phe Leu Val Pro Ala Pro Gly Ala Thr Pro Ile Arg Phe Arg
 1 5 10 15
 Ser Thr Tyr Val
 20

20 <210> 89
 <211> 20
 <212> PRT
 <213> Mycobacterium tuberculosis

25 <400> 89
 Asp Gly Ile Tyr Glu Pro Pro Gln Thr Ala Lys Ala Val Val Val Gln
 1 5 10 15
 Ser Val Pro Glu
 20

30 <210> 90
 <211> 20
 <212> PRT
 <213> Mycobacterium tuberculosis

35 <400> 90
 Pro Lys Leu Phe Thr Ala Ala Ala Val Glu Pro Asp Pro Gly Thr Val
 1 5 10 15
 Ile Ala Asp Thr
 20

40 <210> 91
 <211> 20
 <212> PRT
 <213> Mycobacterium tuberculosis

45 <400> 91
 Asp Glu Gln Glu Pro Ala Asp Pro Pro Arg Lys Leu Ile Ala Thr Ile
 1 5 10 15
 Gly Glu Gln Leu
 20

50 <210> 92
 <211> 20
 <212> PRT
 <213> Mycobacterium tuberculosis

55 <400> 92
 Ala Arg Tyr Gly Pro Arg Ala Pro Gln Leu Trp Leu Pro Pro Leu Asp
 1 5 10 15
 Glu Thr Ile Pro
 20

60 <210> 93
 <211> 20
 <212> PRT

<213> Mycobacterium tuberculosis

<400> 93

Leu Ser Ala Ala Leu Ala Arg Ala Gly Val Gly Pro Arg Gln Trp Arg
5 1 5 10 15
Trp Pro Leu Gly 20

<210> 94
<211> 20
<212> PRT
<213> Mycobacterium tuberculosis

<400> 94

15 Glu Ile Asp Arg Pro Phe Glu Met Arg Arg Asp Pro Leu Val Phe Asp
1 5 10 15
Ala Arg Ser Ser 20

<210> 95
<211> 20
<212> PRT
<213> Mycobacterium tuberculosis

<400> 95

25 Ala Gly Asn Met Val Ile His Gly Gly Pro Lys Ser Gly Lys Ser Thr
1 5 10 15
Ala Leu Gln Thr 20

<210> 96
<211> 20
<212> PRT
<213> Mycobacterium tuberculosis

<400> 96

30 Phe Ile Leu Ser Ala Ala Ser Leu His Ser Pro His Glu Val Ser Phe
1 5 10 15
Tyr Cys Leu Asp 20

<210> 97
<211> 20
<212> PRT
<213> Mycobacterium tuberculosis

<400> 97

35 Tyr Gly Gly Gly Gln Leu Arg Ala Leu Gln Asp Leu Ala His Val Gly
1 5 10 15
Ser Val Ala Ser 20

<210> 98
<211> 20
<212> PRT
<213> Mycobacterium tuberculosis

<400> 98

40 Ala Leu Glu Pro Glu Arg Ile Arg Arg Thr Phe Gly Glu Leu Glu Gln
1 5 10 15
Leu Leu Leu Ser 20

<210> 99
<211> 20
<212> PRT

<213> Mycobacterium tuberculosis

<400> 99

5 Arg Gln Gln Arg Glu Val Phe Arg Asp Arg Gly Ala Asn Gly Ser Thr
1 5 10 15
Pro Asp Asp Gly
20

10 <210> 100
<211> 20
<212> PRT
<213> Mycobacterium tuberculosis

<400> 100

15 Phe Gly Glu Val Phe Leu Val Ile Asp Asn Leu Tyr Gly Phe Gly Arg
1 5 10 15
Asp Asn Thr Asp
20

20 <210> 101
<211> 20
<212> PRT
<213> Mycobacterium tuberculosis

25 <400> 101

Gln Phe Asn Thr Arg Asn Pro Leu Leu Ala Arg Val Thr Glu Leu Val
1 5 10 15
Asn Val Gly Leu
20

30 <210> 102
<211> 20
<212> PRT
<213> Mycobacterium tuberculosis

35 <400> 102

Ala Tyr Gly Ile His Val Ile Ile Thr Thr Pro Ser Trp Leu Glu Val
1 5 10 15
Pro Leu Ala Met
20

40 <210> 103
<211> 20
<212> PRT
<213> Mycobacterium tuberculosis

<400> 103

Arg Asp Gly Leu Gly Leu Arg Leu Glu Leu Arg Leu His Asp Ala Arg
1 5 10 15
50 Asp Ser Asn Val
20

55 <210> 104
<211> 20
<212> PRT
<213> Mycobacterium tuberculosis

<400> 104

60 Arg Val Val Gly Ala Leu Arg Arg Pro Ala Asp Ala Val Pro His Asp
1 5 10 15
Gln Pro Gly Arg
20

65 <210> 105
<211> 20
<212> PRT

<213> Mycobacterium tuberculosis

<400> 105

5 Gly Leu Thr Met Ala Ala Glu His Phe Leu Phe Ala Ala Pro Glu Leu
1 5 10 15
Asp Ala Gln Thr
20

10 <210> 106
<211> 20
<212> PRT
<213> Mycobacterium tuberculosis

15 <400> 106

15 Asn Pro Val Ala Ala Ile Asn Ala Arg Tyr Pro Gly Met Ala Ala Pro
1 5 10 15
Pro Val Arg Leu
20

20 <210> 107
<211> 20
<212> PRT
<213> Mycobacterium tuberculosis

25 <400> 107

Leu Pro Thr Asn Leu Ala Pro His Ala Val Gly Glu Leu Tyr Arg Gly
1 5 10 15
Pro Asp Gln Leu
20

30 <210> 108
<211> 20
<212> PRT
<213> Mycobacterium tuberculosis

35 <400> 108

Val Ile Gly Gln Arg Glu Glu Asp Leu Ala Pro Val Ile Leu Asp Leu
1 5 10 15
Ala Ala Asn Pro
20

40 <210> 109
<211> 20
<212> PRT
<213> Mycobacterium tuberculosis

45 <400> 109

Leu Leu Met Val Phe Gly Asp Ala Arg Ser Gly Lys Thr Thr Leu Leu
1 5 10 15
50 Arg His Ile Ile
20

55 <210> 110
<211> 20
<212> PRT
<213> Mycobacterium tuberculosis

60 <400> 110

Arg Thr Val Arg Glu His Ser Thr Ala Asp Arg Val Ala Phe Thr Val
1 5 10 15
Leu Asp Arg Arg
20

65 <210> 111
<211> 20
<212> PRT

<213> *Mycobacterium tuberculosis*

<400> 111
5 Leu His Leu Val Asp Glu Pro Leu Phe Pro Asp Asn Glu Tyr Thr Ala
1 5 10 15
Asn Ile Asp Arg
20

10 <210> 112
<211> 20
<212> PRT
<213> *Mycobacterium tuberculosis*

15 <400> 112
15 Ile Ile Pro Ala Met Leu Gly Leu Ala Asn Leu Ile Glu Ala Arg Arg
1 5 10 15
Pro Pro Ala Gly
20

20 <210> 113
<211> 20
<212> PRT
<213> *Mycobacterium tuberculosis*

25 <400> 113
Met Ser Ala Ala Glu Leu Ser Arg Trp Thr Phe Ala Gly His Thr His
1 5 10 15
Tyr Leu Ile Ile
20

30 <210> 114
<211> 20
<212> PRT
<213> *Mycobacterium tuberculosis*

35 <400> 114
Asp Asp Val Asp Gln Val Pro Asp Ser Pro Ala Met Thr Gly Pro Tyr
1 5 10 15
Ile Gly Gln Arg
20

40 <210> 115
<211> 20
<212> PRT
<213> *Mycobacterium tuberculosis*

45 <400> 115
Pro Tyr Ile Gly Gln Arg Pro Trp Thr Pro Leu Ile Gly Leu Leu Ala
1 5 10 15
50 Gln Ala Gly Asp
20

55 <210> 116
<211> 20
<212> PRT
<213> *Mycobacterium tuberculosis*

60 <400> 116
Leu Ala Gln Ala Gly Asp Leu Gly Leu Arg Val Ile Val Thr Gly Arg
1 5 10 15
Ala Thr Gly Ser
20

65 <210> 117
<211> 20
<212> PRT

<213> Mycobacterium tuberculosis

<400> 117

5 Gly Arg Ala Thr Gly Ser Ala His Leu Leu Met Thr Ser Pro Leu Leu
1 5 10 15
Arg Arg Phe Asn
20

<210> 118

10 <211> 20
<212> PRT
<213> Mycobacterium tuberculosis

<400> 118

15 Leu Leu Arg Arg Phe Asn Asp Leu Gln Ala Thr Thr Leu Met Leu Ala
1 5 10 15
Gly Asn Pro Ala
20

<210> 119

<211> 20

<212> PRT

<213> Mycobacterium tuberculosis

<400> 119

Leu Ala Gly Asn Pro Ala Asp Ser Gly Lys Ile Arg Gly Glu Arg Phe
1 5 10 15
Ala Arg Leu Pro
20

30 <210> 120

<211> 20

<212> PRT

<213> Mycobacterium tuberculosis

35 <400> 120

Glu Arg Phe Ala Arg Leu Pro Ala Gly Arg Ala Ile Leu Leu Thr Asp
1 5 10 15
Ser Asp Ser Pro
20

<210> 121

<211> 20

<212> PRT

45 <213> Mycobacterium tuberculosis

<400> 121

Leu Thr Asp Ser Asp Ser Pro Thr Tyr Val Gln Leu Ile Asn Pro Leu
1 5 10 15
50 Val Asp Ala Ala
20

<210> 122

<211> 20

<212> PRT

<213> Mycobacterium tuberculosis

<400> 122

60 Asn Pro Leu Val Asp Ala Ala Val Ser Gly Glu Thr Gln Gln Lys
1 5 10 15
Gly Ser Gln Ser
20

<210> 123

<211> 20

<212> PRT

<213> Mycobacterium tuberculosis

<400> 123

5 Ala Glu Pro Leu Ala Val Asp Pro Thr Gly Leu Ser Ala Ala Ala Ala
1 5 10 15
Lys Leu Ala Gly
20

10 <210> 124
<211> 20
<212> PRT
<213> Mycobacterium tuberculosis

<400> 124

15 Ala Ala Ala Ala Lys Leu Ala Gly Leu Val Phe Pro Gln Pro Pro Ala
1 5 10 15
Pro Ile Ala Val
20

20 <210> 125
<211> 20
<212> PRT
<213> Mycobacterium tuberculosis

25 <400> 125

Gln Pro Pro Ala Pro Ile Ala Val Ser Gly Thr Asp Ser Val Val Ala
1 5 10 15
Ala Ile Asn Glu
20

30 <210> 126
<211> 20
<212> PRT
<213> Mycobacterium tuberculosis

35 <400> 126

Ser Val Val Ala Ala Ile Asn Glu Thr Met Pro Ser Ile Glu Ser Leu
1 5 10 15
Val Ser Asp Gly
20

40 <210> 127
<211> 20
<212> PRT
<213> Mycobacterium tuberculosis

<400> 127

Ile Glu Ser Leu Val Ser Asp Gly Leu Pro Gly Val Lys Ala Ala Leu
1 5 10 15

50 Thr Arg Thr Ala
20

<210> 128
<211> 20
<212> PRT
<213> Mycobacterium tuberculosis

<400> 128

60 Lys Ala Ala Leu Thr Arg Thr Ala Ser Asn Met Asn Ala Ala Ala Asp
1 5 10 15
Val Tyr Ala Lys
20

<210> 129
<211> 20
<212> PRT

<213> Mycobacterium tuberculosis

<400> 129

5 Ala Ala Ala Asp Val Tyr Ala Lys Thr Asp Gln Ser Leu Gly Thr Ser
1 5 10 15
Leu Ser Gln Tyr
20

10 <210> 130
<211> 20
<212> PRT
<213> Mycobacterium tuberculosis

<400> 130

15 Leu Gly Thr Ser Leu Ser Gln Tyr Ala Phe Gly Ser Ser Gly Glu Gly
1 5 10 15
Leu Ala Gly Val
20

20 <210> 131
<211> 20
<212> PRT
<213> Mycobacterium tuberculosis

25 <400> 131
Ser Gly Glu Gly Leu Ala Gly Val Ala Ser Val Gly Gly Gln Pro Ser
1 5 10 15
Gln Ala Thr Gln
20

30 <210> 132
<211> 20
<212> PRT
<213> Mycobacterium tuberculosis

35 <400> 132
Gly Gln Pro Ser Gln Ala Thr Gln Leu Leu Ser Thr Pro Val Ser Gln
1 5 10 15
Val Thr Thr Gln
20

40 <210> 133
<211> 20
<212> PRT
<213> Mycobacterium tuberculosis

<400> 133

45 Pro Val Ser Gln Val Thr Thr Gln Leu Gly Glu Thr Ala Ala Glu Leu
1 5 10 15
50 Ala Pro Arg Val
20

55 <210> 134
<211> 20
<212> PRT
<213> Mycobacterium tuberculosis

<400> 134

60 Ala Ala Glu Leu Ala Pro Arg Val Val Ala Thr Val Pro Gln Leu Val
1 5 10 15
Gln Leu Ala Pro
20

65 <210> 135
<211> 20
<212> PRT

<213> Mycobacterium tuberculosis

<400> 135

5 Pro Gln Leu Val Gln Leu Ala Pro His Ala Val Gln Met Ser Gln Asn
1 5 10 15
Ala Ser Pro Ile
20

10 <210> 136
<211> 20
<212> PRT
<213> Mycobacterium tuberculosis

15 <400> 136
15 Met Ser Gln Asn Ala Ser Pro Ile Ala Gln Thr Ile Ser Gln Thr Ala
1 5 10 15
Gln Gln Ala Ala
20

20 <210> 137
<211> 20
<212> PRT
<213> Mycobacterium tuberculosis

25 <400> 137
Ser Gln Thr Ala Gln Gln Ala Ala Gln Ser Ala Gln Gly Gly Ser Gly
1 5 10 15
Pro Met Pro Ala
20

30 <210> 138
<211> 20
<212> PRT
<213> Mycobacterium tuberculosis

35 <400> 138
Gly Gly Ser Gly Pro Met Pro Ala Gln Leu Ala Ser Ala Glu Lys Pro
1 5 10 15
Ala Thr Glu Gln
20

40 <210> 139
<211> 20
<212> PRT
<213> Mycobacterium tuberculosis

45 <400> 139
Ala Glu Lys Pro Ala Thr Glu Gln Ala Glu Pro Val His Glu Val Thr
1 5 10 15
50 50 Asn Asp Asp Gln
20

55 <210> 140
<211> 20
<212> PRT
<213> Mycobacterium tuberculosis

60 <400> 140
His Glu Val Thr Asn Asp Asp Gln Gly Asp Gln Gly Asp Val Gln Pro
1 5 10 15
Ala Glu Val Val
20

65 <210> 141
<211> 20
<212> PRT

<213> Mycobacterium tuberculosis

<400> 141
5 Asp Val Gln Pro Ala Glu Val Val Ala Ala Ala Arg Asp Glu Gly Ala
1 5 10 15
Gly Ala Ser Pro
20

10 <210> 142
<211> 20
<212> PRT
<213> Mycobacterium tuberculosis

<400> 142
15 Asp Glu Gly Ala Gly Ala Ser Pro Gly Gln Gln Pro Gly Gly Val
1 5 10 15
Pro Ala Gln Ala
20

20 <210> 143
<211> 20
<212> PRT
<213> Mycobacterium tuberculosis

25 <400> 143
Gly Gly Gly Val Pro Ala Gln Ala Met Asp Thr Gly Ala Gly Ala Arg
1 5 10 15
Pro Ala Ala Ser
20

30 <210> 144
<211> 20
<212> PRT
<213> Mycobacterium tuberculosis

35 <400> 144
Ala Gly Ala Arg Pro Ala Ala Ser Pro Leu Ala Ala Pro Val Asp Pro
1 5 10 15
Ser Thr Pro Ala
20

40 <210> 145
<211> 20
<212> PRT
<213> Mycobacterium tuberculosis

<400> 145
45 Ser Pro Leu Ala Ala Pro Val Asp Pro Ser Thr Pro Ala Pro Ser Thr
1 5 10 15
50 Thr Thr Thr Leu
20

<210> 146
55 <211> 18
<212> PRT
<213> Mycobacterium tuberculosis

<400> 146
60 Met Ser Arg Gln Ala Ser Arg Gln Val Ser Ile Ile Arg Ser Ala Gly
1 5 10 15
Asp Gly

65 <210> 147
<211> 18
<212> PRT

<213> Mycobacterium tuberculosis

5 <400> 147
Ile Arg Ser Ala Gly Asp Gly Asn Arg Ser Cys Gly Cys Val Thr Pro
1 5 10 15
Lys Glu

10 <210> 148
<211> 18
<212> PRT
<213> Mycobacterium tuberculosis

15 <400> 148
Gly Cys Val Thr Pro Lys Glu Gly Val Trp Val Val Thr Leu Arg Val
1 5 10 15
Val Pro

20 <210> 149
<211> 18
<212> PRT
<213> Mycobacterium tuberculosis

25 <400> 149
Thr Ala Arg Leu Ala Ala Ala His Ala Gly Ala Ala Pro Ala Ile Thr
1 5 10 15
Ala Val

30 <210> 150
<211> 18
<212> PRT
<213> Mycobacterium tuberculosis

35 <400> 150
Ala Ala Pro Ala Ile Thr Ala Val Val Ala Pro Ala Ala Asp Pro Val
1 5 10 15
Ser Leu

40 <210> 151
<211> 18
<212> PRT
<213> Mycobacterium tuberculosis

45 <400> 151
Pro Ala Ala Asp Pro Val Ser Leu Gln Ser Ala Val Gly Phe Ser Ala
1 5 10 15
Leu Gly

55 <210> 152
<211> 18
<212> PRT
<213> Mycobacterium tuberculosis

60 <400> 152
Ala Val Gly Phe Ser Ala Leu Gly Ser Glu His Ala Ala Ile Ala Gly
1 5 10 15
Glu Gly

65 <210> 153
<211> 18
<212> PRT

<213> Mycobacterium tuberculosis

<400> 153

5 His Ala Ala Ile Ala Gly Glu Gly Val Glu Glu Leu Gly Arg Ser Gly
1 5 10 15
Val Ala

10 <210> 154

<211> 18

<212> PRT

<213> Mycobacterium tuberculosis

<400> 154

15 Gly Val Glu Glu Leu Gly Arg Ser Gly Val Ala Val Gly Glu Ser Gly
1 5 10 15
Ile Gly

20 <210> 155

<211> 18

<212> PRT

<213> Mycobacterium tuberculosis

25 <400> 155

Ala Val Gly Glu Ser Gly Ile Gly Tyr Ala Ala Gly Asp Ala Val Ala
1 5 10 15
Ala Ala

30 <210> 156

<211> 18

<212> PRT

<213> Mycobacterium tuberculosis

35 <400> 156

Ala Ala Gly Asp Ala Val Ala Ala Ala Thr Tyr Leu Val Ser Gly Gly
1 5 10 15
Ser Leu

40 <210> 157

<211> 27

<212> DNA

<213> Artificial Sequence

<400> 157

ctgagatctc aggtaccgga ttccggcg 27

50 <210> 158

<211> 27

<212> DNA

<213> Artificial Sequence

55 <400> 158

ctccccatggt catgactgac tcccctt 27

<210> 159

<211> 27

<212> DNA

<213> Artificial Sequence

<400> 159

60 ctgagatcta tgacgttgcg agtggtt 27

<210> 160

<211> 27
<212> DNA
<213> Artificial Sequence

5 <400> 160
ctcccatggt cagccgcccc cgacccc 27

10 <210> 161
<211> 27
<212> DNA
<213> Artificial Sequence

15 <400> 161
ctgagatctg ctactgttaa cagatcg 27
<210> 162
<211> 27
<212> DNA
<213> Artificial Sequence

20 <400> 162
ccgctcgagc tacaacgttg tggttgt 27

25 <210> 163
<211> 27
<212> DNA
<213> Artificial Sequence

30 <400> 163
cccaagctta tgagtattac caggccg 27

35 <210> 164
<211> 30
<212> DNA
<213> Artificial Sequence

40 <400> 164
ctcccatggt cacgacttct gctgaagcaa 30
<210> 165
<211> 53
<212> DNA
<213> Artificial Sequence

45 <400> 165
ggggacaagt ttgtacaaaa aagcaggctt agtgttttc gtgtatggcat acc 53
<210> 166
<211> 48

50 <212> DNA
<213> Artificial Sequence

55 <400> 166
ggggaccact ttgtacaaga aagctggtc ctattagctg gccgccc 48
<210> 167
<211> 51
<212> DNA
<213> Artificial Sequence

60 <400> 167
ggggacaagt ttgtacaaaa aagcaggctt agtgacgttg cgagtcgttc c 51
<210> 168
<211> 53
<212> DNA

<213> Artificial Sequence
 <400> 168
 5 ggggaccact ttgtacaaga aagctgggtc ctatagccca ccgctgagat acg 53
 <210> 169
 <211> 52
 <212> DNA
 10 <213> Artificial Sequence
 <400> 169
 ggggacaagt ttgtacaaaa aaggaggctt agtgtcttc actgcgcaac cg 52
 15 <210> 170
 <211> 51
 <212> DNA
 <213> Artificial Sequence
 <400> 170
 20 ggggaccact ttgtacaaga aagctgggtc ctagccggtg accacagcgt t 51
 <210> 171
 <211> 15
 <212> PRT
 25 <213> Mycobacterium tuberculosis
 <400> 171
 Met Lys Ala Lys Val Gly Asp Ile Leu Val Ile Lys Gly Ala Thr
 1 5 10 15
 30 <210> 172
 <211> 15
 <212> PRT
 <213> Mycobacterium tuberculosis
 35 <400> 172
 Asp Ser Thr Glu Asp Phe Pro Ile Pro Xaa Arg Met Xaa Ala Thr
 1 5 10 15

40